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General Introduction

1 The human genome, a complex blue print
The human genome consists of approximately 3 billion base pairs of deoxyribonucleic 
acid (DNA) which includes the instruction set that initiates and coordinates most 
biological processes in human cells12.
1.1 Structural organization
DNA is organized into large discrete structural units, called chromosomes (Figure 
1.1A). Human cells have 23 different pairs of chromosomes, resulting in 46 
chromosomes per cell. Of these, 22 pairs are similar irrespective of an individual’s sex 
and are termed autosomal chromosomes, or autosomes. Autosomal chromosomes 
vary in size from approximately 47 to 247 million base pairs (Mb). In general, each 
chromosome consists of a short p-arm and a longer q-arm, which are connected 
by a centromere (Figure 1.1A). The ends of each chromosome arm are capped 
by specific structures termed telomeres. The 23rd pair of chromosomes are the sex 
chromosomes. Females have a pair of X chromosomes, and males have a single X 
and single Y chromosome. All chromosomes are located inside the nucleus of the 
cell (Figure 1.1B). The genetic information encoded by the DNA is passed to each 
offspring (i.e., inherited) after re-combination between the maternal- and paternal- 
derived homologous chromosomes.
Figure 1.1. (A) The genome is organized into chromosomes. Each chromosome consists 
of a short arm, “p” and a long arm, “q” which are connected by a centromere; the ends of 
the chromosomes are capped by telomeres. (B) The chromosomes are located inside the 
cell nucleus. Chromosomes can vary in length from 47 to 247 million base pairs.
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The human genome contains many repetitive DNA sequences, which either can 
occur in tandem or be dispersed throughout the genome. Segmental duplications 
are one class of dispersed repeat DNA sequence. Which are characterised by a 
stretch of 1,000 or more base pairs (bp) exhibiting more than 90% sequence identity 
to another sequence located elsewhere in the genome3. Segmental duplications 
may include genes, such duplicated copies create redundancy in the genome, 
and allow the two copies to acquire separate functions4. The second major class 
of repetitive elements are termed Transposons, based on their ability to move to 
different positions within the genome. Transposons are sub-classified into long 
interspersed nuclear elements (LINEs, usually longer than 5,000 bp) and short 
interspersed nuclear elements (SINEs, typically shorter than 500 bp)56. The human 
genome contains approximately 20,000 -  40,000 LINEs (21% of the genome) and 
1,500,000 SINEs (13% of the total genome).
1.2 Functional organization
A gene is a functional unit within the genome which holds the information to build and 
maintain cells, regulate biological processes and pass genetic traits to offspring78. 
Genes are spaced unevenly across the genome. They can encode functional 
molecules such as proteins or ribonucleic acids (RNA), and may contain sub­
elements such as intervening sequences (“introns”) and/or regulatory elements9. 
Regulatory elements control gene expression and include promoters, transcription 
enhancers and silencers. Besides introns and transposons, pseudogenes are 
another class of non-protein coding DNA elements, which are non-functional copies 
of genes present elsewhere in the genome. In humans, approximately 1.5% of the 
genome contains coding DNA, encompassing approximately 20,000 genes, which 
are transcribed into RNA. The remainder of the genome consists of non-coding 
sequences10-12. Until recently, most research has focused on the part of the genome 
that contains genes. As a result, little is known about the exact role and function of 
the non-coding sequences. Initially it had been thought that non-coding sequences 
represent decaying remnants of evolution or “junk DNA” with no real purpose in 
the genome. Studies have increasingly shown that non-coding sequences are 
not randomly constructed, are pervasively transcribed and may contain important 
elements responsible for gene regulation13.
1.3 The genome is changing
During evolution, the genomic organization has changed considerably. DNA has, 
for example continuously been “purified” of deleterious mutations (an evolutionary 
process thereby called “purifying selection”). It is estimated that purifying selection 
acts on 2.5 -  5.0% of the total genome. Under particular conditions (e.g. selective 
pressure, diseases, environment) some beneficial mutations are “accepted” or 
maintained in the population (“positive selection”)1415. However, in general selection 
is relatively rare and the (large) majority of the genome is under so called neutral 
selection. Neutral selection occurs when mutations that are not selected for, or against 
accumulate in the genome. Evolution of the human genome can be measured e.g. by 
comparing the human genome to that of other species. For example, comparison of
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the human and chimpanzee genomes through Zoo-FISH hybridization approaches 
has demonstrated that these genomes are 99% identical16-18. Such approaches are 
powerful for identifying conserved stretches of DNA, but are limited by their inability 
to determine relative positioning of genes contained within these stretches. Evolution 
can also be measured by comparing the fraction of genes shared between species, 
the so called orthologs. A gene has an ortholog when divergent copies of the same 
single gene can be identified in two different species (for example in the human and 
mouse). Alternatively, evolution can be measured by comparing the spatial clustering 
and relative positions of orthologous genes between the different genomes19.
2 We are not alike
The genomes of any two individuals at the base pair level are not identical, and 
variation exists within and between human populations20. The more closely two 
people or populations are related, the more similar their genomes. On average, 
the difference between the genetic material of any two non-related individuals is 
estimated to be 0.5% of the total genome, which is equivalent to 1.5 million base 
pairs221. These differences can occur as (random) errors during meiotic cell division 
or as the result of evolutionary processes. The term genomic variation describes 
how the genomes of individuals differ and this variation can occur in many different 
forms.
2.1 Size of genomic variation
Genomic variation occurs in different sizes, ranging from individual base pairs to 
small insertions and deletions to large stretches of DNA containing millions of base 
pairs (Figure 1.2). Genomic variation also exists at different frequencies throughout 
the human genome, ranging from single occurrence rare variants to frequently 
occurring common variants. Single base pair variations are estimated to occur at a 
rate of between 1.7 to 2.5x10-8 per base per human generation22 23. This equates to 
approximately 150 new single base pair variants per newborn. When the frequency 
of a single base pair variant in the population exceeds 1%, it is termed a single 
nucleotide polymorphism (SNP)124. Many SNPs have been identified in the human 
genome. dbSNP (version 130) is a public database used to store SNPs discovered 
in the human genome and currently contains over 12,8 million entries25. In contrast, 
aneuploidy occurs when whole chromosomes are either lost or gained. Recently, 
the term copy number variant (CNV) has been coined for a loss or gain of genomic 
material encompassing more than 1,000 base pairs (bp)26 27. Approximately 5% of 
the human genome has been shown to be involved in CNVs (see 4.2 CNVs in 
the general population)28 29. The first complete genomic sequence from a single 
individual revealed 62 CNVs (32 losses and 30 gains compared to the reference 
human genome), thereby highlighting the plasticity and variability of the human 
genome2. As CNVs each contain thousands to millions of base pairs of DNA, 
quantitatively the majority of the variant base pairs in the genome can be attributed to 
CNVs and not to SNPs. Consequently, CNVs are of major importance for elucidating 
human genetic diversity26 30-34.
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Figure 1.2. Genomic variation ranges from changes at the individual base pair level, such 
as SNPs, small insertions and deletions (“ indels”), to copy number variants that affect 
thousands to millions of base pairs (CNVs).
3 Detecting genomic variation
3.1 From karyotype to microarray
Through the years, several different technologies have become available for the 
detection of genomic variation. Variants larger than 5 - 10 Mb are visible by staining 
chromosomes and viewing them under a light microscope35-37. After staining the 
chromosomes can be arranged into a karyotype (Figure 1.3A). Assessment of the 
different banding patterns specific to each chromosome allows the identification 
of genomic variants, including copy number variants, genome-wide. However, 
karyotyping is limited by its intrinsic low resolution and, depending on the 
staining method used, variants smaller than 5 to 10 Mb can rarely be visualized 
microscopically. In contrast, DNA sequence analysis (for example the Sanger dye- 
termination sequencing method) allows the comprehensive detection of single base 
pair variants such as SNPs, but only by targeting specific known locations within 
the genome (Figure 1.3B)38. Furthermore, because Sanger-based DNA sequence 
analysis is usually preceded by PCR amplification it does not ordinarily allow the 
detection, characterisation or quantification of structural variants such as CNVs. 
Recently, a novel genome-wide high-resolution technology has been developed, 
termed array comparative genomic hybridization (array CGH), which is based on
14
the use of DNA microarrays (Figure 1.3C). This novel technology has proven to 
be robust and cost-effective for the genome-wide detection of CNVs, achieving a 
resolution that by far exceeds that of karyotyping, especially when large numbers of 
targets are used on the microarray (see below).
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Figure 1.3. (A) Normal female karyotype obtained after G-banding of the chromosomes. 
(B) Identification of a SNP (marked by red arrow) after Sanger dye termination sequencing 
of three individuals, (C) Genome-wide array CGH based DNA copy number screen. 
Examples of a copy number gain (up) and loss (down) are marked by arrows.
3.2 Development of the genomic microarray
A microarray allows the simultaneous measurement of many reactions on a single 
platform. A genomic microarray consists of an arrayed series of microscopic spots of 
DNA on a support medium. Each probe is designed to target, detect and quantify the 
presence of specific DNA sequences in the sample to be tested. Detection occurs 
when fluorescently labelled target DNA (e.g. a sample from a patient) is hybridized
15
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to the probes. The fluorescent signal intensities of the sample are quantified by 
scanning the microarray (see Figure 1.4B) and compared to the signal intensities 
from a reference (e.g. DNA from (pooled) normal individuals). Test over reference 
ratios are then calculated for each probe and depicted as gains or losses in genomic 
material in comparison to the reference sample(s) (Figure 1.4C). A disadvantage 
of genomic microarrays is that they are unable to detect balanced inversions or 
translocations where the DNA is rearranged without gain or loss of genetic material. 
Advances in microarray manufacturing technologies have resulted in a rapid increase 
from 8039 to 2.7 million40 probes per microarray. Different types and lengths of DNA 
fragments have been used to construct microarray probes, including large insert 
clones (40-200 kilobases (kb) in length) such as bacterial artificial chromosomes 
(BACs), small insert clones (1.5-4.5kb) such as plasmids, cDNA clones (0.5-2kb), 
(genomic) PCR amplified products (100bp-1.5kb) and oligonucleotides (25-80 
nucleotides). Large insert clones, due to their length, provide a high degree of 
specificity to their target sequences. As a result test over reference ratios from 
microarrays constructed with large insert clones (such as BACs) are less affected by 
experimental noise because fewer probes will cross hybridize to incorrect targets41. 
In contrast, the use of relatively short length oligonucleotides results in a lower signal 
to noise ratio for each probe, but a higher sensitivity for accurately mapping the 
boundaries of a CNV (break point)4243. Despite the higher cross hybridization risk, 
recent developments in microarrays have resulted in, not only an enormous increase 
in the number of probes per array, but also in a trend towards shorter hybridization 
targets. Developments in microarray technologies for CNVs detection are driven by 
the need (i) to have comprehensive genome wide coverage, (ii) to accurately detect 
the break points of CNVs and (iii) to be able to detect small CNVs 1kb in size.
16
Figure 1.4. From patient sample to causal copy number variant. (A) A test sample 
(for example blood) is collected from a patient. DNA is extracted from the sample, purified 
and prepared for a microarray analysis. (B) A genomic microarray consists of an arrayed 
series of probes. The test DNA is hybridized to the microarray and an image is created 
after scanning of the microarray. (C) The probes on the microarray correspond to known 
locations throughout the genome. “Test over reference” ratios are calculated representing 
losses and gains in the genomic material of the sample. Segments are identified where the 
copy number varies. (D) Since most samples contain many CNVs, databases are used to 
annotate each CNV. Using the annotation data, the CNV most likely to be pathogenic is 
identified.
17
Chapter 1 
Introduction
3.3 Analysis of microarrays
The identification of CNVs from a microarray scan is preceded by a number of 
data processing steps (Figure 1.5C-D). The individual probe intensities must be 
extracted from the scanned image of the microarray (Image processing). These 
probe intensities are then transformed into copy number ratios (Calculation o f copy 
numbers), systematic biases are removed (Removing systematic biases) and 
segments with aberrant copy number are identified (Determining the copy number 
state). Each of these steps is accompanied by several quality control steps designed 
to quantify the effects of random and systematic sources of experimental noise.
3.3.1 Image processing
The process of identifying and converting individual probe intensities from the 
scanned microarray image into probe intensities is known as probe level processing. 
This step involves many image processing techniques to correctly identify the probes 
and their intensities in the scanned image4144.
The scanned image of a microarray and its measured probe intensities contains 
background noise in addition to the true probe intensities (as a direct result of 
fluorescent molecules attached to hybridized DNA) (Figure 1.5)45. Background 
noise can occur for example when the glass coating on which the microarray resides 
fluoresces. Also, the scanner itself may be a source of background noise. The 
microarray contains probes that are specifically designed to measure the background 
noise. True probe intensities reflecting hybridization strengths are obtained by 
subtracting the background noise from the scanned microarray image.
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Figure 1.5. Removing noise from the scanned image of a microarray. (A) The initial image 
of the microarray captured by the scanner, (B) The background noise contained within the 
microarray image is subtracted. (C) The corrected image of the microarray after removal 
of background noise.
3.3.2 Calculation o f copy numbers
To compare the hybridization strengths and thus the amount of genomic material 
targeted by each probe, the true probe intensities are transformed into ratios of the 
test sample in comparison to a reference sample(s). These ratios are also commonly
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termed “test over reference” ratios (Figure 1.4C). The variance in probe intensities 
due to experimental noise is correlated to the probe intensity. Probes with a low 
intensity can be highly variable whereas probes above a certain intensity tend to 
be more stable. This effect is often fortified after the background noise has been 
subtracted from the image. To reduce probe intensity-dependent variance, the data 
is transformed by shifting the test over reference ratios into the log space. A log 
scale with base 2 is used as there are 2 copies of each autosomal chromosome in 
a normal genome. Furthermore, the resulting log2 ratios have a normal distribution, 
providing a greater flexibility downstream when analysing the data with statistical 
methods.
3.3.3 Removing systematic biases
Normalization of probe intensities removes systematic biases that have been 
introduced into the data. The most appropriate normalization method depends on 
the type of microarray platform used and the source of systematic bias. For example, 
“channel balancing” is often required for 2 colour microarrays due to specific dye 
biases, whereas local normalization such as Lowess (locally weighted scatter plot 
smoothing) is often used to remove spatial effects within different sectors of the 
microarray46.
Systematic biases globally affecting the results of a microarray experiment must 
also be removed. For example, probe intensities can be systematically biased by 
differences in the length and GC content of the hybridized fragments. These effects 
can be reduced by using quantile regression (Figure 1.6)47. Regression can also be 
used to reduce waves in copy number ratios, due to GC biases and DNA isolation 
methods48. However, while the correction of systematic biases in the log2 ratios is 
essential to avoid being misled by artefacts in the data, attempted corrections can 
themselves introduce biases. Therefore, as a general rule, data manipulation should 
be minimized49.
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Before correction
length GC content
Figure 1.6. Normalization of probe intensities. A  systematic bias in a sample visualized by 
plotting the log2 ratio against fragment length and fragment GC content (upper panel). The 
log2 ratios are normalized to correct for this bias first by compensating for the fragment 
length (middle panel), then for the GC content (bottom panel)47.
3.3.4 Determining the copy number state
After individual probe level processing, the log2 ratios are analyzed to identify 
continuous segments where gains or losses in genomic material have occurred. This 
processing step is termed segmentation. Continuous genomic regions with a similar 
copy number state are defined and break points where these state changes occur 
are identified. For the clinical and biological interpretation of CNVs it is essential to 
accurately identify the precise genomic locations where copy number state changes 
occur. Many different algorithms have been developed for the identification of 
CNVs42 47 50-72. Identification of continuous segments based on the discrete log2 ratios 
is often complex due to the experimental noise that remains in the log2 ratios despite 
data normalization (see above), the uneven spacing of microarray probes and the 
edges of the signals at telomeres and centromeres. Segmentation methods are 
based on a wide assortment of algorithms such as the Smith-Waterman algorithm68, 
modified adaptive weights smoothing73, expectation maximization edge placement 
algorithm74, circular binary segmentation75 and Hidden Markov Models52. The 
selection of a segmentation algorithm and algorithm parameters is the result of a 
trade-off between acceptable false-positive and false-negative CNV detection rates. 
Alternatively, false-positives can be reduced by combining the results of multiple 
segmentation algorithms and only considering CNVs that are identified by more than 
one algorithm as true CNVs34.
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Despite preliminary attempts76, true comparisons and benchmarking of segmentation 
algorithms is still lacking. Comparisons between different algorithms is challenging 
due to non-standardized algorithm parameters, lack of stable reference material with 
well characterised CNVs, uncertainty of exact breakpoints positions, and laboratory 
specific biases in experimental data. As a consequence, the CNVs detected in a 
microarray experiment will not only differ depending on the microarray platform 
used, but also on the segmentation algorithm (and the algorithm parameters) used.
4 CNV interpretation
4.1 Types of CNVs
Genomic abnormalities such as CNVs can give rise to severe phenotypic 
consequences and, hence, disease. Such genomic variants are termed pathogenic. 
Genomic variants are defined as fully penetrant when all individuals carrying the 
variant also display the CNV-associated trait (phenotype). Genomic variants that do 
not have a phenotypic effect are termed benign variants. However, determining if a 
CNV is truly benign and has no phenotypic consequences is extremely difficult. In 
between these two extremes, genomic CNVs can be termed risk factors - variants that 
increase the probability of an individual to develop a particular disease. Identifying 
pathogenic variants as well as genetic risk factors within this complex landscape of 
genome variability is a major challenge, yet fundamental for understanding disease 
aetiology.
CNVs exhibit a non-uniform distribution throughout the genome77. This is in part 
due to ascertainment biases but also to locus-specific differences in CNV formation 
rates. Structural features of the genome, such as repetitive elements, predispose to 
the formation of CNVs during meiotic recombination. Consequently, this affects the 
frequency at which particular CNVs are observed to occur in the general population. 
The phenotypic consequences of a CNV also affect its frequency. CNVs that exert 
a dominant harmful phenotypic effect tend to be less frequent. In addition, different 
rates of natural selection (see 1.3 The genome is changing) are enforced throughout 
the genome, thus CNVs are tolerated to different degrees throughout the genome78.
The base copy number throughout the genome is assumed to be two, however this 
copy number can differ per locus and ethnic group79. A single copy number loss or 
gain occurs when one allele is either deleted or duplicated. When both alleles are 
deleted and no genomic material is present, a homozygous deletion has occurred. 
The magnitude of duplicated material can also vary from a single gain, to higher order 
gains where the number of copies may have doubled, quadrupled or be even higher. 
Therefore, it is not only important to identify which genes are affected by a CNV but 
also how they are affected. The loss of genomic material is usually assumed to have 
a different effect than the gain of genomic material at a particular locus.
21
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4.2 CNVs in the general population
Recently, a plethora of CNVs have been discovered in the general population. A 
first generation map of CNVs in the human genome was created based on 270 
Hapmap individuals from 3 different ethnic backgrounds; Caucasian, Yoruban, and 
Han Chinese-Japanese. In this study 1,447 regions, encompassing 360 Mb (12%) 
of the genome were reported to be affected by CNVs. Differences in copy number 
variation between populations were also observed26. Since this initial screen, public 
repositories have been created to catalogue CNV discoveries, such as the Database 
of Genomic Variants (DGV)80. Approximately 18.8% of the genome is now reported 
in the DGV to be involved in CNVs34. Unfortunately, only a fraction of the CNVs 
stored in the DGV has been validated81, which raises the possibility (in particular for 
rare CNVs) that they may in fact be erroneous entries resulting either from detection 
errors or poor phenotyping. Early studies using microarrays with large insert clones 
may also have overestimated the size of many CNVs82. Recent studies suggest that 
5% is a more accurate estimate for the proportion of the genome to be involved 
in CNVs in the general population28 29. This initial overestimation emphasizes the 
importance of the accurate detection of CNV breakpoints.
Recently developed deep sequencing methodologies identified 600 to 900 CNVs 
(larger than 1kb) per individual2 83. These recent studies also uncovered a CNV size 
continuum84 and the inverse relationship between the number of CNVs in the human 
genome and their size (Figure 1.7)85. CNVs observed in the general population may 
contain hundreds of genes, disease loci and functional elements. Parent-offspring 
analyses indicate that the large majority of CNVs considered to be benign follow 
normal inheritance patterns, supporting the view that they are not selected against. 
In contrast, the formation of new (de novo) CNVs was found to be extremely rare 
in the general population26. However, the lack of extensive phenotyping of control 
individuals makes it difficult to assess the exact impact of CNVs occurring in the 
general population, in particular in late onset and/or complex disorders.
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Figure 1.7. Distribution of CNVs based on size; large CNVs are less common than small 
CNVs. Recent studies have shown that the vast majority of CNVs is smaller than 50kb84.
4.3 Gene dosage
In general, gene expression is tightly regulated and highly dependent on a variety 
of different factors such as developmental stage, cell or tissue type, metabolic 
state and environmental factors. Genes whose expression is affected as a result 
of a CNV are termed dosage sensitive genes. Not all genes have been found to 
be dosage sensitive and in some cases, a CNV does not appear to have a direct 
impact on gene expression (except for when a homozygous deletion occurs). A 
gene may be subject to haplo-insufficiency when it requires more than one active 
copy for normal functioning86. Therefore, a loss in genomic material (e.g. due to a 
CNV) encompassing a haploinsufficient gene can result in an abnormal phenotype. 
Interpreting gene dosage effects resulting from a gain in genomic material is more 
difficult as its effects are strongly dependent on the exact location of the breakpoints. 
When a CNV breakpoint falls within a gene and disrupts its coding sequence, the 
gene may no longer be able to function correctly and a loss of function may occur. 
However, if a gain in genomic material completely spans a gene the gene may still 
be functional, resulting in a higher level of expression than normal, i.e., a gain of 
function. Studies have shown that 18% of all genes are dosage sensitive87. The 
majority of dosage sensitive genes (80%) are positively correlated to the copy 
number; that is a CNV causing a loss of genomic material also results in less gene 
expression and a CNV causing a gain in genomic material results in more gene 
expression. In comparison, 20% of gene expression was found to be negatively 
correlated to the copy number87 88.
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4.4 CNVs in common disease: Mental Retardation as a model 
disease
CNVs contribute to all classes of disease with a genetic aetiology, such as 
developmental disorders and mental retardation (MR)89-92, complex disorders93-97 
and infectious diseases98-100. The most direct example of CNVs and disease are 
dominant monogenic disorders where a particular CNV always results in the 
same phenotype. The loss of a single copy of the CHD7 gene for example always 
causes CHARGE syndrome101102. Individuals with CHARGE syndrome have mental 
retardation as well as a number of distinctive phenotypic traits such as heart defects. 
Many diseases however are not dominantly acting and monogenic. CNVs can also 
contribute to recessive diseases by unmasking a mutation on the remaining allele 
after a CNV loss has occurred. Alternatively, as in complex diseases, many genomic 
variations including CNVs may in combination contribute to the disease.
MR affects approximately 1-3% of the general population103 104. Approximately 50% 
of MR cases are believed to be have a genetic cause and 5-16% are thought to 
be a result of environmental factors105. MR is an example of a common disease 
that exhibits locus heterogeneity. Many different rare fully penetrant variants acting 
independently can result in this disorder. Using traditional cytogenetic techniques, 
such as karyotyping, chromosomal aberrations can be found in approximately 5% 
of all cases81 92 106. At present, MR research has mainly focused on isolated patients 
with a clinically recognizable MR syndrome, on familial cases and on non-syndromic 
MR caused by alterations on the X chromosome.
4.4.1 Clinical symptoms
The human brain is highly complex, and its normal development and functioning is 
critically dependent on the correct and tightly regulated activity of a large number 
of genes. MR is a clinically and genetically heterogeneous disorder of brain 
development105 the cause of which remains largely unexplained. Individuals with an 
intellectual quotient (IQ) below 70, two standard deviations below an average IQ 
(100), are considered to have MR. Over a thousand syndromes are listed in the 
Online Mendelian Inheritance in Man (OMIM) for which MR is at least one of the 
phenotypes, but for which the number and severity of clinical symptoms can vary 
greatly12.
4.4.2 Chromosome aberrations and mental retardation
The discovery of whole chromosome trisomies with very specific mental retardation- 
related phenotypes, such as trisomy 21 in Down syndrome and trisomies 13 and 
18 in Patau and Edwards syndrome, respectively, launched the field of clinical 
cytogenetics107-109. The subsequent identification of specific recurring genomic 
anomalies has been instrumental for the definition of several additional MR 
syndromes110. For example the 22q11.2 deletion syndrome, also called Velo-Cardio- 
Facial or Di George syndrome, is caused by a 1.5-3 Mb deletion on chromosome 22.
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Mental retardation and a number of congenital defects, such as heart defects, palate 
defects, neuromuscular problems, facial dysmorphisms and/or recurrent infections, 
characterize Di George syndrome. The chromosome 5p deletion syndrome, also 
called Cri du Chat syndrome, is another MR syndrome that is associated with a 
characteristic cat-like cry111. Nevertheless, the identification of causative autosomal 
dominant genes remains a challenge for individuals with no specific phenotype. 
Conventional genetic family-based analyses of autosomal dominant traits are usually 
not possible as severe MR mutations are frequently effectively reproductive lethal. 
Consequently, large pedigrees are unlikely to appear in the population112.
4.4.3 Clinical interpretation o f CNVs in mental retardation
DNA microarrays allow the genome-wide detection of CNVs in individuals without 
the need to target specific genomic locations. As a result, genome-wide screening 
with microarrays is highly suited to the delineation of the heterogeneous nature of 
MR. Initial studies using low resolution genomic microarrays have linked CNVs to 
MR in 10-15% of cases92113.
In general CNVs identified in MR patients are categorized as either a benign, 
pathogenic, or of unknown clinical significance. The identification of pathogenic 
CNVs relies on the use of parental samples to determine if the CNV has been 
inherited or has occurred de novo. In addition, large control cohorts of unrelated 
individuals can be used to establish whether a CNV is rare (Figure 1.8). This form 
of interpretation relies on the basic assumption that neither the control cohorts nor 
the parents are affected by MR and, hence, that MR co-segregates with a CNV 
that exerts a dominant effect77. This methodology also uses the observation that 
relatively large de novo CNVs are extremely rare in the general population26. Once 
a CNV has been identified as rare and de novo, other sources of information can 
also be used for clinical interpretation such as its genomic size, its gene content, or 
information about the particular CNV in literature81 92 106.
De Novo Inherited
Rare + ?
Common -
Figure 1.8. Current clinical interpretation of CNVs in patients with MR. Rare de novo CNVs 
are considered pathogenic (+), and common inherited CNVs benign (-). Rare inherited 
CNVs are given the status unknown clinical significance (?).
Stating that rare de novo CNVs are clinically relevant is dangerous as our 
current knowledge on CNV formation rates within the general population is still 
too rudimentary. Similarly while inherited CNVs are currently not considered to 
be clinically relevant, it is difficult to prove that these variants are definitely non- 
pathogenic especially when they are rare in the general population114. The use of 
control datasets for excluding CNVs as potentially causative may be influenced by 
false assumptions about the inheritance pattern underlying the causal variant. For
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example, recessive and variably expressive dominant alleles will be contained in 
‘control’ datasets115. Likewise, the assumption that all CNVs currently annotated in 
public databases are benign polymorphisms is misleading84. These shortcomings 
in interpretation have recently been highlighted by the discovery of a number of 
CNVs exhibiting incomplete penetrance116-120. Such CNVs are rarely observed in the 
general population, but can be inherited from healthy parents. Nonetheless, these 
rare inherited CNVs may occur at a much higher frequency among MR patients.
The current CNV interpretation approach categorizes: (1) rare de novo CNVs as 
pathogenic; (2) common inherited CNVs as benign; and (3) rare inherited CNVs as 
unknown clinical significance. Although this approach has been highly successful 
in associating CNVs to MR, it is still limited and potentially oversimplifies CNV 
interpretation due to various reasons: (1) it is often impossible to obtain both parental 
samples for proving de novo occurrence. (2) inherited CNVs may also result in 
disease: an inherited deletion may for example uncover a recessive mutation on the 
other allele (Figure 1.9), (3) a CNV-related phenotype may show variable expression 
and/or reduced penetrance, (4) the effect of a CNV may be allele-specific. (5) CNVs 
may act as susceptibility loci, which complicates direct linking of these CNVs to 
disease and (6) the phenotypic effect of a given CNV may depend on the exact copy 
number.
DeNovo Inherited
Pathoger
1
1
Benign
Rare
'Frequent
Figure 1.9. Conceptual relationship between de novo and inherited CNVs in comparison 
to pathogenic and benign CNVs. The majority of de novo CNVs is most likely pathogenic, 
but some inherited CNVs may also be pathogenic. Pathogenic CNVs are less frequent than 
benign CNVs. The majority of inherited CNVs will most likely be benign, yet some de novo 
CNVs may also lack phenotypic consequences.
5 Aim of this thesis
Recent improvements in microarray-based DNA copy number analysis techniques 
allow for a more precise demarcation of CNVs, a prerequisite for obtaining meaningful 
data for large-scale genome profiling and gene identification studies. As of yet, 
however, the clinical interpretation of CNVs is still in its infancy.
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Gene 3
Figure 1.10. A two-step approach is used to identify dosage sensitive genes associated 
to mental retardation. First, a pathogenic CNV is identified then, by analyzing the genes 
affected by the CNV, the causative gene can be identified.
The aim of this thesis was to improve the clinical interpretation of CNVs through the 
development of new techniques to identify dosage sensitive genes in MR-associated 
CNV regions (Figure 1.10). In doing so, we have taken microarray-based genomic 
profiling studies from the identification and collection phase to the interpretation 
phase, allowing us to distinguish CNVs with a phenotypic effect from those without 
a phenotypic effect. To achieve this goal, we first developed a method to determine 
objectively the resolution of genomic microarray platforms for CNV identification. 
Following this, we performed in-depth bio-informatic analyses of CNVs identified 
in patients with MR, as well as CNVs identified in the general population. Finally, 
we developed a probabilistic model to predict the phenotypic effects of CNVs. It is 
anticipated that this model will serve as an invaluable tool for the clinical diagnosis 
of patients with MR and beyond.
Specifically, our objectives were:
CNV Identification
(I) Develop techniques to test the detection limits of microarrays (Chapter 2)
(II) Determine the robustness of SNP microarrays for diagnostic applications
(Chapter 3)
CNV Interpretation
(III) Systematically characterize CNVs occurring in control individuals (Chapter
4)
(IV) Systematically characterize CNVs associated with MR (Chapter 5)
(V) Develop and validate computation methods to distinguish MR-associated
from benign CNVs (Chapter 6)
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Abstract
Recently, comparative genomic hybridization onto BAC arrays (array CGH) has 
proved to be successful for the detection of submicroscopic DNA copy number 
variations in health and disease. Technological improvements to achieve a higher 
resolution have resulted in the generation of additional microarray platforms 
encompassing larger numbers of shorter DNA targets (oligonucleotides). Here we 
present a novel method to estimate the ability of a microarray to detect genomic copy 
number variations of different sizes and types (i.e. deletions or duplications). We 
applied our method, which is based on statistical power analysis, to four widely used 
high-density genomic microarray platforms. By doing so, we found that the high- 
density oligonucleotide platforms are superior to the BAC platform for the genome- 
wide detection of copy number variations smaller than 1 megabase. The capacity 
to reliably detect single copy number variations below 100 kilobases, however, 
appeared to be limited for all platforms tested. In addition, our analysis revealed 
an unexpected platform-dependent difference in sensitivity to detect a single copy 
number loss and a single copy number gain. These analyses provide a first objective 
insight into the true capacities and limitations of different genomic microarrays to 
detect and define DNA copy number variation.
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Introduction
Conceptual and technological developments in molecular cytogenetic techniques 
are now enhancing the resolution power of conventional chromosome analysis from 
the megabase to the kilobase level. Array-based comparative genomic hybridization 
(array CGH), the application of CGH to an array of genomic fragments such as 
bacterial artificial chromosomes (BACs), has been the method of choice for genome- 
wide copy number analysis in the last few years12. The density of the various “whole- 
genome” BAC clone sets commonly used varies from one clone per megabase3-5 to 
an overlapping clone set covering the entire human genome with one clone per 100 
kilobases67. Array CGH has rapidly become an important genome analysis tool in 
cancer research8-10, in the identification of novel microdeletion syndromes and gene 
identification studies11-15, in the diagnosis of patients with congenital malformation 
syndromes and/or unexplained mental retardation51617 and in prenatal diagnosis1819. 
While disease-causing genomic alterations are thought to be rare, recent work using 
high-resolution microarray approaches has indicated that genomic copy number 
variation without immediate phenotypic consequences is widespread throughout the 
entire human genome1720-23.
Most currently used genomic copy number profiling microarrays are produced in 
academic settings and the resolution of these microarrays varies depending on the 
type and number of genomic targets selected, the protocols used and the data- 
analysis tools employed. Only recently, private enterprises embarked on this novel 
microarray application and several companies are now offering microarrays for 
genomic copy number profiling. Most of these microarrays encompass 25 to 85- 
mer oligonucleotides targeting random genomic sequences24-26 or single nucleotide 
polymorphisms (SNPs)27-31. The theoretical advantages of using such commercial 
platforms are numerous: (1) they provide a higher genome coverage than most 
microarrays generated in academia, (2) they can be produced in large quantities 
according to industrial quality standards, (3) they are available to all researchers, also 
those without dedicated microarray facilities, (4) their widespread use will generate 
large comparable data sets that facilitate data comparison and cooperation between 
research groups. At present, however, little is known about the actual performance 
of these platforms and a first-time user will find limited guidance on which platform 
is most appropriate for his or her applications and requirements. Although various 
platform comparison studies have been reported for microarray-based expression 
profiling32-35, as yet a comprehensive platform comparison for genomic profiling, 
including an adequate statistical power analysis, has not been reported.
A prerequisite for a performance comparison of genomic microarrays is the availability 
of a comprehensive method that accounts for specific requirements associated 
with genomic microarray data such as adjacency of probes and asymmetric y-axis 
measurements associated with deletions and/or duplications. Here we introduce a 
method that adheres to these requirements, and that is based on statistical power 
calculations to compare the practical resolution of individual genomic microarray 
experiments obtained using different microarray platforms. The method is validated
40
using simulated data sets as well as data sets obtained using our in-house tiling- 
resolution BAC array and commercially available 100k SNP, 250k SNP and 385k 
oligonucleotide microarray platforms. From our results we conclude that the 
increased probe density of the commercially available microarray platforms, although 
accompanied by a lower signal-to-noise ratio, results in a higher genome-wide copy 
number detection resolution.
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Methods
Patients and healthy donors
The platform comparison was performed using DNA from 13 patients harboring 
submicroscopic genomic copy number variations previously identified by tiling- 
resolution array CGH17. Genomic DNA was isolated from blood leukocytes by 
standard procedures. Male and female reference DNA pools previously used for 
tiling-resolution BAC array analysis were also used for hybridization to the NimbleGen 
oligonucleotide microarrays. These reference pools contain equal amounts of 
genomic DNA from 10 healthy donors (male or female). For the Affymetrix SNP 
oligonucleotide microarray experiments, using single color hybridizations, two male 
and two female reference pools were used for normalization purposes.
Tiling-resolution BAC array CGH
Previously, we reported an array CGH study17 using a tiling-resolution microarray 
encompassing 32,447 overlapping BAC clones selected to cover the entire human 
genome67. Hundred patients with unexplained mental retardation were hybridized 
in duplicate against a sex-mismatched reference pool to this microarray. Based on 
these hybridizations, we selected thirteen patients with validated submicroscopic 
copy number variations, both single copy number gains and losses, for hybridization 
to the other platforms.
Affym etrix 100k SNP arrays
The Affymetrix 100k SNP array contains 25-mer oligonucleotides representing a 
total of 116,204 SNPs, distributed over two microarrays. Array experiments were 
performed according to protocols provided by the manufacturer (Affymetrix, Inc., 
Santa Clara, CA). In brief, total genomic DNA was digested with either XbaI or HindIII, 
ligated to appropriate adaptors and amplified by a generic primer. After purification, 
the amplified DNA was digested with DNase I, labeled with biotin and hybridized 
onto a microarray. Hybridized probes were captured by streptavidin-phycoerythrin 
conjugates and the arrays were scanned and genotypes called as described36. 
Copy-number estimations were determined using the recently published software 
package CNAG (Copy Number Analyzer for Affymetrix GeneChip Mapping 100k 
arrays, Version 2.0 by Nannya et al.28). This algorithm strongly improves the signal- 
to-noise ratios of the copy number data by (1) accounting for the length and GC 
content of the PCR products using quadratic regressions, and by (2) normalizing the 
patient samples to reference samples run in parallel.
A ffym etrix 250k SNP arrays
Affymetrix provides two microarrays each containing approximately 250,000 SNPs, 
together forming the 500k assay. For this study we selected the Nsp 250k SNP 
array, which contains 262,264 25-mer oligonucleotides. As for the 100k SNP 
array experiments, the 250k SNP array experiments were performed according to 
protocols provided by the manufacturer (Affymetrix, Inc., Santa Clara, CA). Briefly, 
total genomic DNA was digested with Nsp, ligated to appropriate adaptors and 
amplified by a generic primer. After purification, the amplified DNA was digested with
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DNase I, labeled with biotin and hybridized onto the microarray. Hybridized probes 
were captured by streptavidin-phycoerythrin conjugates and the array was scanned 
and genotypes called as described36. Copy number estimates where determined 
using CNAG version 2.0 by Nannya et al.28.
NimbleGen 385k oligonucleotide arrays
The NimbleGen whole genome oligonucleotide microarray contains 386,165 
isothermal probes (45-75mer), spanning the human genome at a mean probe spacing 
of 7 kb. Isothermal oligonucleotide design, array fabrication, DNA labeling, CGH 
experiments, data normalization and log2 (Cy3/Cy5) copy number ratio calculations 
were performed by NimbleGen according to published procedures26.
Hidden Markov analysis
The normalized ratios were analyzed for loss and gain of regions by a Hidden Markov 
Model (HMM)17. Using the results from our previous study, we then subsequently 
optimized the HMM for each of the microarray platforms across all samples. 
Maximizing the detection of the known validated aberrations, while minimizing the 
false positive rate. The HMM has the following three hidden states for each probe on 
the microarray: normal, loss or gain. The probability that HMM yields a certain state, 
given the normalized log ratio x of each probe, is given by
P(s | x ) = n P(x, | s, ) P(s,. | s,-1 ) (1)
with the transition probability
in which A, denotes the base-pair distance between two adjacent probes , and ,-1, 
and g a normalizing constant. The observed log ratio x is assumed to be Gaussian 
distributed, with the variance s 2 and mean m, where the latter depends on the state sj
P(Xi | s, = Loss) = N(/u,oss, s 2) moss < 0 
P(x, | s, = Gain) = N(jugain, s 2, mgain > 0
To find the most likely hidden state, given the log probe intensities, we used 
a standard Viterbi algorithm that optimizes equation 137. This results in a path in 
which regions of consecutive probes that are in the normal, loss or hidden state, are 
detected. Application of the Viterbi algorithm results in a pre-estimate of the copy 
number state s..I
Statistical power analysis
For each of the four microarray platforms, we performed a statistical power analysis 
of adjacent targets surrounding a specific locus on a chromosome. This reveals 
the relationship between the genomic length of the copy number variation, the 
noise contained in measurements and, ultimately, the false positive and false 
negative detection rates for the microarray. Thus providing a platform independent 
discrimination statistic describing the ability of a microarray to detect single copy
(2)
P(x,. | s, = Normal) = N(0, s 2) (3)
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number variations.
The statistical power analysis comprises the following steps,
1. Determine the distribution of the noise.
2. Establish estimates for significant changes and the variance of noise within 
each experiment.
3. Calculate the number of data points required for detection of copy number 
variations.
4. Determine the resolution of a microarray platform.
Determine the distribution of the noise
The method assumes a normal distribution of noise within the copy number data. We 
used a Chi-Square goodness of fit test38, using a p-value of less than 0.05, and could 
not reject this hypothesis, thereby justifying the application of the method used for 
calculating the statistical power.
Establishing estimates for significant changes and variance of no,se 
In order to provide an estimation of a single copy number loss, the mean log2 ratio 
is calculated over all targets on the X chromosome39, excluding those mapped to 
the pseudo-autosomal regions. This provides an estimate of a significant change 
to be used in the power calculations, and requires that experiments used for the 
comparison are performed on the basis of sex-mismatch (either in silico or in vitro, 
depending on the microarrayA platform used). From the estimate of a single loss an 
estimate of a single gain ( m ) is calculated via,
r^Gain
A chrX  , 3
m Ga,n =  ChrX  ° g2 2
theoretical
(4)
where chrX  is the mean log2ratio of targets located on chromosome X and 
ch rX theoretical is the theoretical ratio of a single loss (see Supplementary Methods). 
The standard deviation of all log2 ratios from autosomal targets, excluding those 
known to be involved in validated copy number variations, is used as an estimate of 
the variance.
Calculation of the number of data po'mts requred for detection of genom'tc copy 
number vacations
We calculate the number of data points required to detect a genuine single copy 
number variation (as estimated by the mean chromosome X values) given the 
autosomal standard deviation, with a confidence factor determined by the desired 
statistical power. This is done by determining the number of data points required 
to lie in the outer regions of the distribution of the copy number ratios for it to be 
deemed unusual in terms of the expected (normal) distribution. We use the non­
central T cumulative distribution in order to determine the number of sample points 
required to satisfy the desired power given estimates of significant changes and an 
estimate of the variance40 41.
In this study we chose to use a power of 95% and a two-sided t-Test, given the
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required significance level a. Note that the statistical power (1-p) is the probability 
that a true aberration of n adjacent probes is detected (Type II error). The significance 
level a is the probability of observing a particular deviation between the mean of 
the n adjacent probes and the rest of the probes on the chromosome, when no 
actual copy number variation is present (Type I error). Hence we aim to solve the 
following series of equations for the desired power (1-S)=0.95. We first define the 
non-centrality parameter, as
ncp = '
' s  (5)
where m  = estimate of the ratio pertaining to the copy number variation, m0 = the 
autosomal ratios mean, 6  = the standard deviation, estimated using the autosomal 
targets and n is the number of adjacent targets per aberration. We define two cut­
offs, via the inverse of the Student’s T cumulative (central) distribution function (http:// 
mathworld.wolfram.com/NoncentralStudentst-Distribution.html), T-1, using the desired 
power, and the inverse of the power. The cut-offs, C' and C2 are defined as follows, 
where the degrees of freedom, df = n-1 and a is the required significance level
C1 = T1 (a/2,df)
C2 = T  ((1-a)/2,df) (6)
The power is then calculated with the noncentral cumulative T distribution function, 
Tnc as follows
power = TNc(Cr df, ncp) + 1 - TNJ  C2,df ncp) (7)
We then find the number of adjacent probes n (in equation 5) required to solve the 
function power in order to achieve our desired power.
Determining the resolution of a microarray platform
To calculate the resolution of a microarray platform, the outcome of the power analysis 
is used in conjunction with the platform’s genomic coverage. The distribution of the 
microarray probes throughout the genome is determined by the size of the gaps 
between the microarray targets. For our calculation we take into account the uneven 
genomic distribution of the microarray targets but assume that the distribution of non­
detected and detected copy number variation is independent from the distribution of 
the arrays genome coverage, and that variations are evenly distributed throughout 
the whole genome. Next we create a window with size equal to the number of data 
points required to detect a copy number variation, as given by the power calculation, 
and determine the number of instances within the genome where the window has 
a size less than the size of the variation to be detected. This is compared to the 
total possible number of windows that occur within the genome. By doing so, we 
create a genome-wide probability that a copy number variation with a particular size, 
irrespective of whether it is due to natural copy number variance and independent 
to its genomic location, will be detected by a microarray platform. We calculated the
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resolution for single copy number variations with genomic sizes ranging from 10 kb 
to 1 Mb, separately for gains and losses.
20 40 60 80 100 120 20 40 60 80 100 120
Position on chromosome 9 (Mb) Position on chromosome 9 (Mb)
F igure 2.1. Detection o f known and va lidated subm ic roscop ic  copy num ber varia tions 
by h igh-dens ity  BAC, SNP and o ligonuc leo tide  arrays. Individual chromosome plots are 
shown for patient 8 (chromosome 9), with the log2 T/R (test over reference) values plotted 
on the Y-axis versus the genomic position on chromosome 9 on the X-axis. Results are 
shown for the tiling resolution 32k BAC array (A), the 100k SNP array (B), the 250k SNP 
array (C) and the 385k oligonucleotide array (D). A known and validated microdeletion of 
0,54 Mb on 9q33.1 is detected by all four genomic microarray platforms (see black arrow). 
In addition, a previously undetected microduplication is clearly visible on the chromosome 
profile obtained by the 250k SNP array (see grey arrow). This figure also shows the different 
levels of microarray noise present for the different microarray platforms.
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Table 2.1: Detection of known and validated submicroscopic copy number variations onto high-density BAC, SNP and oligonucleotide 
microarrays.
r  Nr. of targets in region Avg. ratio targets in region Detected by HMM* 
Patient Chr. rLz® 32k 100k 250k 385k 32k 100k 250k 385k 100k 250k 385k 
________ nu ________  ^ j BACs SNPs SNPs Oligos BACs SNPs SNPs Oligos SNPs SNPs Oligos
1 Loss 1 3.93 42 125 230 n.d. -0.41 -0.51 -0.45 n.d. yes yes n.d.
2 Gain 1 2.12 21 50 120 176 0.44 0.49 0.77 0.59 yes yes yes
3 Loss 2 0.92 11 47 64 127 -0.59 -0.43 -0.52 -0.45 yes yes yes
4 Gain 5 1.24 16 40 n.d. n.d. 0.29 0.30 n.d. n.d. yes n.d. n.d.
5 Loss 7 0.35 18 1 13 30 -0.23 -0.52 -0.40 -0.24 no no yes
6 Gain 9 0.23 5 23 38 40 0.35 0.30 0.47 0.27 yes yes yes
7 Loss 9 2.85 30 145 320 n.d. -0.39 -0.45 -0.44 n.d. yes yes n.d.
8 Loss 9 0.54 6 22 70 88 -0.50 -0.44 -0.44 -0.37 yes yes yes
9 Loss 11 9.15 80 551 923 1299 -0.35 -0.47 -0.47 -0.50 yes yes yes
10 Gain 12 2.30 39 69 n.d. 353 0.32 0.26 n.d. 0.23 yes n.d. yes
11 Loss 15 1.65 16 4 40 204 -0.33 -0.36 -0.50 -0.35 no yes yes
12 Gain 17 2.89 28 64 151 420 0.37 0.26 0.46 0.29 yes yes yes
12 Gain 17 1.43 14 18 91 198 0.36 0.19 0.44 0.31 yes yes yes
12 Gain 17 2.88 30 205 279 442 0.41 0.29 0.45 0.28 yes yes yes
12 Gain 17 1.48 24 21 64 189 0.33 0.26 0.52 0.31 yes yes yes
13 Loss 22 2.66 35 36 130 306 -0.41 -0.47 -0.41 -0.23 yes yes yes
Chr, chromosome; Mb, megabase; Nr, number; Avg, average; HMM, Hidden Markov Model; n.d., not done. *AII copy number variations were 
initially detected by an automated HMM on the 32k BAC array.
Table 2.2: Signal-to-noise parameters of the four genomic copy number profiling platforms.
32k BAC array
Duplicate 
32k BAC 
array
Affymetrix 100k 
SNP array
Affymetrix 250k 
SNP array
NimbleGen 385k 
Oligonucleotide 
array
Patient Mean X1 AutoSTD2 Auto STD Mean X
Auto
STD Mean X
Auto
STD Mean X
Auto
STD
1 0.47 0.10 0.06 0.48 0.15 0.49 0.18 n.d n.d
2 0.49 0.14 0.08 0.48 0.13 0.48 0.14 0.42 0.20
3 0.49 0.12 0.07 0.48 0.16 0.45 0.16 0.35 0.25
4 0.42 0.13 0.07 0.47 0.14 n.d n.d n.d n.d
5 0.40 0.09 0.05 0.45 0.16 0.46 0.18 0.29 0.24
6 0.45 0.10 0.05 0.47 0.17 0.43 0.13 0.38 0.28
7 0.46 0.12 0.06 0.48 0.14 0.43 0.13 n.d n.d
8 0.47 0.11 0.06 0.46 0.13 0.42 0.15 0.35 0.24
9 0.40 0.12 0.06 0.48 0.24 0.47 0.16 0.51 0.21
10 0.49 0.11 0.07 0.48 0.13 n.d n.d 0.39 0.22
11 0.43 0.09 0.06 0.45 0.16 0.49 0.14 0.41 0.25
12 0.56 0.13 0.07 0.48 0.16 0.44 0.14 0.43 0.21
13 0.50 0.10 0.06 0.48 0.17 0.48 0.17 0.32 0.20
average 0.46 0.11 0.06 0.47 0.16 0.46 0.15 0.38 0.23
1 Mean log2 transformed test-over-reference ratio of the X chromosome, excluding the pseudo-autosomal regions, obtained from calculations in sex- 
mismatched hybridization experiments. For the BAC and the NimbleGen platforms data were obtained within each two-color experiment, for the Affymetrix 
SNP platform data initially reference pools for each gender were made, and then combined in silico with different one-color experiments.
2 Standard deviation calculated over the log2 transformed test-over-reference ratios for all autosomal targets, excluding the genomic regions known to harbor 
submicroscopic copy number variations.
Results
Study design
In this study we assessed the capacity of various genomic microarray platforms 
to detect submicroscopic single copy number variations, including deletions and 
duplications. We selected 13 patient samples in which we have previously identified 
and validated copy number variations using our in-house produced tiling-resolution 
32k BAC arrays17. These samples were hybridized onto 100k Affymetrix SNP arrays, 
250k Affymetrix SNP arrays and 385k NimbleGen oligonucleotide arrays. As an 
example, Figure 2.1 shows the chromosome profile obtained for the various platforms 
in a patient with a 0.54 Mb sized deletion at 9q33.1. We applied a standard Hidden 
Markov Model (HMM) algorithm to automatically detect copy number variations onto 
the different platforms. Next, we developed and tested a novel method based on 
statistical power analysis for an objective comparison of the detection resolution of 
the different platforms.
Automatic detection o f copy number aberrations by HMM
In order to obtain independent information on the performance of the different 
microarray platforms in identifying submicroscopic copy number variations, we 
applied a single automated HMM algorithm to the experiments performed in this 
study (Table 2.1). The known and validated copy number changes were previously 
identified on the 32k BAC microarray platform17, and ranged in sizes from 230 
kilobases (kb) to 8,9 megabases (Mb). Ten patient samples were tested on the 385k 
NimbleGen oligonucleotide microarray platform, and all of the previously identified 
and validated copy number variations were detected by the automated HMM 
algorithm. In contrast, two of the previously identified and validated copy number 
variations out of the 13 tested were not automatically detected on the Affymetrix 
100k SNP array platform. One of these was a 350 kb deletion on chromosome 
7q11.21 (patient 5), the other was a 1.65 Mb deletion on chromosome 15q24 (patient 
11). The HMM algorithm correctly detected 10 out of 11 previously identified and 
validated copy number variations on the Affymetrix 250k SNP microarray. Again, the 
350 kb deletion on 7q11.21 could not be detected automatically, whereas the 1.65 
Mb deletion on 15q24 was readily detected on this platform. In addition to the known 
and validated copy number variations, a large number of additional copy number 
variations was detected but not validated.
Verification of power calculation using simulated data
In order to verify the power calculation, we created a step function of a single 
copy number loss based on our model for an aberration and corrupted it with a 
noise signal that had a normal distribution to simulate a single copy number loss 
(Supplementary Figure 1a). The results of the power analysis on this data set are 
displayed in Supplementary Figure 1b. This analysis shows that a minimum of 4 
data points with log2 ratios outside the normal distribution is required for a single 
copy number loss to be detected with the desired power (95%). Subsequently, a 
Monte Carlo simulation was used to test the behavior of the power calculation. We
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^  Table 2.3: Result of the statistical power analysis: How many consecutive targets are required to detect a single copy number loss or gain, 
o  __________________________________________________________________________
32k BAC 
array
Duplicate 
32k BAC 
array
Affymetrix 
100k SNP 
array
Affymetrix 
250k SNP 
array
NimbleGen 385k 
Oligonucleotide 
array
Patient Loss Gain Loss Gain Loss Gain Loss Gain Loss Gain
1 4 4 3 3 4 6 5 7 n.d n.d
2 4 11 3 4 4 6 4 6 5 13
3 4 5 3 3 4 7 5 7 10 19
4 4 6 3 4 4 6 n.d n.d n.d n.d
5 4 5 3 3 5 8 5 8 11 31
6 3 5 3 3 5 8 4 6 9 27
7 4 5 3 3 4 6 4 6 n.d n.d
8 4 5 3 3 4 6 5 8 8 24
9 4 5 3 4 7 9 4 7 5 8
10 3 5 3 4 4 6 n.d n.d 7 14
11 3 5 3 4 5 7 4 6 7 18
12 3 5 3 4 5 8 4 5 5 16
13 3 4 3 4 5 7 4 7 9 14
average 4 5 3 4 5 7 4 7 8 18
For this analysis we used a power of 95%.
Chapter 2 Microarray Platform Comparison
Figure 2.2: Result of the power analysis of the 4 genomic microarray platforms for detection of a single copy number gain or 
loss contained by different numbers of consecutive targets. The resulting power for a single copy number gain (dotted) and a single 
copy number loss (line) are displayed for the 32k BAC array platform (A), the 100k SNP array (B), the 250k SNP array (C), and 385k 
oligonucleotide array platform (D). The increase in number of targets has a varying impact on the resulting power across the 4 different 
microarray platforms. In addition, the number of consecutive targets required to detect single copy number gains differs considerably from 
the number of targets needed to detect a single copy number loss, and this difference appears to be platform-dependent.
artificially generated 400 samples of size 4 under the null hypothesis with a mean of 
0, and another 400 with a mean resembling a loss, which represents the alternate 
hypothesis. The results of this analysis are illustrated in Supplementary Figure 
1c, where the null hypothesis converges to the expected 5% and the alternative 
hypothesis to 95%. This analysis shows that the power calculation is effective in 
determining the required data points for the successful detection of a copy number 
variation.
Power calculation on experimental data
After having verified the power calculation, and having confirmed that the distribution 
of the experimental noise was normal (Supplementary Figure 2), we applied this 
method to the experimental data set described above. For each sex-mismatched 
experiment we calculated the mean of all unique chromosome X log2 ratios and the 
standard deviation of the autosomal log2 ratios to provide an initial insight into the 
performance of each microarray platform and the values to be used in the power 
calculations (Table 2.2). The average log2 ratios of these chromosome X targets 
were similar for the BAC array platform and the Affymetrix SNP array platform 
(~0.47), whereas the NimbleGen oligonucleotide platform exhibited a lower average 
of approximately 0.38. The average standard deviation of the log2 ratios of the 
autosomal targets varied two-fold between the different microarray platforms. The 
32k BAC platform exhibited the lowest standard deviation, and the 385k NimbleGen 
oligonucleotide platform the highest. In addition, since all BAC array hybridizations 
were performed in duplicate, we were able to determine the influence of replicate 
analyses on the noise level. As can be seen in Table 2.2, the autosomal standard 
deviation is reduced by almost 50% after averaging data from two experiments.
Next, the statistical power analysis was used to determine the minimum number 
of adjacently located autosomal targets required for the reliable detection of a 
single copy number loss or gain (Table 2.3, Supplementary Table 1). An average 
of 4 adjacently located BAC clones showing a single copy number loss provided 
95% confidence of representing a true copy number variation, as did the 250k 
microarray platform. A similar power for detection of a copy number loss required on 
average 5 consecutive SNPs on the 100k microarray platform, and 8 consecutive 
oligonucleotides on the 385k platform. The reliable detection of a single copy 
number gain required more consecutive targets, as could be expected based on 
the theoretical log2 ratio difference between a single copy number loss (-1) and gain 
(0.66). For the 32k BAC, the 100k SNP and 250k SNP array platforms, this increase 
was moderate, with one and two additional targets being required, respectively. For 
the 385k oligonucleotide platforms this increase was considerable, i.e., at least twice 
as many targets were required for reliable detection of a single copy number gain 
(Figure 2.2).
These power analysis results can be translated into genome-wide copy number 
detection resolutions by combining these results with the genomic coverage of the 
different microarray platforms (Table 2.4, Supplementary Table 2, Supplementary 
Figure 3). This resulted for each platform in a probability to detect a single copy
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number gain or a loss throughout the genome with a size range from 10 kb to 1 Mb 
and a desired power of 95%. From this analysis, it can be concluded that (1) high- 
density oligonucleotide/SNP-based platforms are significantly better in detecting 
copy number variations below 1 Mb than the BAC array platform, (2) copy number 
variations smaller than 100kb remain difficult to detect even onto these high-density 
platforms, despite an average target spacing of 7, 12 or 30 kb, and (3) small sized 
single copy number gains are much more difficult to detect than single copy number 
losses of the same size.
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Table 2.4: Probability to detect a single copy number gain or loss with different genomic sizes onto the four platforms.
32k BAC array Affymetrix 100k SNP array
Affymetrix 250k 
SNP array
NimbleGen 385k 
Oligonucleotide array
Loss Gain Loss Gain Loss Gain Loss Gain
10 kb 0.00 0.00 0.03 0.01 0.12 0.02 0.00 0.00
50 kb 0.01 0.00 0.28 0.14 0.68 0.38 0.28 0.00
100 kb 0.02 0.01 0.56 0.39 0.88 0.75 0.94 0.01
200 kb 0.11 0.05 0.81 0.71 0.94 0.91 0.95 0.93
300 kb 0.32 0.16 0.88 0.83 0.95 0.94 0.95 0.94
400 kb 0.60 0.36 0.91 0.88 0.95 0.94 0.95 0.94
500 kb 0.83 0.60 0.93 0.91 0.95 0.95 0.95 0.95
1 Mb 0.95 0.95 0.94 0.94 0.95 0.95 0.95 0.95
This table combines the results from Table 3 with those of Supplementary Table2.
Discussion
We have developed a novel method for establishing the practical resolution of a 
genomic microarray to detect copy number variation and applied this method, based 
on statistical power analysis, to 3 commercially available microarray platforms and 
our in-house BAC microarray platform. For each platform we calculated the number 
of adjacent targets required to reliably detect a single copy number variation (gain 
or loss), given the required minimum rate of false positive and false negatives. 
Based on this calculation, we determined the probability of detecting copy number 
variations of different sizes onto a genomic microarray, taking into account the 
number and genomic position of all targets on the microarray platform used. This 
unbiased resolution statistic is an important performance measure for genomic 
microarray platforms as well as for individual microarray experiments, which had 
not been established for genomic microarrays before. Previously, the resolution 
of a genomic microarray could only be judged by the mean spacing of targets, a 
measure that solely reflects the overall genomic coverage. The results of our power 
analysis, however, clearly demonstrate that the level of noise and the sensitivity 
of copy number measurements co-determine the practical resolution. In addition, 
our analysis revealed an unexpected platform-dependent difference in sensitivity 
to detect a single copy number loss and a single copy number gain. Accurate 
performance measures are not only important for researchers in order to gauge 
the sensitivity and specificity of individual experiments or different platforms. Also 
in a diagnostic setting, where microarray-based genome profiling is rapidly being 
introduced17 30, it will be essential to have a robust estimate of the practical resolution 
of the genome-wide scan.
Several platform comparisons have been performed for gene expression 
microarrays32-35. The statistical methods described in these studies, however, cannot 
be used for genomic microarrays as they do not account for various intrinsic aspects 
of genomic microarrays such as the adjacency of targets and the difference between 
detecting a single copy number loss and a single copy number gain. Several 
statistical methods have been developed for different aspects of genomic microarray 
analysis, such as preprocessing (normalization17 28), automatic detection of copy 
number variations42 43, and the analysis of type I errors across genomic microarrays 
obtained from multiple experiments and samples44. Here we report on a resolution 
statistic for genomic microarrays that uses an approach based upon hypothesis 
testing and statistical power calculations. The method is based on the following 
variables: (1) the genomic coverage of the platform, (2) an estimate of the noise in 
the microarray experiment (the standard deviation of the autosomal targets), (3) an 
estimate of a single copy number loss (ratio of the chromosome X unique regions 
of sex-mismatch experiments39, and (4) the desired statistical power. The method 
requires a normal distribution of the noise, which was confirmed by a Chi-Squared 
test, thereby allowing the use of the t-distributions. We validated our method using a 
Monte Carlo technique to simulate the Type I and Type II detection errors for a single 
copy number loss, requiring a statistical power of 95%. These simulations were in 
agreement with the calculated Type I and Type II errors resulting from a two-sided
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t-Test. The calculations yielded the minimal number of required adjacent targets at 
each locus in order to detect a single copy number variation, taking into account the 
required statistical power38 45. By combining the genomic location of targets with the 
minimally required sample size we obtained an objective genome-wide resolution 
statistic.
We used our method to characterize the detection performance of the 4 genomic 
microarray platforms using experimental data from 13 samples with submicroscopic 
copy number variations hybridized to the different platforms. Automatic copy number 
analyses detected the large majority of known submicroscopic copy number 
variations on all genomic microarray platforms. Two genomic variations were not 
detected by the 100k SNP array platform, due to poor SNP coverage for these 
regions, a problem reported also by others46 (see also Supplementary Figure
3). This can be reduced by simply adding more targets for these regions. Indeed, 
one of the two variations was identified automatically by the 250k SNP array. This 
analysis also revealed considerable and reproducible differences in signal-to-noise 
ratios between the different platforms. Signal-to-noise ratios were highest for the 
BAC array platform, which may be due to a more robust hybridization performance 
of larger genomic fragments as compared to the smaller targets used for the other 
platforms. The Affymetrix SNP arrays containing only 25-mers, however, showed 
signal-to-noise ratios which were only slightly lower than the BAC array platform 
after data normalization using the CNAG package28. It should be noted that no such 
data preprocessing was performed for the NimbleGen oligonucleotide platform which 
displayed the lowest signal-to-noise ratios. This may indicate that preprocessing of 
the data can have a significant effect on the detection resolution of an individual 
genomic microarray experiment and argues for a significant effort to be made in this 
field of genomic microarray data analysis45. In addition, the noise in a genomic 
microarray experiment can be significantly reduced using replicate analyses, as was 
shown for the BAC array platform.
The statistical power analysis indicated that on average 4 consecutive BACs are 
required for the reliable detection of a single copy number loss as are 4 consecutive 
SNP required on the 250k platform. Where as 5 SNP probes are required on the 
Affymetrix 100k, and 8 oligonucleotide probes on the NimbleGen 385k oligonucleotide 
platform. These numbers are markedly different for the detection of single copy 
number gains (see Figure 2.2). This is caused by the fact that the theoretical ratio 
of a single copy number gain (3 vs. 2 copies) is much closer to the random noise 
level than a single copy number loss (1 vs. 2 copies). Therefore it is relatively difficult 
to discriminate between a true copy number gain and random experimental noise. 
This poses a serious problem for those platforms that display a high noise level. The 
estimate for a single copy number loss on the NimbleGen oligonucleotide platform is 
-0.38 and that for a single copy number gain is 0.22, within one standard deviation 
of the mean (0.23 for this platform, see Table 2.2 and Supplementary Table 1). 
As a consequence, reliable detection of a single copy number gain on this platform 
requires 10 consecutive oligonucleotides more (18) than detection of a single copy 
number loss (8). In contrast, the detection of a single copy number gain on the
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BAC array platform with the lowest noise level requires only one consecutive clone 
more (5) than that of a single copy number loss (4). These results demonstrate the 
impact of the different detection limits regarding single losses and gains, resulting 
in more targets being required in the latter case48. It is important to account for this 
asymmetric detection limit caused by the different signal to noise ratios associated 
with gains and losses.
The commercially available microarrays contain 3 to 12 times as many targets as 
our tiling resolution BAC microarray, and this can compensate for the lower signal-to- 
nose level obtained on these platforms. In addition, the targets on these microarrays 
are much smaller in size as compared to BAC clones with an average insert size 
of 170 kb, thereby theoretically allowing the detection of aberrations below 100 
kb. Table 2.4 shows the probability of detecting a single copy number gain or loss 
with different genomic sizes onto the four platforms. This table clearly shows that 
the commercial platforms outperform the BAC array platform for the detection of 
aberrations below 1 Mb in size. The Affymetrix 250k SNP array appeared most 
sensitive for the detection of copy number variations below the 100 kb level, especially 
for copy number gains. However, even on this platform the probability of detecting 
a single copy number gain with a genomic size of 50 kb was only 38% (68% for a 
single copy number loss). Extending this calculation for the 500k Affymetrix SNP 
platform results in a probability of detecting a gain with size of 100kb of 72% and 
87% for a loss (Supplementary Table 2), indicating that even these high-density 
platforms have problems in detecting single copy number variations smaller than 
100 kb. As stated above, the use of replicate measurements and/or improvements in 
data preprocessing can significantly improve the sensitivity of the different genomic 
microarray platforms. We provide a genome wide rating of the detection capabilities 
of a specific microarray platform regardless the type of copy number change being 
detected. However as recently reported, the microarray design such as the decision 
to exclude SNP’s from recurrent normal copy number variant regions remains as 
important factor when selecting the an appropriate microarray platform46.
Next to performance, many other factors may affect the choice for a certain microarray 
platform, including the availability and consistency in quality of microarrays over 
time, the amount and quality of input DNA required, the price, and the access to a 
microarray facility or service company. An important advantage of using a widely 
available commercial platform is that it facilitates data exchange between research 
groups. In addition, the production of arrays containing more than a hundred 
thousand targets is not practically achievable for academic groups, especially since 
most currently available microarray spotters have a practical limitation of ~60,000 
spots per slide. An important bonus of using SNP arrays is that it allows genotyping 
together with CGH. This provides additional information such as copy number 
neutral loss-of-heterozygosity. Besides Affymetrix and NimbleGen companies such 
as Agilent and Illumina have also developed high-density genomic microarrays that 
can be used for CGH applications24 31.
In conclusion, we present a straightforward statistical method for establishing the
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practical resolution of an individual genomic microarray experiment. Application 
of this method to different genomic microarray platforms clearly shows that these 
platforms vary in their capacity to reliably detect copy number variations of different 
sizes and different types. This should be taken into account for estimating the 
practical resolution of a platform to detect genomic copy number variations.
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Abstract
Recently, genomic microarrays have been implemented in the diagnosis of patients 
with unexplained mental retardation. This diagnosis, although revolutionizing 
cytogenetics, is still limited towards the detection of rare de novo CNVs. This is 
mainly due to the fact that our molecular and clinical understanding of other forms 
of genomic variation linked to disease is still far from complete. Genome-wide 
SNP microarrays have the advantage that they allow us to obtain high-resolution 
genotype as well as CNV information in a single experiment. We hypothesize that the 
widespread use of these microarray platforms can be exploited to greatly improve our 
understanding of the genetic causes of mental retardation and many other common 
disorders, while already providing a robust platform for routine diagnostics. Here we 
report a detailed validation of Affymetrix 500K SNP microarrays for the detection of 
CNVs associated to mental retardation. After this validation we applied the same 
platform in a multicenter study to test a total of 120 patients with unexplained mental 
retardation and their parents. Rare de novo CNVs were identified in 15% of cases, 
showing the importance of this approach in daily clinical practice. In addition, much 
more genomic variation was observed in these patients as well as their parents. 
We provide all of these data for the research community to jointly enhance our 
understanding of these genomic variants and their potential role in this common 
disorder.
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Introduction
Rare de novo copy number variations (CNVs) are a frequent cause of many common 
neurological disorders, including autism12, schizophrenia34 and mental retardation 
(MR)56. Clinically relevant CNVs can occur throughout the human genome, with a 
theoretical minimum genomic size of approximately 1 kb78. Optimal detection of these 
CNVs thus requires high-resolution genome-wide technologies such as genomic 
microarrays or paired-end sequencing. Diagnostic application of these technologies 
additionally requires a high level of robustness, reproducibility and straightforward 
interpretation (see Lee et al., 20 079 as well as Koolen et al., 200810 for a review of 
literature on the application of genomic microarray to MR and a practical workflow 
for diagnostic applications).
Genomic microarray technology has greatly matured over the past decade and 
many diagnostic genetics laboratories have started to implement this technology 
into a routine diagnostic setting. Commercially available oligonucleotide arrays are 
increasingly being used as they can be produced according to industrial quality 
standards, offer very high genomic coverage and resolution and are available to all 
laboratories. Widespread implementation of such arrays will generate large reference 
datasets that will greatly facilitate clinical interpretation. Several genomic microarray 
platform comparisons have been recently published, indicating that all widely used 
high-resolution platforms are powerful tools when screening for CNVs larger than 
1 Mb11-14. However, significant differences are observed between platforms for the 
detection of CNVs smaller than 1 Mb, due to differences in sensitivity and specificity, 
differences in number of probes per array as well as the distribution of the probes 
throughout the genome. Importantly, none of the high-resolution platforms has 
been adequately tested so far for applications in a clinical setting. In this setting the 
reliable detection of single copy number changes in a single genomic region is of 
crucial importance. Here, we present a multicenter study in which three European 
diagnostic centres assessed the use of Affymetrix Mapping 500K SNP arrays for 
molecular karyotyping in patients with MR.
First, we tested the sensitivity of this technology in a blinded fashion using 38 
previously identified submicroscopic copy number variations (CNVs) associated 
to MR. These validation samples included those with CNVs at genomic regions 
associated with mental retardation such as subtelomeric regions and known 
microdeletion/duplication syndromes, as well as rare de novo CNVs previously 
identified by tiling-resolution and 1 Mb genome wide BAC arrays. In a second phase 
of our study, each centre tested DNA from 40 patients with unexplained mental 
retardation together with their parents. The SNP genotype information present 
on the Affymetrix arrays was used to test the added power of combining intensity 
based copy number analysis with genotyping data specific to SNP-based microarray 
platforms. Our results validate the use of this platform for applications in a postnatal 
diagnostic setting. The significant diagnostic yield in our application study, as well 
as the added value of the genotype information, demonstrate its advantages over
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conventional cytogenetics as well as a number of advantages over non-SNP based 
platforms.
Methods
Patients
Validation study
For validation purposes we selected 38 patients harbouring a total of 44 previously 
identified CNVs associated to MR. The genomic regions affected included those 
associated with known MR syndromes (n=7), frequently affected subtelomeric 
regions (n=20) as well as interstitial regions throughout the human genome (n=17). 
The large majority of cases were selected to harbour submicroscopic CNVs, not 
detectable by routine karyotyping. Techniques initially used to detect these CNVs 
included whole genome tiling-path BAC array, 1Mb coverage BAC array, targeted 
multiplex ligation-dependent probe amplification (MLPA), and targeted fluorescent in 
situ hybridisation (FISH) (see Table 3.1).
Application study
For application purposes we prospectively included 120 patients with unexplained MR 
and their parents, 40 trios from each of the three collaborative centers (Department 
of Human Genetics, Nijmegen, The Netherlands, Department of Medical Genetics, 
Tübingen, Germany and West Midlands Regional Genetics Services, Birmingham, 
United Kingdom). The majority of patients and parents were of Caucasian descent. All 
patients had normal G-banded karyotypes and no consanguinity was self-reported. 
Patients were referred by clinical geneticists and a clinical scoring system based on 
the presence of family history of MR, prenatal-onset growth retardation, postnatal 
growth retardation or advanced growth, facial dysmorphism and multiple congenital 
abnormalities (MCA) was applied with scores ranging from 0 to 1015 (Supplementary 
Figure 2). Genomic DNA was isolated from peripheral blood leucocytes using routine 
procedures and quality was assessed by NanoDrop spectrophotometer (ND-1000) 
optical density metrics and gel electrophoresis.
A ffym etrix 500K SNP arrays
Study design
For the validation study DNA of all 38 cases was hybridized to the Affymetrix 
GeneChip human mapping 500K array set (Affymetrix, Santa Clara, USA), consisting 
of 2 arrays, one that uses Nsp1 and one that uses Sty1 restriction enzyme. For the 
application study DNA from all 120 patients was also hybridized to both the Nsp1 
and the Sty1 arrays to give a combined 500K coverage. In addition, 60 maternal 
samples (20 from each centre) were also processed at 500K resolution to generate 
site-specific pooled reference data sets. The remaining 60 maternal samples and all
120 paternal samples were processed only onto the 250K Nsp1 array to determine 
CNV inheritance and genotype-generated loss of heterozygosity (LOH). All data are
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available with GEO accession id GSE13117.
SNP array methodology
Samples were processed in accordance with the manufacturer’s instructions. In 
brief, 250ng of genomic DNA was digested with Nsp1 and/or Sty1 and then ligated to 
adaptors. Generic primers recognizing the enzyme specific adaptor sequences were 
used to amplify adaptor-ligated DNA. After purification, 90^g of PCR product was 
fragmented and labelled with biotin. Hybridization was performed in the Affymetrix 
GeneChip Hybridization Oven 640 and arrays were washed and stained in the 
Affymetrix GeneChip Fluidics Station 450. Arrays were scanned with the Affymetrix 
GeneChip Scanner 3000 7G. Hardware scripts were enabled and image processing 
was performed via Affymetrix GeneChip Command Console Software (AGCC). 
Genotypes were called with Affymetrix Genotyping Console Software v2.1(GTC) 
using the BRLMM algorithm with default calling threshold of 0.5 and a prior size of 
10,000 bases. Samples were required to have a minimum Quality Control SNP call 
rate of 90%.
Data Analysis
Copy number analysis
To assess optimal application of SNP array methodology in the clinical context two 
commonly used copy number specific software packages were used. All samples 
were analysed with both Copy Number Analyzer for GeneChip (CNAG) v2.016, and 
the Affymetrix CN4 algorithms within GTC v2.1. The predicted copy numbers as 
well as the start and end of each CNV segment were determined using the Hidden 
Markov Model (HMM) incorporated in each package. In all datasets hg18 was used, 
were necessary segments were remapped to the correct human genome build. 
We used the 60 maternal samples processed on both Nsp1 and Sty1 arrays as an 
in silico reference set for genome wide copy number analysis. In addition, the X 
chromosome in male patients was analyzed in CNAG using the paternal samples 
as reference, thus limiting the male chromosome X analysis to the 250k Nsp1 array 
data. Within CNAG, we compared the influence of the reference sample selection, 
see description in the Results section and Supplementary Table 1. The standard 
deviation (SD) of log2 test-over-reference autosomal ratios as calculated in CNAG 
was used as a measure of the noise. Only samples with a SD < 0.20 were included 
in the analysis.
Analysis of CNV inheritance and frequency in control cohorts 
Each CNV larger than 100 kb identified in a patient with unexplained MR was collected 
(Supplementary Table 2) and compared to (1) the CNVs identified in his or her 
unaffected parents, (2) the CNVs identified in the other 238 unaffected parents and 
(3) a collection of benign CNVs from 270 unaffected HapMap samples, previously 
identified on a very similar platform, the Affymetrix 500K EA array set17. CNVs not 
overlapping by more than 50% with these three sample collections were considered 
rare de novo CNVs associated to MR (Figure 3.1 and Table 3.2), whereas the 
remaining inherited CNVs can either be common CNVs or rare, privately inherited 
CNVs (Table 3.3 and Supplementary Table 3).
68
Table 3.1. Results from the Validation Study; 38 cases with known deletions and duplications, the segments are reported as identified 
using the Hidden Markov Model (HMM) algorithm within Affymetrix Genotyping Console (GTC) v2 .1, in base pairs, and then compared to 
the segment identified using CNAG, including the resulting difference in gene count contained within each segment.
cn
vo
Known
syndrome,
telomere,
interstitial
Diff. in Diff. Diff. in Diff. Diff. in
# gene 
CNAG - 
GTC
ID HMMState
Start
Position
GTC
End
Position
GTC
Genomic 
Size GTC
start 
pos. 
CNAG -
in end 
pos. 
CNAG -
# SNP 
GTC
start 
SNP 
CNAG -
in end 
SNP 
CNAG
#
Gene
GTC
GTC GTC GTC -G T C
1
1 pter 
deletion 1 742,429 3,167,340 2,424,911 0 30,983 156 0 8 83 0
2
Interstitial
deletion 1 18,209,490 20,345,766 2,136,276 25,156 18,663 514 20 2 27 1
2
Interstitial
deletion
1 27,114,596 30,092,630 2,978,034 35,397 9,166 298 1 2 52 3
3
1 qter 
deletion 1 239,717,641 246,933,526 7,215,885 22,061 6,262 1140 7 1 91 0
4
Interstitial
duplication
Interstitial
deletion
32,460,827 33,205,175 744,348 36,114 20,123 109 2 8 3 0
5 1 148,867,828 150,007,686 1,139,858 0 0 136 0 0 5 0
6
Interstitial
deletion
1 238,078,077 242,663,303 4,585,226 0 33,487 658 5 3 67 0
6
10pter
duplication
214,961 3,475,920 3,260,959 113,006 20,150 989 0 4 20 1
7
2qter
deletion 1 240,394,885 242,663,303 2,268,418 81,324 0 300 8 0 44 1
8
Interstitial
deletion
1 165,341,177 165,651,851 310,674 24,229 47,602 32 11 7 0 0
9
3qter
deletion
1 197,132,905 198,812,612 1,679,707 98,263 0 154 4 0 27 3
10 W HS(1) 1 900,520 5,882,422 4,981,902 134,651 61,571 869 5 4 69 7
10
Interstitial
duplication
3 6,528,873 8,020,633 1,491,760 36,781 31,291 153 3 14 6 0
11
5qter
duplication
3 170,466,335 171,832,929 1,366,594 103,742 21,573 276 11 2 11 0
12
6 pter
H p l p t i n n
1 110,391 1,922,442 1,812,051 0 28,328 480 0 6 12 0
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Known . p .
syndrome, HMM „ % „  GenomicID . , * Position Positiontelomere, State Size GTC. . .... . b io  b iointerstitial
,|2 Interstitial 
duplication 
Interstitial14
duplication 
WBS®^  V V D O
duplication
16 WBS 
deletion
17 Spter 
deletion 
Interstitial 
deletion
19 9Pter 
duplication
20 11 Pter
duplication
20 9pter
duplication
20 9pter 
deletion
21 9P‘er 
duplication
2 2  Interstitial 
deletion
23 9qter 
duplication
2 4  9q‘er 
deletion
25 10pte 
deletion
26 Hqter 
deletion
2 7 12pter 
deletion
3 44,098,177 57,184,511 13,086,334
3 90,707,871 91,425,176 717,305
3 72,393,456 73,927,865 1,534,409
1 72,393,456 73,771,865 1,378,409
1 180,568 7,278,542 7,097,974
1 70,035,287 72,733,698 2,698,411
3 30,910 445,196 414,286
3 878,150 1,101,474 223,324
1 30,910 14,841,892 14,810,982
3 14,980,485 38,761,831 23,781,346
3 30,910 4,360,901 4,329,991
1 117,147,386 117,826,670 679,284
3 133,105,930 140,207,187 7,101,257
1 139,496,489 140,207,187 710,698
1 101,955 768,091 666,136
1 125,243,828 134,449,982 9,206,154
1 36,594 320,584 283,990
Table 3.1 continued
Diff. in 
start 
pos. 
CNAG - 
GTC
Diff. 
in end 
pos. 
CNAG - 
GTC
# SNP 
GTC
Diff. in 
start 
SNP 
CNAG - 
GTC
Diff. 
in end 
SNP 
CNAG 
-G T C
#
Gene
GTC
Diff. in
# gene 
CNAG - 
GTC
0 173,836 1812 0 21 93 1
51,288 37,449 179 8 14 2 0
0 0 84 0 0 26 0
0 156,000 83 0 1 24 2
0 0 2590 0 0 47 0
35,478 0 464 5 0 12 0
0 5,681 90 0 1 4 0
62,373 0 29 2 0 4 6
0 0 4209 0 0 60 0
127,080 0 5072 21 0 186 1
0 21,748 1471 0 6 19 0
38,843 54,960 152 2 1 2 0
105,873 0 908 8 0 158 1
0 0 70 0 0 12 0
0 7,112 121 0 5 4 0
38,438 0 2105 6 0 57 2
0 0 56 0 0 4 0
Table 3.1 continued
Known
syndrome,
telomere,
interstitial
Diff. in Diff. Diff. in Diff. Diff. in
# gene 
CNAG - 
GTC
ID HMMState
Start
Position
GTC
End
Position
GTC
Genomic 
Size GTC
start 
pos. 
CNAG -
in end 
pos. 
CNAG -
# SNP 
GTC
start 
SNP 
CNAG -
in end 
SNP 
CNAG
#
Gene
GTC
GTC GTC GTC -G T C
28
Interstitial
deletion
1 46,380,084 62,010,635 15,630,551 10,334 0 2496 3 0 65 0
29 PWS® 1 21,205,735 26,203,954 4,998,219 0 0 891 0 0 17 0
30 CMT1 A (4) 3 14,093,529 15,451,581 1,358,052 54,527 29,747 321 5 3 8 2
31 SMS<5> 1 15,876,995 18,308,103 2,431,108 32,668 78,168 240 5 2 53 4
32
Interstitial
deletion
1 40,897,439 41,630,337 732,898 48,555 17,566 193 2 5 12 2
33
Interstitial
duplication
3 69,391,769 70,142,026 750,257 46,173 33,336 131 18 10 13 0
34
Interstitial
duplication
3 29,309,964 32,377,195 3,067,231 374 67 0 41,889 0 1 1
35
20qter
duplication
3 53,553,699 62,376,958 8,823,259 1636 138 22,479 0 21 0 0
35
22qter
deletion
1 42,672,731 49,576,671 6,903,940 1506 90 115,053 0 8 0 2
36 d g s (6) 1 17,270,967 20,139,185 2,868,218 340 76 0 119,456 0 1 4
37
Interstitial
deletion
1 6,492,092 8,051,924 1,559,832 162 6 0 0 0 0 0
38
Interstitial
deletion
1 7,103,716 10,736,275 3,632,559 392 16 0 0 0 0 0
('W olf-H irschhorn Syndrome,(2)Willams-Beuren Syndrome, (3)Prader Willi Syndrome, (4)Charcot-Marie-Tooth Syndrome Type 1A, (5)Smith-Magenis Syndrome, 
(6)DiGeorge Syndrome
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Deletion confirmation by genotype analysis, paternal concordance check, parent- 
of-origin analysis, homozygosity mapping and UPD analysis 
The use of a SNP-based array platform and the availability of patient-parents trios 
allowed us to use the genotyping information for a number of additional analyses 
besides the intensity-based CNV analysis. These additional analyses included 
(1) confirmation of heterozygous deletion CNVs by detection of hemizygosity, (2) 
paternal concordance check, (3) parent-of-origin detection for both loss and gain 
CNVs and (4) homozygosity mapping and (segmental) UPD analysis.
Confirmation of deletion CNVs by detection of homozygosity 
By definition, a single copy number deletion should result in an absence of 
heterozygous SNP calls for the SNPs in the deleted region. We determined the 
number of heterozygous SNP calls for all deletion CNV regions associated to MR in 
the validation study as well as all de novo deletion CNV regions in the application 
study.
Paternal Concordance Check
In order to make sure that a CNV was not wrongly classified as de novo for a 
patient due to a sample mix-up or incorrect paternity information, paternity testing 
was carried out. This analysis was performed using standard procedures with both 
the “Sample Mismatch Report” and the “Pedigree Check”, tools available in the 
Affymetrix GTYPE software.
Parent-of-origin detection
To determine whether the maternal or the paternal allele was affected by the de novo 
copy number change, genotyping calls were generated via the BRLMM algorithm 
and exported for each trio in the respective de novo region. This procedure was 
performed for all de novo single copy losses and single copy gains. Only homozygous 
calls were considered when analysing a de novo single copy loss. For each probe 
within the region the genotype call of the affected individual was compared to its 
parents and ignored if non-informative, classified as a Mendelian error or used to 
determine the preserved parental allele18. In order to determine the parent-of-origin 
for a single copy gain, the heterozygous genotype calls were combined with the 
allele contrast score (see Affymetrix Genotyping Console Manual). By using the 
allele contrast score the duplicated allele in the affected individual was identified 
(either A or B), then the origin of the duplicated allele was determined by inspecting 
the genotypes of the parents or classified as a Mendelian error or non-informative.
Homozygosity mapping and uniparental disomy (UPD) analysis 
Continuous segments of homozygosity were identified in all samples using a sliding 
window of 100 targets with a positive LOH state indicated by GTC. The complement 
of homozygous segments was taken with identified copy number loss segments, 
producing a set of copy neutral homozygous segments (Supplementary Table
4). Samples with more than 3 times the standard deviation in the average length 
or the number of homozygous regions were considered outliers (Supplementary
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Figure 1). The parental samples (excluding outliers) were used as a reference set 
of common homozygous regions. Rare regions of homozygosity in patients were 
identified by calculating the overlap between segments of homozygosity found in 
patients compared to the parental segments (Figure 3.1 and Table 3.3). A 50% 
overlap was used to identify similar regions. The detection of segmental UPD 
(isodisomy) was performed similarly to the detection of parent-of-origin for a single 
copy number loss19. The inheritance of each SNP was calculated using genotyping 
calls for homozygous regions, excluding any heterozygous calls, and summed over 
the region to determine which parental allele is the source of the UPD.
Confirmation experiments
Different techniques were applied to validate the rare de novo CNVs associated to 
MR, varying from targeted FISH, MLPA or quantitative PCR analysis to 1 Mb BAC 
arrays and Affymetrix 6.0 SNP arrays. All approaches were performed according to 
routine procedures.
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Figure 3.1. Example cases of rare de novo CNVs, rare inherited CNVs and rare 
copy number neutral homozygous regions, as identified in patients with MR. These 
chromosome plots were obtained using the CNAG software package (Nannya et al., 200528). 
Each case consists of 4 panels; In the top panel the normalized and log2-transformed 
patient-over-reference intensity ratio for each SNP is displayed (in red) according to its 
chromosomal position. This plot also shows the result of the statistical HMM algorithm in 
blue, with a normal copy at the 0-line, a copy number loss going down and a gain going 
up. Below this plot, a moving average of these intensity ratios from 10 adjacent SNPs 
is displayed (in blue). Below each chromosome drawing with indicated banding pattern 
is shown, and on the bottom all heterozygous SNPs are displayed (in green) to identify 
stretches of homozygosity. The pink as well as the blue horizontal bars below these plots 
show homozygous regions detected with high confidence.
A-D) Examples of rare de novo CNVs smaller than 1 Mb: (A) Patient B18 with a 671 kb 
de novo duplication at 8q21, (B) Patient B28 with a 163 kb de novo deletion at 9q34, (C)
74
patient T32 with a 163 kb de novo deletion at 16q23, and (D) patient T14 with a 750 kb de 
novo deletion at 17p13.
E-H) Examples of rare inherited CNVs larger than 1 Mb: (E) patient T26 with a 3.1 Mb rare 
inherited deletion at 16p13, (F) patient N16 with a 5.9 Mb rare inherited deletion at 4q22, 
(G) patient B14 with a 1.5 Mb rare inherited duplication at 16q22, and (H) patient N20 with 
a 1.3 Mb rare inherited duplication at 3p14.
I-L) Examples of rare copy number neutral homozygous regions larger than 1 Mb: (I) patient 
T9 with a 10.7 Mb rare copy neutral homozygous region at 3q13, (J) patient T38 with a 5.3 
Mb rare copy neutral homozygous region at 7q21, partially overlapping with a rare inherited 
duplication, (K) patient T6 with a 8.7 Mb rare copy neutral homozygous region at 3q12, and 
(L) patient N17 with a 7.8 Mb rare copy neutral homozygous region at 16p13.
75
C
hapter 3 
M
ulti-C
enter S
tudy
Results
The main goal of our study was to validate and apply Affymetrix 500K SNP arrays 
for routine diagnostic copy number profiling in patients with unexplained MR. For 
this we first performed a Validation Study for which we selected 38 DNA samples 
with mostly submicroscopic CNVs known to be associated with MR. These samples 
were hybridized onto the Affymetrix 500K SNP arrays and analyzed in a blinded 
fashion using two different software packages and compared to results from previous 
analyses. Next, we prospectively selected 120 patients with unexplained MR and 
their parents, 40 from each center participating in this study, for an Application Study 
using the same microarray platform. Although our main goal was to use the microarray 
data for copy number analysis, genotype data collected from these microarrays was 
used for confirming paternal concordance, parent-of-origin analysis, homozygosity 
screening and uniparental disomy (UPD) analysis.
Validation Study
The 38 samples harbouring CNVs associated with known microdeletion and/or 
microduplication syndromes, rare de novo CNVs throughout the genome including 
subtelomeric CNVs, were hybridized onto Affymetrix 500K SNP arrays and analyzed 
using both the CNAG software package v2.016 and the Affymetrix CN4 algorithm 
within GTC v2.1. As reference pool we used data from the 60 maternal samples 
run for the Application Study. After identification of all CNVs per sample using the 
HMM algorithm incorporated in both software packages, we compared the results 
obtained for both to the results of the previous studies performed on these samples. 
All previously identified submicroscopic CNVs associated to disease (n=44) were 
identified both with CNAG and with CN4 (Table 3.1). The genomic length of these 
causative CNVs varied between 223 kb and 23 Mb, and included 11 CNVs smaller 
than 1 Mb (6 deletions, 5 duplications). High resolution array analysis allowed for a 
more precise estimation of the genomic content of each CNV than most previous 
studies, an important factor when determining the clinical and biological interpretation 
of CNVs and their role in disease. There were, however, some discrepancies between 
the results using the two different software packages. Of the 88 genomic breakpoints 
associated with these 44 CNVs, 38 breakpoints matched perfectly in both packages, 
with the same start or end SNP identified. For the remaining 50 breakpoints, the 
difference was less than 100 kb for 41 breakpoints. For 9 breakpoints the difference 
was larger than 100kb, with the largest difference being 173 kb between the genomic 
position of the last SNP detected by CNAG and the last SNP detected by CN4 for the 
same case, carrying a 13 Mb duplication (case 13, Table 3.1). This analysis shows 
that identification of CNVs larger than 200 kb is straightforward using 500K SNP 
arrays in combination with either the CNAG or CN4 algorithms, but fine-mapping 
of the exact genomic content involved is not perfect and this should be taken into 
account when interpreting patient results in a clinical setting.
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Application Study
Study set-up
After having validated the use of Affymetrix 500K SNP arrays to identify CNVs 
associated to MR, we decided to further evaluate the potential of this approach 
in the three different genetic institutes involved. In each center, 40 patients with 
unexplained MR and a normal karyotype were prospectively collected together with 
their parents for analysis onto the 500K platform. The analyses were performed 
by each center separately. In our study we used a combined reference pool of all 
unaffected mothers per institute for analysis of CNVs on the autosomes as well 
as on chromosome X in female patients. An additional analysis of chromosome X 
CNVs was performed in male patients using an institute-specific combined paternal 
reference pool. The influence of the reference sample choice on the quality of the 
copy number profiling results was evaluated in CNAG (Supplementary Table 
1 ). This analysis clearly indicated that it is essential to use locally run reference 
samples, as the standard deviation of the intensity-based copy number ratios is two 
times lower when compared to reference samples from one of the other institutes. 
Employing this approach, we collected all CNVs in the 120 patients and 240 parents 
using the CNAG package.
Identification of rare de novo CNVs associated to MR
We identified a total of 735 CNVs in the 120 patients using the CNAG software 
package, of which 363 were larger than 100 kb in genomic size (mean 3 CNVs > 100 
kb per patient). Similarly, 1043 CNVs were identified in the 240 parents, of which 602 
were larger than 100 kb (mean 2.5 CNVs > 100 kb per parent). All CNVs identified 
in both patients and parents are listed in Supplementary Table 2. For patient CNVs 
larger than 100 kb we determined whether there was a 50% or greater overlap 
with CNVs observed in either parent. In addition we tested whether any CNV > 
100kb overlapped by 50% or greater with CNVs present in any of the remaining 238 
parents, or with CNVs detected in a large cohort of 270 unaffected individuals from 
the HapMap study which were analyzed via the 500K EA SNP platform17. From these 
analyses 31 potential rare de novo CNVs were detected by both CNAG and CN4. 
Visual inspection of these 31 regions in the parent samples showed that although 11 
regions were not identified automatically by the HMM algorithm, the intensity ratios 
clearly indicated a similar CNV in one of the parents. The 20 remaining regions 
included one complete gain of chromosome Y in a male patient as identified by 
an aberrant ratio for the pseudo-autosomal region on Xpter, and 19 more subtle 
CNVs in a total of 18 patients, varying in size from 163 kb to 13 Mb (Table 3.2 
and Figure 3.1). In one patient two relatively large CNVs on chromosome 18 were 
observed that, although originally missed by routine karyotyping, could in retrospect 
be detected at the limits of conventional cytogenetic analysis. Again, the genomic 
position of the start and end of the majority of these CNVs differed when using either 
CNAG or CN4, with a median difference in genomic position of 35 kb at either end. 
All these CNVs were validated independently by either FISH, qPCR, MLPA, 1 Mb 
BAC arrays or Affymetrix 6.0 SNP arrays. We used the genotyping information to 
confirm paternal concordance in all cases and perform a parent-of-origin analysis. 
Table 3.2 shows that there was complete paternal concordance in our series. There
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Table 3.2. Results of the Application Study; 19 Clinically relevant CNVs identified in 18 patients with unexplained MR. Each segment 
oo is reported as identified using the Hidden Markov Model(HMM) algorithm within Affymetrix Genotyping Console (GTC) v2.1, in base 
pairs, and then compared with the finding from CNAG v2.0, with the total parental cohort and with the Hapmap cohort. The results of the 
parent-of- origin analysis identifying the affected allele and the age of the identified parent at birth of the affected child is shown with a 
short clinical description.
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Severe MR, GR, MC, FD,
lq21.3 152,762,910 154,137,040 1,374,130 47 -39,241 28,899 -3 no no Pat 22 ACC, BP, ASD, polydactyly,
syringomyelie(8)
/Dim 1 lcl43 239,588,948 243,904,424 4,315,476 28 -27,917 7,782 0 no no Pat 31 Moderate(BIO) H epilepsy, MC, FD, ASD(4)
3 
(B l)
4
(B32)
Severe MR, GR, FD,
1 2q22.3 146,517,837 152,184,376 5,666,539 16 -77,075 73,959 0 no no Mat 36 pulmonary valve stenosis
(7)
Severe MR, GR (prenatal),
1 3pl4.2 59,891,354 65,530,765 5,639,411 17 -61,419 17,181 -1 no no Pat 27 autism, hydronephrosis,
hypospadias (5)
5 Severe MR, epilepsy, MC1 5ql4.3 86,979,034 88,550,068 1,571,034 2 -98,745 0 0 no no Pat 25 H y*
(B20) (2)
Severe MR, ACC, FD,
1 7 q ll.2 3  72,393,456 73,927,865 1,534,409 26 0 156,000 -2 no no Mat 17 hydronephrosis, Total
(B40) Anomalous Pulmonary
Venous Drainage (5) 
Moderate MR, epilepsy,
8q21.13 81,240,524 81,893,055 652,531 3 0 -19,180 0 no no Mat 41 BP, FD, hydronephrosis,
7
(B18)
syndactyly fingers/toes (4)
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8
(B24)
1 9q34.3 139,496,489 139,653,450 156,961 6 -90,148 -96,329 -1 no no ND
Severe MR, hyptonia, 
autism, BP, FD (2)
9
(N18)
1 llq 24 .1 121,419,135 134,449,982 13,030,847 120 -25,303 0 0 no no Pat 34
Moderate MR, GR, FD, 
trigonocephaly (6)
10
(B26)
1 12q24.21 114,108,592 116,337,327 2,228,735 10 -46,377 4,077 0 no no Mat 26
Moderate MR, BP, FD, 
hydronephrosis (3)
11
(N40)
3 15q23 65,668,983 67,091,259 1,422,276 13 116,869 -107,247 3 no no Mat 35
Severe MR, autism, FD, 
trachea anomaly (4)
12
(N39)
1 16pl3.3 26,671 1,675,672 1,649,001 90 0 133,077 -3 no no Pat 25
Severe MR, hypotonia, FD, 
cryptorchidism (5)
13
(T2)
3 16q23.2 79,820,017 88,690,776 8,870,759 118 7,980 0 0 no no Pat 42
Moderate MR, FD, ASD, 
hypospadias (6)
14
(T32)
1 16q23.3 81,618,912 81,870,986 252,074 1 -47,848 41,159 0 no no ND
Severe MR, FD, behavioural 
problems (1)
15
(T14)
1 17pl3.3 1,150,367 1,977,257 826,890 25 -76,578 0 -1 no no Mat 28 Moderate MR, GR, FD (5)
16
(T7)
3 18pll.32 150,887 10,140,262 9,989,375 43 0 0 0 no no Pat
Moderate MR, FD, atresia 
auditory canal, clubfeet (4)
16
(T7)
1 18q22.3 69,885,704 76,115,554 6,229,850 36 -52,349 0 0 no no Pat
17
(B16)
1 19pl3.2 8,413,177 13,704,233 5,291,056 150 -362,652 1,732,9952 -53 no no Mat 33
Moderate MR, GR, FD, ASD, 
hypospadias (6)
18
(N27)
3 Xql3.2 72,582,914 72,864,085 281,171 2 431,297 -56,384 4 no no Pat 33
Severe MR, hypotonia, MC, 
cerebral atrophy (2)
vi
VO
1CNVs not overlapping by more than 5 0 % ,2 Sample contains high level o f experimental noise and characteristic wave pattern in log2 ratios, see discussion 
section. Abbreviations:Pat=Paternal, Mat=Maternal, ND=Not Determined, MR=Mental Retardation, GR=Growth Retardation, MC=Microcephaly, FD=Facial 
Dysmorphism, ACC=Agenesis Corpus Callosum, BP=Behavioural Problems, ASD=Atrium Septum Defect
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was no evidence for any parent-of-origin bias in our series: For the 15 de novo CNVs 
in which parent-of-origin could be established 8 CNVs originated on maternally 
inherited chromosomes and 7 on paternally inherited chromosomes. The mean age 
of these 15 parents at their affected child’s birth was 30.
The presence of rare inherited CNVs
In addition to rare de novo CNVs we were also interested in inherited CNVs that were 
only observed in single trios and not reported in the HapMap control data reported by 
Redon etal. 200617. The clinical relevance of these private CNVs is yet unclear; some 
may contribute to the MR phenotype but show incomplete penetrance or uncover as 
yet undescribed mutations on a remaining allele in the case of deletions. In total 
we observed 42 such rare inherited CNVs larger than 100 kb, seven of which were 
larger than 1 Mb (Figure 3.1, Table 3.3 and Supplementary Table 3). The largest 
rare inherited CNV was a 5.8 Mb deletion at 4q22.3 that affected 9 refseq genes. A 
comparison of these 42 regions with a previously collected list of 148 rare de novo 
CNVs associated with MR10 did not reveal any overlap in size of more than 95%.
Homozygosity Mapping
We used the LOH-analysis tool in GTC to identify large stretches of homozygosity in 
both patients and parents. For ease of comparison we only used the results from the 
Nsp1 array as this was performed for all patients and parents. The HMM algorithm 
within the LOH-analysis tool identifies these stretches automatically, and we collected 
all regions containing a minimum of 100 SNPs. After excluding homozygosity caused 
by deletions, we identified 5,306 copy-number neutral homozygous regions in the
120 patients (mean of 44 regions per patient), and 10,099 in the 240 parents (mean 
of 42 per parent), see distribution of these regions in Supplementary Table 4). 
The size of these regions varied between 0.2 Mb and 80 Mb, with an average of 
1.5 Mb, see Supplementary Figure 1 for the distribution of copy number neutral 
homozygous regions per patient and parent. One sample (B39) included a total of 83 
homozygous regions of which 22 were larger than 10 Mb, indicating consanguinity. 
After excluding this patient and two other outlier patients, one with 94 homozygous 
regions (B37) and another one with 5 homozygous regions larger than 10 Mb (T37), 
as well as all cases in which we already identified a rare de novo CNV, we observed
121 homozygous regions in a total of 72 patients that did not overlap for more than 
50% with the homozygous regions identified in the parental cohort (examples in 
Figure 3.1, overview in Supplementary Table 5). For all of these 121 regions we 
studied the pattern of inheritance to determine whether the homozygosity could be 
caused by partial or segmental UPD; however no indication was obtained to support 
this hypothesis in any of the regions. Of interest, rare homozygous regions in two 
patients had more than 95% overlap with a deletion CNV previously associated with 
MR (T17:Chr12p13.33, overlap with deletion CNV in (Wagenstaller et al., 20076); 
N1:Chr19p13.11-p12, overlap with deletion CNV in (Hoyer et al., 200720)).
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Table 3.3. The 10 largest rare inherited CNVs and the 10 largest rare copy neutral 
homozygous segments identified in patients with unexplained mental retardation 
from the application study.
Patient
ID Chr Start Pos End Pos Size
HMM 
State in 
Patient
Parent
-of-
Origin
Top 10 largest rare inherited CNVs
N16 4q22.1q23 93,769,725 99,661,778 5,892,053 1 Pat
T26 16p13.11p12.3 15,403,659 18,514,090 3,110,431 1 Mat
B14 16q22.3q23.1 72,838,074 74,355,880 1,517,806 3 Pat
T38 7q21.13 88,032,648 89,529,352 1,496,704 3 Mat
N20 3p14.2 59,680,884 60,996,377 1,315,493 3 Pat
B2 7p11.2 56,468,013 57,730,637 1,262,624 3 Mat
B34 14q13.2q13.3 34,745,315 35,617,682 872,367 3 Pat
B33 1p35.3p35.2 29,730,945 30,532,350 801,405 3 Mat
N7 13q32.3q33.1 100,391,121 101,046,536 655,415 3 Mat
T32 18q23 74,706,295 75,314,143 607,848 3 Mat
Top 10 largest rare copy number neutral homozygous regions
T9 3q13.31q21.3 116,886,618 127,669,194 10,782,576
T6 3q12.1q13.13 100,884,328 109,645,892 8,761,564
N5 6q14.1q15 80,765,046 89,245,413 8,480,367
N38 6q23.1q23.3 130,469,917 138,558,934 8,089,017
N17 16p13.2p13.11 6,523,126 14,365,573 7,842,447
B30 11q14.3q22.1 91,322,451 98,111,333 6,788,882
N20 12q12q13.11 40,005,793 45,929,200 5,923,407
B30 8q24.12q24.13 120,803,465 126,623,221 5,819,756
T38 7q21.11q21.13 83,496,605 88,841,520 5,344,915
B30 3p24.3 16,644,022 21,974,899 5,330,877
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Discussion
Genomic microarray analysis is rapidly replacing conventional chromosome analysis 
by karyotyping due to the dramatic increase in the power to detect causative CNVs 
in neurological disorders like mental retardation21. Using tiling resolution BAC arrays5 
estimated that the diagnostic yield of this approach in the population of patients with 
MR is at least twice as high as that of standard GTG-banded karyotyping. There is 
an increasing global trend towards the use of oligonucleotide microarrays targeting 
shorter genomic sequences or SNPs and with considerably higher genome wide 
coverage and theoretical resolution than BAC arrays. Hence the diagnostic yield 
may even be higher than was calculated using the BAC arrays.
In this multicenter study we extensively validated the Affymetrix 500K SNP array 
platform for potential diagnostic application in patients with undiagnosed mental 
retardation. The first and foremost goal of our application study was to use these 
arrays for reliable genomewide detection of rare de novo CNVs in patients with 
MR, using a genomic size threshold of 100 kb. The identification of a (1) relatively 
large, (2) rare and (3) de novo CNV in such a patient is a strong indicator of clinical 
significance, as this combination is extremely rare in the normal population due to a 
low structural mutation rate22 23. In addition, we also wanted to assess the presence 
of rare or privately inherited CNVs, as an increasing number of genomic loci were 
recently reported with variable inheritance and penetrance. Examples of this have 
been reported for CNVs at 1q21.124, 15q13.325, and 16p13.1126 27. Furthermore, 
the genotype information obtained using these microarrays allowed us to obtain 
a detailed insight into the presence of large homozygous regions in the genomes 
of these patients. The clinical relevance of rare inherited CNVs as well as rare 
homozygous regions is largely eluding us at present. All of our SNP and CNV data is 
freely available because larger numbers of cases and controls are needed to unravel 
the potential role of these genomic variants in the aetiology of mental retardation.
Our validation study showed 100% detection of all 44 previously detected CNVs 
present in 38 samples. Our application study revealed de novo CNVs >100kb in 
size (range 163 kb to 13 Mb) in a total of 18 patients Detection of these CNVs in 
both studies was independent of the software package used, but the two software 
packages suggested a different start and/or end breakpoint in the majority of cases 
(18 kb median difference in breakpoint position for the validation CNVs). The most 
extreme difference was observed for a de novo CNV on chromosome 19, with a 
360 kb difference in start position and a 1.7 Mb difference in end position using both 
software packages. Visual inspection of the genomic profile of this sample revealed 
a typical wave-like pattern, as has been described by Marioni et al., 200728. It can 
perhaps be expected that CNV detection will be most troublesome in noisy samples 
and this case is definitely an outlier in our series, but even a limited discrepancy 
between the result of different software packages may affect clinical interpretation of 
the CNVs. Precise mapping of CNVs is important when determining overlap with CNV 
in parents and control cohorts, as well as for determining the functional content in 
these regions and performing detailed genotype-phenotype correlations. Our results
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and those of others29 indicate that further optimization of automatic copy number 
detection algorithms is required for optimal CNV identification and characterization 
via genome wide microarray platforms. At present we suggest performing CNV 
identification with two software packages and/or to include the gene content of the 
surrounding 100 kb for clinical/molecular interpretation. Ideally a second technology 
should be used for fine-mapping each CNV but this cannot be expected to become 
a standard procedure in most diagnostic laboratories. The use of microarrays with 
even higher coverage such as the Affymetrix SNP 6.0 will likely result in an improved 
mapping of CNVs and thereby overcome this problem, at least for CNVs larger than 
100 kb30. Our analysis also showed the importance of using local reference samples 
for obtaining the lowest noise in the test-over-reference intensity ratios for all SNPs 
used to identify CNVs. Independently hybridized reference samples are a necessity 
for microarray platforms using single colour hybridizations and our data indicate that 
these should be run in parallel with test samples on a regular basis.
We limited ourselves to the analysis and follow-up of CNVs with a minimum size 
of 100 kb as they are most reliably detected onto this platform12, even though the 
presence of many smaller CNVs was indicated by both software packages. Using 
this 100 kb threshold, our application study revealed rare de novo CNVs in a total 
of 18 patients, varying in size from 163 kb to 13 Mb. The diagnostic yield of de 
novo CNVs in our study is 15%, which is slightly higher than the average reported 
by previous genome-wide microarray studies (see for an overview Koolen et al., 
200810). Five of our rare de novo CNVs were smaller than 1 Mb, of which two were 
approximately 160 kb in size, at the lower limits of detection by BAC arrays, even 
with tiling path coverage12. For genotype-phenotype correlation studies the smallest 
CNVs are likely of greatest value, as their limited genomic content will more easily 
point to candidate gene(s). Five CNVs in our study contained less than 10 genes, 
and our smallest CNV, validated by qPCR, only affected two exons of a single gene, 
CDH13, member of the cadherin superfamily. This particular cadherin is a putative 
mediator of cell-cell interaction in the heart and may act as a negative regulator of 
neural cell growth31. The girl has no speech development until the age of 5 years, 
her gait is unsteady. She was microcephalic at birth, head circumference at 5 
years is in the lower normal range. She displays mild EEG abnormalities, seizures 
have not been observed. Case 8 had a de novo interstitial deletion of five genes 
at 9q34.3 including the EHMT1 gene, shown to be causative of the craniofacial 
features associated with the 9q subtelomeric deletion syndrome32. Interestingly, in 
this particular case previous 9q subtelomeric FISH was carried out based on clinical 
suspicion of this syndrome. This analysis, however, did not identify the subtle de 
novo deletion due to the fact that the subtelomeric FISH clone did not target this 
region, highlighting the limitations of targeted approaches such as FISH and MLPA, 
particularly when there may be a correlation between deletion size and severity of 
the phenotype33. These results and that of others6 strongly support the notion that 
the use of higher resolution oligonucleotide microarrays increases the diagnostic 
yield of rare de novo CNVs in patients with unexplained mental retardation and aids 
in genotype-phenotype correlation studies. Another interesting example was case 6 
with a 1.4 Mb de novo deletion at 7q11.23, usually associated with Williams-Beuren
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syndrome. This particular case has a more severe phenotype than usually observed 
in patients with this syndrome and he has a less severely affected brother who 
does not carry the 7q11.23 deletion (data not shown).This suggests an additional 
causative mutation, possibly X-linked, which remains undetected in this family 
and may be masking the classic Williams-Beuren phenotype in the more severely 
affected sib. This case illustrates the utility of a whole genome approach in detecting 
imbalances associated with well delineated syndromes in atypical cases. Apart from 
rare de novo CNVs, recent studies have indicated that it is also of clinical importance 
to study inherited CNVs, especially when they are rare in the normal population24-27. 
One genomic region of 1.5-1.6 Mb for which this may be the case is 16p13.11. 
A deletion of this region, even if inherited, appears to be a risk factor for mental 
retardation. The effect of a duplication in this region is unclear; it may be associated 
with autism26, but it may also be a rare benign variant27. In our study we detected 
one maternally inherited deletion of 3 Mb that completely overlaps this region. The 
mother of the index patient is healthy, family history is uneventful. The patient was 
born at 31 weeks of gestation. Pregnancy was complicated by oligohydramnion and 
intrauterine growth retardation, and motor and speech development were delayed. 
MRI revealed a general brain atrophy with pachygyria and molar tooth sign, not 
typical for 16p13.11 cases.
Our unique approach of testing patient-parent trios onto high resolution genome 
wide microarrays allowed us to obtain a detailed insight in the distribution and 
frequency of privately inherited CNVs in a largely Caucasian population. A total 
of 42 rare inherited CNVs >100 kb were detected in our series of 120 patients, 
so one in three carried such a private CNV. This frequency is much higher than it 
was previously reported using lower resolution microarrays34 35, demonstrating that 
private CNVs are very frequent at higher resolution and emphasizing that routine 
parental analysis is of utmost importance for clinical interpretation of the CNVs 
(see also Lee et al., 20079; Koolen et al., 200810), especially when most control 
cohorts contain CNV data from less than 1,000 individuals. The rare inherited CNVs 
observed in our study occurred randomly throughout the genome involving almost 
all chromosomes, and the majority (65%) were copy number gains, consistent with 
previous reports35. The median size of copy number gains was twice that of copy 
number losses, consistent with the accepted theory of gain of genetic material being 
generally better tolerated than loss. The largest rare inherited CNV in our study, 
however, is a 5.9 Mb deletion at 4q22.1q23. This deletion affects nine refseq genes, 
including the GRID2 or delta2 glutamate receptor gene that plays a crucial role in the 
induction of cerebellar long-term depression, a form of synaptic plasticity underlying 
motor learning36. The patient was hypotonic as a neonate and had, subsequently, a 
delay in early motor development. His father with the similar deletion did not have 
any cognitive problems. So at this moment it remains unclear whether this deletion 
contributed to the early problems in this young child.
In addition to CNVs, the SNP microarray platform also allows the use of genotype 
information for various analyses. This is especially useful when parental samples 
have been analyzed on the same array platform. In all patients with de novo CNVs
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paternity was concordant. The genotypic data also allowed us to confirm deletion 
CNVs and to determine the parent-of-origin in 15 out of the 17 cases, as we 
developed an algorithm to do this both for deletions and duplications. The parent-of- 
origin was impossible to detect in the two smallest CNVs due to a lack of sufficient 
informative SNPs. This analysis did not indicate a gender specific parent-of-origin 
bias in our cohort. Determining the parent-of-origin is of practical use in diagnostics 
as it will limit cytogenetic follow-up analyses (e.g. analysis of potential predisposing 
rearrangements by FISH) to a single parent. Perhaps most interestingly, the 
genotypic data allowed us to perform a genome-wide analysis of copy number 
neutral homozygous regions in patients and their parents. This analysis identified 
three patients with an unusual number of homozygous regions and/or unusually large 
homozygous segments (Supplementary Figure 1), which indicate consanguinity 
and may be of importance for further counselling and genetic analysis. Similarly, 
McQuillan et al., 200837, recently described the identification of outlier cases with 
large stretches of homozygosity (>5 Mb) in 4% of the Scottish samples studied. After 
excluding these outlier cases, we identified a total of 121 homozygous regions in the 
patients that did not overlap for more than 50% with homozygous regions identified 
in the 240 parents. As there are also several homozygous regions in the unaffected 
parents that do not overlap with those in the patients, the identification of these 
regions does not suggest any direct clinical relevance. However recording these 
regions may be of later use, particularly in detecting regions harbouring imprinted 
or genes inherited in an autosomal recessive manner. As an example, we identified 
two rare homozygous regions which completely overlapped with previously reported 
de novo deletion CNVs in patients with mental retardation6 20.
In conclusion, this study validates the use of Affymetrix 500K SNP arrays for the 
diagnosis of rare de novo CNVs >100 kb in patients with unexplained mental 
retardation. Further studies are needed in order to reveal the clinical significance of 
rare inherited CNVs and of homozygous regions present in the genomes of these 
patients.
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Abstract
Copy number variation is a dominant contributor to genomic variation and may fre­
quently underlie an individual’s variable susceptibilities to disease. Here we question 
our previous proposition that copy number variants (CNVs) are often retained in the 
human population because of their adaptive benefit. We show that genic biases of 
CNVs are best explained, not by positive selection, but by reduced efficiency of se­
lection in eliminating deleterious changes from the human population. Of four CNV 
data sets examined, three exhibit significant increases in protein evolutionary rates. 
These increases appear to be attributable to the frequent coincidence of CNVs with 
segmental duplications (SDs) that recombine infrequently. Furthermore, human or­
thologs of mouse genes, which, when disrupted, result in pre- or postnatal lethality, 
are unusually depleted in CNVs. Together, these findings support a model of re­
duced purifying selection (Hill-Robertson interference) within copy number variable 
regions that are enriched in nonessential genes, allowing both the fixation of slightly 
deleterious substitutions and increased drift of CNV alleles. Additionally, all four CNV 
sets exhibited increased rates of interspecies chromosomal rearrangement and nu­
cleotide substitution and an increased gene density. We observe that sequences 
with high G+C contents are most prone to copy number variation. In particular, fre­
quently duplicated human SD sequence, or CNVs that are large and/or observed 
frequently, tend to be elevated in G+C content. In contrast, SD sequences that ap­
pear fixed in the human population lie more frequently within low G+C sequence. 
These findings provide an overarching view of how CNVs arise and segregate in the 
human population.
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Introduction
Copy number variants (CNVs) contribute more than single nucleotide polymorphisms 
to the number of bases differing between a pair of human genomes12, and as such 
are expected to contribute substantially to phenotypic variation. CNVs have been 
identified for a large proportion (up to 12%)1 of the human euchromatic sequence, 
together encompassing up to 1,5003, 1,8004, or 2,9001 genes. Most individual CNVs, 
however, are observed only rarely (<1%) in the human population56. Given the large 
size and abundance of CNVs in each human genome it is unsurprising that copy 
number variation is associated with disease susceptibility7-17. Nevertheless, if we are 
to better appreciate the broader relevance of CNVs to human disease, it is essential 
that we better understand the biases underlying their detection, how they arise and 
segregate in the human population, as well as the selective processes that act upon 
them.
Copy number variation has not been observed uniformly within the human genome. 
It is particularly concentrated near proximally duplicated regions518-21, especially seg­
mental duplications (SDs), defined as duplicated sequences sharing >90% identity 
over at least 1 kb in the reference human genome assembly22 23. This assembly is a 
mosaic comprised of sequence from multiple individuals’ genomes. Consequently, it 
is expected that some SDs in the reference assembly represent duplication alleles. 
However, owing to the rarity of most CNV alleles, the frequent coincidence of human 
CNVs and reference assembly SDs is not a trivial result. The nonuniform distribu­
tion of CNVs may arise from nearby repetitive sequences, facilitating a duplication 
or deletion via nonallelic homologous recombination (NAHR)24-26. CNVs, SDs, and, 
indeed, other fragile portions of genomes such as synteny breakpoints, are also 
associated with further mutational biases, such as elevated nucleotide substitution 
rates6 27 28. Genomic regions both rich in SDs and prone to recombination are ex­
pected also to be enriched in CNVs, as allelic homologous recombination and NAHR 
are intimately related29.
We previously presented evidence that positive selection of CNVs has occurred 
within the modern human population6. For that study we considered a set of 627 
human CNV regions (CNVRs), collated from a variety of sources that had used 
diverse experimental protocols. We argued that their significantly increased den­
sity of genes, particularly those encoding secreted products and those possessing 
functions involved in the sensing of the environment, suggested the past action of 
positive selection. This conclusion was also consistent with elevated rates of protein 
evolution for these regions, estimated over the long time period spanning the human 
and mouse lineages. For this we assumed that these rate elevations were caused in 
great part by episodes of positive selection on amino acid substitution, and that these 
ancient episodes mirror more recent episodes of positive selection on copy number 
change30 31. As these effects were most pronounced for the more frequent CNVRs 
(those observed on at least two occasions), we further argued that CNVs might have 
been driven to high frequency in the human population as a consequence of their 
adaptive benefit. In that publication, we did not consider whether selection on human
94
CNVs is dominated instead by reduced purifying selection.
We felt it important to revisit this issue using recently available and genome-wide 
data sets, each acquired using a different experimental protocol. In addition to a 
new set of CNVs, we analyzed the properties of three previously described sets 
of CNVs13. This allowed us to investigate whether biases associated with different 
array-based platforms could influence our evolutionary conclusions. The origin and 
rates of fixation of CNVs were also addressed by analyzing the large numbers of 
SDs that are apparent from the human genome reference sequence. By exploiting 
both CNV and SD data, we reconsidered whether nonadaptive processes, rather 
than positive selection, might underlie our previous observations. We were particu­
larly concerned by four potential confounding factors. First, we were concerned that 
CNVs’ increased gene densities might have arisen simply because of a positive 
correlation with the G+C nucleotide content30 32, although our previous study had 
not revealed such a G+C content bias. We also needed to reconsider the issue of 
gene density in the light of recent reports from Redon et al. (2006)1 and Conrad et 
al. (2006)33 that some CNV sets are gene poor, not gene rich. Second, there was a 
need to consider whether selective and mutational forces have acted differentially 
on small versus large, or rarely versus frequently observed CNVs. Third, CNV genes 
might have acquired an elevated number of deleterious rather than advantageous 
amino acid changes if they have often been subject to reduced rates of recombina­
tion (“Hill-Robertson interference”)34-36. Finally, the concentration of CNVs in certain 
genomic regions, and their enrichments in “environmental” genes, might reflect se­
lective in addition to mutational biases. Specifically, CNV regions may be largely 
spared from strong constraint on copy number that applies to the remaining bulk of 
the genome.
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Results
We divide our studies between those investigating the mutational processes of how 
CNVs arise and others seeking to understand the impact of selection on CNVs. We 
first introduce the CNV data sets we use, and then we describe a nucleotide content- 
dependent bias on how frequently CNVs arise in a genomic region. Subsequently, 
we question whether CNVs have been negatively or positively selected in the human 
population. For these studies we also took advantage of SDs from the reference hu­
man genome sequence, considering these to be duplications that either were fixed 
or remain polymorphic in the human population.
CNV data sets
Analyses were performed on four CNV data sets identified by either Redon et al. 
(2006) (two sets) or by Wong et al. (2007), or by ourselves (Table 4.1). For each set, 
overlapping CNVs were merged (see Methods) in order to obtain nonoverlapping 
CNVRs (Table 4.1). In order to consider platform-specific biases, we considered 
CNVs identified by Redon and colleagues separately by each platform. Our own pre­
viously unpublished data set contains 1,276 “Nijmegen” CNVs that were identified 
as a by-product of a study of diagnostic genome profiling in mental retardation9, and 
were purged of those variants that arose spontaneously, and thus might be causally 
linked to disease (see Methods; Supplemental Table 1).
As expected, CNVs identified using the Affymetrix SNP array platform tended to be 
smaller than those found with array comparative genomic hybridization (aCGH). In 
contrast, Nijmegen CNVRs were larger and were observed less frequently (Supple­
mental Figure 1; Table 4.1), likely owing to a more stringent CNV calling protocol 
and to the use of a pooled set of genomes as reference in these aCGH experiments, 
respectively (see Methods). For three of the four sets, the majority of CNVs lay with­
in CNVRs in which both gain and loss CNVs are observed (Table 4.1). These “gain- 
and-loss CNVRs” might represent instances where the reference genomes contain 
both CNV alleles and where subject genomes are homozygous for one allele. How­
ever, many gain-and-loss CNVRs contain at least one CNV pair whose boundaries 
are not equivalent (94%, 64%, 95%, and 36% of CNVRs for the Nijmegen, Redon 
et al. aCGH, Redon et al. Affymetrix, and Wong et al. data sets, respectively). Even 
when the inaccuracies of CNV boundary determination are considered, it appears 
likely that gain-and-loss CNVRs often reflect recurrent CNV changes, rather than 
heterozygosity in the reference genomes. We, and others, have demonstrated that 
CNV changes can be recurrent37 38.
Mutational biases
SDs frequently coincide both with CNVs and with breakpoints in conserved synteny 
for mammalian chromosomes27 39. Thus, we were interested in whether an increased 
density of synteny breakpoints would be found within CNVRs. Indeed, all four CN- 
VRs sets contain more breakpoints in synteny between dog and human chromo­
somes than expected by chance alone (P < 2x10-3) (Figure 4.1A,B; Supplemental 
Table 2). (To establish this significance and that for subsequent observations un-
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Table 4.1. Properties of CNV and CNVR sets for Nijmegen, Wong et al., Redon et al. Affymetrix, and Redon et al. aCGH data. ^
cn
Median Percent of CNVRs 
percent G+C 
content (SD/ 
non-SD)
Percent of 
the CNVs 
contained in 
the gain-and- 
loss CNVRs 
subset
Set Experimen­tal type
No. of CNVs/ 
no. or CN­
VRs
size (in kb)/ 
total size (in 
Mb) of the 
CNVRs
CNVRs with 
an observed 
frequency > 
1%
Percent of 
SD bases of 
the CNVRs
Fold SD bases 
coverage3
Nijmegen
aCGH, 32K 
clones
1276/144 812/145 20 20
44.04
(44.49/40.10)
4.21 88
Redon et 
al. Affyme­
trix
SNP, 500k 
Affymetrix
6461/883 59/153 26 25
40.91 
(41.62/39.63)
4.52 56
Redon et 
al. aCGH
aCGH, 26K 
clones
18,735/993 225/301 38 30
41.74
(42.58/40.00)
4.46 73
Wong et al.
aCGH, 26K 
clones
5132/4433 169/754 37 7
41.49
(42.68/40.93)
3.98 17
For each data set, the array technique used to detect CNVs and the number of CNVs identified are shown. Values for properties such 
as sizes, proportion having a population frequency > 1%, percentage of bases overlapping SDs, G+C content (overall and split accord­
ing to their overlap with SDs), and fold coverage in SDs are presented for each of the four CNVR sets. The fold coverage in SDs is 
calculated by dividing the total size of SDs by the total size of merged overlapping SDs for each CNVR set.
aWong et al. restricted some of their downstream analyses only to those CNVRs that they observed at least three times, whereas we 
have considered all of their published CNVs.
Figure 4.1. The departures from expected values for the coincidence of CNVRs with 
human and dog synteny breakpoints (A,B) and human and dog orthologs' synonymous 
substitution rates within CNVRs (C,D), calculated for sets of Nijmegen CNVRs and Redon 
et al. aCGH CNVRs. Results are shown as percentage differences from values expected 
by random sampling of the human genome reference assembly (see Methods). (A,C) 
Nijmegen aCGH CNVRs; (B,D) Redon et al. aCGH CNVRs. For either Nijmegen or Redon 
et al. aCGH data, the set of genomic regions are: “All CNVRs,” all CNV regions; “Rare 
CNVRs,” genomic regions in which CNVs were identified in <1%  of the individuals sampled; 
“Frequent CNVRs,” CNVRs in which CNVs were identified in >1% of the individuals 
sampled; “CNVRs with SDs,” CNV regions overlapping with at least one SD; “CNVRs 
without SDs,” CNV regions having no overlap with SDs; and “All SDRs,” the set of all 8051 
SD regions (shown accompanying each CNVR set). Bars annotated with an asterisk (*) 
are significant at P < 0.025.
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less otherwise stated, we constructed 500 randomly sampled sets of nonoverlap­
ping genomic segments matched in number and in size to each of the CNVR sets 
considered; no set of random segments possessed as many breakpoints in synteny 
as any of the CNVR sets [i.e., P < 2x10-3].) By partitioning the four sets of CNVRs 
according to their overlap with SDs (see Methods), we found that, as expected, it is 
only those CNVR subsets that also overlap SDs that are significantly enriched with 
synteny breakpoints (Figure 4.1A,B). The frequent coincidence of CNVRs, SDs, 
and synteny breakpoints indicate that the most recently fragile regions of the human 
genome have also been fragile throughout mammalian evolutionary history.
Genomic regions that are prone to copy number variation are known to possess high 
rates of nucleotide substitution6 27 40. Each of the four sets of CNVRs we analyzed ex­
hibit this bias, with median synonymous nucleotide substitution rates being elevated 
by between 11% and 45% (Figure 4.1C,D). Genes present in SDs also exhibit in­
creased synonymous substitution rates (+38% elevation), and similar elevations are 
observed for orthologous transposable elements (“ancestral repeats”) in CNVRs and 
in SDs (data not shown). As most of the CNVR sets exhibit unexpectedly high G+C 
contents (see below), these elevated rates are due, in part, to the well-established 
positive correlation between G+C or CpG contents and substitution rates40 41. How­
ever, even for CNVRs that do not possess unusual G+C contents, such as those 
reported from the Redon et al. (2006) Affymetrix platform and even for CNVRs lack­
ing SDs (see below), substitution rates remain significantly elevated. These findings 
suggest that a common cellular mechanism could underlie the increased rates of 
substitution and copy number changes in these regions6.
G+C content bias
The CNVR set we analyzed previously6, and those identified by Redon et al. (2006) 
or Wong et al. 2007), have each been reported to possess nucleotide contents that 
reflect the G+C content of the genome as a whole. It came as a surprise, therefore, 
to observe that each of the three aCGH CNVRs sets is actually enriched in G+C con­
tent. To assess the departure of their G+C contents, we performed randomizations 
as before. The median G+C content for each randomized genomic set was found to 
be 40.9% (Figure 4.2).
The elevation of G+C content is significant for each of the three aCGH CNV sets (P 
< 2x10-3). Nijmegen CNVRs exhibit the largest G+C content of 44.0%, ~3% higher 
than expected from the genome-wide randomized samples; Wong et al. (2007) and 
Redon et al. (2006) aCGH CNVRs possess G+C contents of 41.5% and 41.7%, re­
spectively. The increase in G+C for the Nijmegen set is substantial, since only 20.6% 
of 50kb windows in the human genome possess a G+C content higher than 44.0%. 
No significant nucleotide G+C bias was, however, observed for the CNVRs from the 
Redon et al. Affymetrix set: Their G+C content of 40.9% exactly matches the value 
expected by random sampling.
The largest G+C content increases are always associated with CNVRs that are ob­
served frequently; hence, rarely (<1%) observed CNVRs possess the lowest G+C
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Figure 4.2. Percentage of G+C contents for CNVRs and SDRs compared with size- 
matched randomized sets for Nijmegen CNVRs (indicated within black arrows), Redon 
et al. Affymetrix CNVRs (cyan), Redon et al. aCGH (green), Wong et al. CNVRs (red), 
and SDRs (pink). The first column shows G+C contents for the entire sets. The G+C 
contents of CNVR sets partitioned according to frequency are shown in the second and 
third columns (“Frequent,” CNVRs at >1% observed population frequency; “Rare,” CNVRs 
at <1% observed population frequency). The fourth and fifth columns show G+C contents 
of CNVR sets partitioned according to their overlap, or not, with SDs. Additionally, the G+C 
contents of SDRs overlapped, or not, by CNVs, are shown in the fourth and fifth columns, 
respectively. The frequency distribution of the G+C contents for 500 randomly sampled 
sets of genomic regions, matched in size to Nijmegen CNVRs (gray density curve) and to 
SDRs (pink density curve), are also shown.
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contents (Figure 4.2). This contrast is particularly pronounced for Nijmegen CNVRs 
(46.0% for frequent vs. 43.2% for rarely observed CNVRs) (Figure 4.2). We also 
note that for all four data sources, CNVR partitions that overlap SDs exhibit marked 
increases in G+C content, whereas those outside of SDs exhibit reduced G+C con­
tents (Figure 4.2). The four CNVR sets are associated with very different amounts 
of SDs, but all are significantly higher than the 5.3% of human SDs present genome- 
wide (P < 2x10-3)42. A total of 20%, 25%, 30%, and 7% of Nijmegen, Redon et al. 
Affymetrix, Redon et al. aCGH, and Wong et al. CNVR bases, respectively, lie within 
segmentally duplicated sequence (see also Cheng et al. 200543; Sharp et al. 20 055). 
For all CNVR partitions outside of SDs the G+C content is lower than the genome 
average and is significantly so for each of the two Redon et al. CNVR sets (P < 2x10- 
3). The high G+C content of CNVRs could thus be interpreted as being simply due to 
the substantial overlap between CNVRs and SDs.
Faster turnover of G+C-rich sequence in SDs
This observation led us to investigate the G+C contents of SDs, despite these se­
quences not having previously been noted as containing an increased G+C con­
tent. For this analysis we constructed segmentally duplicated regions (SDRs) from 
overlapping SDs exactly as was previously done for CNVs. Compared with the 
randomized distribution, the G+C content of SDRs is indeed significantly elevated 
(+1.7%, P < 2x10-3) (Figure 4.2).
Why might CNVs observed by aCGH exhibit such pronounced increases in G+C 
content, while CNVRs identified on a single nucleotide polymorphism platform do 
not? Similarly, why might SD-containing CNVRs possess a high G+C content? We 
looked to the biases of size that are inherent in experimental designs to explain 
these differences. We do, indeed, observe that CNVRs of increasingly larger size 
possess elevated G+C content. Plotting the median size of CNVs underlying these 
CNVRs against their median G+C content shows that the G+C content increases 
approximately linearly with CNV size (Figure 4.3). This trend does not simply re­
flect ascertainment biases between platforms, because it is also apparent for data 
acquired with a single platform (Figure 4.3). Thus, across single and multiple data 
sets there appears to be a strong trend for larger CNVs to contain an unusually high 
G+C content.
If the highest G+C portions of the human genome have been particularly susceptible 
to copy number variation in the human population, then we would expect SDs that 
are fixed in the human population to be relatively depleted in G+C content compared 
with SDs that are copy number variable. To examine this proposition, we use as a 
proxy for fixed SDs all SDs that lie outside of any CNV present among the four data 
sets we examined. As expected, nonfixed SDs possess a significantly higher G+C 
content than apparently fixed SDs (43.1% and 41.7%, respectively; P = 1x10-7).
We also might expect sequence containing higher proportions of G or C bases to 
have been more frequently duplicated. To compare genomic regions that have suf­
fered large numbers of SD events with those whose extant duplications have been
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Median CNV size per CNVR in kb
Figure 4.3. Relationships between CNVR size and G+C content. We partitioned by CNVR 
size the Redon et al. aCGH set into four equally populated bins; this data set was chosen, 
as it provides CNVRs covering the broadest logarithmic range of size variation. Differences 
in G+C content between each of the two largest bins when compared with either of the two 
smallest bins are significant (P < 4 103). Even when discarding segmentally duplicated 
bases, the two larger CNVR sets exhibit significantly increased G+C content (Nijmegen 
set, 44.2%; Redon et al. aCGH set, 41.5%; P < 1 103). For each data set, the median size 
of CNVs within a CNVR is plotted against the CNVs' median G+C content (filled circles). 
Redon et al. aCGH CNVRs were also partitioned into four equally populated bins according 
to median CNV sizes (open circles).
102
far less numerous, we computed, for each base pair, the number of overlapping SDs. 
Next, we calculated the G+C content of sequence that either was overlapped by SDs 
more than 12 times, or else once only. We argue that if no G+C-dependencies ex­
ist on deletion or duplication rates, then the G+C content of these two sets should 
be equivalent. Instead, the G+C content of >12-fold SD coverage regions is 2.1% 
higher than that for one fold coverage SD regions (44.5% vs. 42.4%, P < x10-16). We 
conclude that genomic regions possessing high G+C content have been unusually 
susceptible to segmental duplication and, more particularly, to copy number variation 
in the human population.
We observe a positive correlation between G+C content and CNV size (Pearson’s r 
= 0.18, P = 4x10-8; Figure 4.3) and a higher G+C content of CNVRs that overlap SDs 
than of CNVRs that do not. It is thus unsurprising that we also observe a significant 
correlation between the percentage of SD bases within a CNVR and the median 
CNV size within each CNVR (r = 0.25, P = 1x10-14). However, examining first order 
partial correlations, we find that the correlation between G+C content and CNV size 
remains significant even when accounting for SD content (r = 0.16, P < 10-4), as does 
the correlation between SD content and CNV size when accounting for G+C content 
(r = 0.24, P < 10-4). Thus, genomic regions high in either G+C content or SD content 
may be particularly susceptible to the generation of larger CNVs.
A nonadaptive explanation fo r elevated evolutionary rates of CNV genes
We previously showed that genes located within CNVRs tend to exhibit significantly 
elevated rates of protein evolution, as measured using dN/dS ratios (Nguyen et al. 
20 066). For this work we exploited a set of high-quality orthologous gene assign­
ments determined between human and dog Ensembl genes44-46. Due to the shorter 
mutational distance between human and dog (median dS = 0.35) compared with that 
between human and mouse (median dS = 0.56)47, we expect the assignment of or- 
thology between the former species’ pair to be more accurate. By comparing dN/dS 
distributions for genes from different CNVR sets against dN/dS values for all human 
genes (see Supplemental Table 2), we showed that the tendency for increased dN/ 
dS values was also exhibited by genes from the two Redon et al. CNVR sets (me­
dian dN/dS value increases of +25% and +55% for Affymetrix and aCGH data sets, 
respectively; P < 10-10; Kolmogorov-Smirnov [KS] test) (Figure 4.4A). This tendency, 
however, was not found for the two remaining sets (Nijmegen CNVRs, 2%; Wong et 
al. CNVRs, +1%; Figure 4.4A).
To investigate these platform-specific findings we partitioned CNVRs according to 
their overlap with segmentally duplicated sequence. We chose to do this because 
human SD genes exhibit a significant and substantial increase in dN/dS, with a me­
dian value (0.25) over twice that expected from the genome as a whole (0.12) (Fig­
ure 4.4A; Supplemental Table 2) (see also Armengol et al. 200527). Dividing the 
CNVRs from each of the four platforms conditional on their overlap with SDs results 
in eight partitions. Of these CNVR subsets, six accord with a pattern of elevated 
dN/dS values in CNVRs overlapping SDs, and decreased dN/dS values in CNVRs 
lying outside of SDs (Figure 4.4B). We will interpret this pattern observed for the
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Figure 4.4. The departures from expected values for evolutionary rates, recombination 
rates, and disease gene count estimated within Nijmegen CNVRs, Redon et al. Affymetrix 
CNVRs, Redon et al. aCGH CNVRs, Wong et al. CNVRs and SDRs. Evolutionary rates 
and disease gene counts have been obtained only for genes that entirely lie within these 
CNVRs. Results are shown as percentage differences from values expected from random 
sampling of the human genome reference assembly (see Methods). (A) Departures of the 
rate of protein evolution (dN/dS), recombination rate per base (cM/bp) and disease gene 
count are shown as percentage differences from the value expected from random sampling 
of the human genome. Bars annotated with an asterisk (*) are significant at P < 0.025. 
(B) Departures of the same properties as in A, after splitting the different CNVR data sets 
according to their overlap with SDs.
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six CNVR subsets under a model of reduced purifying selection and will thereafter 
return to discuss the remaining two subsets.
The elevation in dN/dS ratios for CNV genes that overlap with SDs might have arisen 
from relaxation of constraints or from positive selection on amino acid substitutions. 
A third possibility is that the dN/dS elevation is due to an increased rate of fixation of 
deleterious, rather than adaptive, substitutions because of unusually low rates of re­
combination (“Hill-Robertson interference”)34-36. Reduced rates of cross-over could 
arise mechanistically simply because polymorphic copy number variants interfere 
with homologous strand invasion26 29 48-50. This third explanation predicts that when 
median dN/dS values are elevated, human recombination rates are reduced, and 
vice versa. Indeed, this inverse relationship was found to hold true for all but one 
of the eight CNVR sets that either overlap, or do not overlap, SDs (Figure 4.4B). 
Hill-Robertson interference thus offers a plausible and nonadaptive explanation for 
the elevated evolutionary rates of protein-coding genes lying within SD regions. We 
emphasize that it appears to be the tendency of infrequently recombining regions, 
SDs, and CNVs to coincide that underlies both the increase in dN/dS ratios of genes 
lying in CNVs and the decrease in dN/dS ratios of genes outside of CNVs.
As we highlight above, two subsets, namely, Nijmegen CNVRs that overlap SDs and 
Redon et al. Affymetrix CNVRs that do not overlap SDs, diverge from our proposed 
model of reduced purifying selection inside SDs, and strong purifying selection out­
side SDs (Figure 4.4B). With regard to Nijmegen CNVRs that overlap SDs, these are 
distinguished from the other sets not only because of their larger sizes, but because 
of their significantly lower proportions of segmentally duplicated bases (Nijmegen: 
0.8%; Wong et al.: 1.5%; Redon et al. aCGH: 1.6%; Redon et al. Affymetrix 4.8%; 
P < 2 x10-4). They are thus expected to be among the least influenced by the ef­
fects of low recombination on increasing dN/dS ratios within segmentally duplicated 
sequence. Finally, we return to the observation that Redon et al. Affymetrix CNVRs 
that do not overlap SDs encompass genes tending to show higher than expected 
dN/dS ratios (Figure 4.4B). We believe this observation arises from this SNP-based 
platform’s preference for sampling relatively short CNVRs (Figure 4.3) that contain 
shorter human genes whose protein evolutionary rates tend to be higher. In support 
of this, we considered all human-dog orthologs and found that the shortest 50% 
of such genes lying outside of human SD sequences tend to possess significantly 
higher dN/dS ratios than the longest 50% of such genes (0.09 vs. 0.13, respectively, 
KS-test P < 1x10-16).
Reduced selection explains the functional biases o f CNVR genes
CNV genes are enriched in “environmental” functions and encode unexpectedly 
large numbers of secreted proteins4 6 51 52. We, and others, previously interpreted 
these observations as indicating that positive selection on duplications has occurred 
for these particular gene categories30 31. However, we need to consider whether 
these enrichments might instead have arisen from nonuniform negative selection 
on gene copy changes: Duplication or deletion of nonenvironmental genes might 
be more frequently deleterious than copy number changes of environmental genes.
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Figure 4.5. The departures from expected values for the coincidence of CNVRs with 
segmentally duplicated basepairs (A,B) and with Ensembl protein-coding genes (C,D), 
calculated for sets of Nijmegen CNVRs and Redon et al. aCGH CNVRs. Results are 
shown as percentage differences from values expected by random sampling of the human 
genome reference assembly (see Methods). (A,C) Nijmegen aCGH CNVRs; (B,D) Redon 
et al. aCGH CNVRs. CNVR sets are described in the legend to Figure 4.2. Bars annotated 
with an asterisk (*) are significant at P < 0.025.
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To distinguish between these two possibilities, we took advantage of phenotypic 
information from two sources that relate to the deleteriousness of gene disruptions. 
First, we identified a set of “essential genes,” defined as human orthologs of mouse 
genes that, when disrupted, result in either pre- or postnatal lethality53. We also 
considered a set of “disease genes” representing human genes that, when mutated, 
have been associated with Mendelian disease; as such disruptions less frequently 
result in pre- or postnatal lethality, it is expected that purifying selection on mutations 
is considerably stronger on essential genes than it is on disease genes. The two 
sets are also distinguished by their gene functions: For example, essential genes are 
unusually depleted (one-third lower) in genes encoding secreted proteins (P < 10-16; 
Fisher’s exact test), whereas disease genes encode a significantly higher proportion 
of such proteins54.
CNVR genes fail to randomly sample the set of essential genes: Each of the four 
CNVR sets is significantly depleted in such genes (P < 2.5 x 10-2; Supplemental 
Table 3). Deficits of essential genes are most pronounced for both frequently ob­
served (>1%) CNVRs and for gain-and-loss CNVRs (Supplemental Table 3). One 
explanation of these findings is that fewer essential genes reside within regions that 
are predisposed to CNV mutations. However, a more likely explanation is that pu­
rifying selection on copy number change acts nonuniformly in the genome. Some 
gene types are poorly represented in CNVs, simply because changes in their copy 
number tend to be strongly deleterious and thus are often purged from the popula­
tion. Conversely, other gene types are over-represented in CNVs, either because 
their changes in copy number are less deleterious, or because deleterious CNV 
alleles are less frequently purified owing to low recombination rates (Hill-Robertson 
interference) (see Discussion).
Disease genes, as opposed to essential genes, show no set pattern of enrichment 
in CNVRs, as they are significantly depleted in the Redon et al. Affymetrix CNVR 
set and significantly enriched in the Wong et al. CNVR set (Figure 4.4A). However, 
when partitioned further according to whether or not they occur in CNVRs that over­
lap SDs, three of the four sets exhibit a disease gene surfeit outside of SDs and a 
deficit inside SDs (Figure 4.4B). The deficit of disease genes within CNVRs that 
overlap SDs is consistent with these regions containing an unusual concentration 
of genes better able to accept the potentially deleterious effects of variable copy 
number and, as we propose above, deleterious substitutions.
The enrichment of disease genes within CNVRs lying outside SDs might imply that 
duplications of such genes are advantageous, perhaps by providing functional com­
pensation when single genes are disrupted. We thus might expect that duplications, 
in other lineages, of genes that are essential in mouse, would be retained in those 
lineages due to selection for beneficial redundancy. Instead, we found that essen­
tial and disease genes have been preferentially retained as single copies in four 
lineages (those of human, mouse, dog, and opossum; see Methods) since their 
last common ancestor. More specifically, we found that among those genes that
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have remained unduplicated over a total of 485 million years of evolutionary time55 56, 
there are significant enrichments of disease genes (81% increase) and essential 
genes (22% increase) when compared with genes that have experienced at least 
one duplication in these lineages (P < 10-16; Fisher’s exact test). We thus propose 
that human disease gene CNVs lying outside of segmentally duplicated sequence 
will, over sufficient numbers of generations, be preferentially purged from the human 
population. By way of contrast, CNVs encompassing essential genes, being more 
deleterious, are purged more rapidly and are thus more rarely observed segregating 
in the human population.
This proposition appears to be at odds with the surfeit of disease genes observed 
in three of the four sets of CNVRs that do not overlap SDs. We considered whether 
disease genes might tend to lie within a sequence that is preferentially sampled by 
each of these three CNV platforms. Owing to our previous observation that each 
of the three aCGH platforms show a preference in sampling sequence with high 
G+C content, we considered whether disease genes also exhibit a preference to 
lie within high G+C sequence. Indeed, the intronic and flanking sequence (5 kb up- 
and downstream) of disease genes, after excluding all other coding sequence, was 
found to be significantly elevated in G+C content compared with genes not known to 
be involved in Mendelian disorders (median 45.7% vs. 44.0%, respectively; KS-test 
P = 1.7x10-8). The fourth platform, that of Redon et al. Affymetrix, shows a deficit of 
disease genes (Figure 4.4B) that may be explained, at least in part, by its lower G+C 
content. It may also be explained, however, by this platform’s preference in detecting 
smaller CNV(R)s (Table 4.1; Figure 4.3): Mendelian disease genes are, on average, 
twice as large as other genes (median sizes 29.3 kb vs. 16.6 kb, respectively; see 
Smith and Eyre-Walker 200357) and are thus less likely to be completely overlapped 
by this set’s CNVRs compared with the other three platforms.
CNVR gene richness and elevated G+C content
If positive selection on human CNVs has occurred frequently, then we might expect 
an increased number of functional elements to be found within such regions. Previ­
ously (Nguyen et al. 20066), we showed that CNVs, especially those found frequently 
in the human population, are indeed enriched in protein-coding genes, consistent 
with some CNVs being preferentially retained within the human population because 
of the benefits accrued from their genes’ copy number changes10 40 58. In our new 
study, all four CNVRs sets also exhibit a strong and significant enrichment in gene 
numbers over that expected from their sizes (46%, 12%, 14%, and 30% increases 
for Nijmegen, Wong et al., Redon et al. Affymetrix, and Redon et al. aCGH CNVRs, 
respectively; P < 0.02) (Figure 4.5A).
Nevertheless, CNVs might contain many genes simply because of a genome-wide 
tendency for a higher density of genes within G+C-rich sequence59, which is more 
frequently subject to copy number change. The enrichment in genes (Figure 4.5C,D) 
and in G+C content (Figure 4.2) within CNVs would be consistent with this alterna­
tive and nonadaptive explanation. Other biases are also consistent with this nonad­
aptive model: CNVRs lying outside of SDs exhibit reduced G+C contents and signifi­
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cantly reduced gene densities (33%, 47%, 34%, and 10% decreases for Nijmegen, 
Redon et al. Affymetrix, Redon et al. aCGH, and Wong et al. data sets, respectively, 
P < 0.02) (Figure 4.5).
The Redon et al. Affymetrix CNVR data might still be considered to support an adap­
tive evolution for CNVs, since these data show no overall elevation of G+C content 
despite a substantial increase in gene content. Nevertheless, here too, a nonadap­
tive explanation can be provided. The Redon et al. Affymetrix CNVR data appear 
to be gene rich on account of their high proportion (~25%) of CNVRs that overlap 
SDs, yet these SDs possess a lower G+C content than SDs occurring within CNVRs 
from other data sets (Figure 4.2). The Affymetrix SNP platform preferentially sam­
ples lower over higher G+C SDs, since higher G+C SD sequence presents greater 
difficulties when unambiguously identifying markers within commonly structurally 
variable regions60 and, as we have argued above, higher G+C sequence is more 
frequently copy number variable.
The CNVR protein-coding proportion (percentage of exonic base pairs) correlates 
significantly with both CNVR G+C-content (Pearson’s r = 0.41, P < 10-16) and with 
SD-fraction (percentage of SD base pairs, r = 0.39, P < 10-16). Examining the first or­
der partial correlations reveals that G+C content remains significantly correlated with 
CNVR protein-coding content having accounted for SD content (r = 0.39, P < 10-4), 
as does SD content when accounting for G+C content (r = 0.37, P < 10-4). Thus, in 
general, we conclude that the gene richness of CNVs is best explained not by posi­
tive selection, but instead by platform-specific biases in sampling CNVs with a high 
G+C-content and/or that overlap SDs.
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Discussion
Our study examined 6,453 genomic regions with copy number variation that were 
identified using four different platforms and experimental protocols. Each of these 
approaches appears to sample CNVs differently according to size and G+C content 
(Figure 4.3). General trends that emerge are that regions showing elevated G+C 
content give rise to larger CNVs and more frequently overlap with sequence-similar 
segmental duplications. Such regions also exhibit tendencies to be gene rich and to 
accumulate more nucleotide substitutions and interspecies synteny breakpoints661, 
although whether these tendencies are causally related remains unknown. Human 
sequence showing high G+C content also tends to experience elevated rates of 
recombination40 62 63. NAHR alone, however, cannot explain such sequences’ higher 
rates of structural rearrangement. This is because, not withstanding methodologi­
cal considerations that we discuss below, CNVs that contain SDs in general exhibit 
lower rather than higher rates of recombination.
The relationships between G+C content and both CNVR size and frequency high­
light an antagonistic relationship between, on the one hand, increased mutation and, 
on the other, increased purifying selection, within high G+C CNVs that are likely to 
be enriched in functional elements. The amount of functional sequence within high 
G+C CNVs is expected to rise as a result of increased duplication rates; however, 
it will also fall because of purifying selection on deleterious copy number increases. 
Nevertheless, as recombination tends to occur at an unusually low rate within hu­
man CNVs, even deleterious copy number changes are more likely to be fixed here 
than elsewhere in the genome. This model has previously been invoked to explain 
regional enrichments of repetitive sequence64. Regions of the human genome that 
are not observed to be copy number variable, on the other hand, tend to contain 
a lower G+C content and a higher efficacy of purifying selection on copy number 
change, in part owing to a higher rate of recombination.
Selection on CNVs
Previously, we presented two lines of evidence that CNVs have been subject to posi­
tive selection in the human population6. The first of these was that CNVs contain an 
unusually elevated gene density, but do not exhibit a concomitant increase in G+C 
content, which would otherwise have represented a confounding factor. Our previ­
ous report that CNVs were not G+C rich sequence might have arisen from some 
of the earlier studies biasing their detection of structural variation either away from 
SDs65 or toward smaller, presumably lower G+C (Figure 4.3) variants20. In this study 
we again found a significantly increased gene density in all CNVR sets (Figure 
4.5A), particularly within frequently observed CNVRs (Figure 4.2). However, on this 
occasion we found that G+C contents were elevated in three of the four CNVRs sets. 
The high gene densities of some CNVs, therefore, can be explained by their frequent 
coincidence with high G+C content SD sequence.
We note that Redon et al. (2006) previously reported their CNVR sets to be gene 
poor, rather than gene rich. However, whereas Redon et al. investigated the number
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of CNVRs overlapping genes, in our study we considered the converse, namely the 
number of genes that are overlapped by CNVs. These findings can be reconciled if 
fewer than expected CNVs overlap genes, yet those CNVs that do overlap contain 
many more genes than expected (M.E. Hurles, pers. comm.). This is indeed what we 
observe: CNVs outside of SDs more rarely contain genes, whereas CNVs overlap­
ping SDs frequently contain many. CNVs that do not overlap SDs may be gene poor 
simply because regions outside of SDs are more likely to harbor genes whose copy 
numbers are more strongly constrained. This is due in part because of increased re­
combination outside of SDs, and therefore more efficient selection, but also because 
mutations involving genes outside of SDs are more likely to be strongly deleterious.
Our previous second line of evidence for positive selection on CNVs was that copy 
number variable genes exhibit higher than expected protein evolutionary (dN/dS) 
rates. We argued then that genes that are more likely to have accumulated beneficial 
amino acid changes during mammalian evolution have also a greater susceptibility 
to more contemporary events of positive selection on gene duplicates6. Here, we 
observed significantly elevated evolutionary rates for genes located within CNVRs 
from both Redon et al. data sets1 (see Figure 4.4A and Results).
Our previous approach to interpreting these data, however, was not comprehensive. 
The observed increases in dN/dS values could have arisen not by positive selec­
tion, but by nonadaptive processes. These might include reduced purifying selection 
or increased fixation of deleterious substitutions in regions with low recombination 
rates36 66 67. An inverse relationship between recombination rate and dN/dS values 
was, indeed, observed for SDRs. Conditional on their overlap with SDs, CNVR data 
that show significantly high recombination rates also exhibited unexpectedly low dN/ 
dS values, and vice versa (Figure 4.4B; Supplemental Table 2). A similar doubling 
of dN/dS rates has also been observed for low- or nonrecombining regions of the 
Drosophila genome67.
It is possible that the measurement of recombination rates across CNV-rich sequence 
may be less accurate than elsewhere in the genome, due both to a lower density of 
SNP markers and increased structural variation that would alter physical distances 
between markers. Nevertheless, recombination rates do remain substantially (26%) 
and significantly (P < 2x10-3) lower than expected for those SDs that are not seen to 
be copy number variable within our four data sets. This argues that the lower recom­
bination rates in SDs are not artifacts of the SNP ascertainment scheme.
This reduction of recombination in SDRs would need to have been sustained for the 
extended periods of time since the last common ancestor of human and dog in order 
for the accumulation of deleterious substitutions to be apparent in increased dN/dS 
values. We present evidence in a separate manuscript that, indeed, recombination 
rates are an ancestral trait of metatherian and eutherian mammals (C. Webber and 
C.P. Ponting, in prep.).
A model of inefficient purifying selection acting on CNV genes explains the previ­
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ously reported surfeit of so-called “environmental” genes within CNVRs6. Instead of 
environmental gene copy number changes being of frequent benefit, we argue that 
they accumulate simply because they are substantially less deleterious than copy 
number changes in other genes. Even if the duplication of such genes is mildly del­
eterious, rather than being neutral or beneficial, they may persist in the population 
because of inefficient purifying selection. A recent study of CNVs within Drosophila 
melanogaster reported that genes overlapped by CNVs have fewer network interac­
tions, reduced lethality, and increased evolutionary rates68. These findings are also 
consistent with a model of reduced selective constraint and, despite the very differ­
ent population dynamics between human and Drosophila, may illustrate common 
features of copy number variants across diverse species.
Conclusions
We conclude that a model of reduced recombination and reduced purifying selec­
tion in G+C-rich and highly duplicating sequence is able to account for the unusual 
evolutionary properties of most CNVRs. An alternative argument that these prop­
erties have arisen because of positive selection on gene copy number (within the 
human population) and amino acid substitution (over mammalian evolution) is disfa­
vored because it cannot account for the inverse relationship observed between gene 
evolutionary rates and recombination rates. Strong selection may account for the 
segregation of CNV alleles in specific instances10 69, but our results imply that such 
examples are exceptions rather than the rule. Our findings indicate that copy number 
changes are most likely to be deleterious, and thus lead to human disease when 
involving genes lying outside of the segmentally duplicated portion of the human ge­
nome. This should be most evident for unduplicated human genes whose orthologs 
have previously been observed to elicit a deleterious phenotype when disrupted in 
mouse. We hope that our findings of ascertainment, mutational, and selective biases 
will now enable improved discrimination of neutral, deleterious, and beneficial CNVs 
in the human population.
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Methods
Identification of Nijmegen CNVs
A 32k tiling resolution genomic microarray consisting of 32,447 overlapping BAC 
clones, selected to cover the entire human genome, was used to generate genomic 
copy number profiles for 494 samples using methods that have been described pre­
viously9. These samples were originally analyzed by this method within a diagnostic 
setting with the aim of identifying copy number changes causally related to mental 
retardation. The samples therefore consisted of patients with unexplained mental 
retardation (n = 405, of which 102 were run in replicate with dye-reversal) as well 
as unaffected parents (n = 89, 38 complete trios). All BAC array data have been 
deposited at the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) with 
accession no. GSE7391; CNV intervals are given in Supplemental Table 1. In all 
cases, genomic DNA was isolated from uncultured blood leukocytes, thereby ex­
cluding culture-induced rearrangements and aneuploidies, as described by Redon 
et al. (2006).
Hybridization was performed in a two-color experiment against a reference pool con­
taining equal amounts of genomic DNA from 10 healthy blood donors, and genomic 
copy numbers were estimated using a highly conservative hidden Markov model9 70. 
Other studies such as Redon et al. (2006) and Wong et al. (2007) use single indi­
viduals for the reference, thus enabling CNVs to be detected in either subject or 
reference individuals. However, for experiments that seek to diagnose copy number 
variation in the subject only, it is preferable to use a reference pool of multiple unre­
lated individuals; this disfavors the detection of CNVs in the reference, whilst enjoy­
ing a low false-positive rate9. Use of a reference pool also allows for an accurate 
estimation of the frequency of each CNV as well as the type of CNV (i.e., loss or 
gain). In a previous study37, we used multiplex ligation-dependent probe amplifica­
tion (MLPA)7172 and validated the presence and frequency of six recurrent CNVs. 
This showed an excellent correlation between these different approaches for CNVs 
identified using our BAC arrays. Because of the use of large-insert clones for the 
detection of CNVs, we decided to include only CNVs larger than 100 kb and required 
a CNV to be covered by a minimum of three BAC clones (see also Hehir-Kwa et al. 
200773). These CNVs are much larger than virtually all SDs; hence, strong signals 
arising from cross-hybridization between highly identical sequences (the “shadow­
ing effect”) are unlikely. As with all array-CGH experiments, the sizes of CNVs and 
overlapping CNV regions we report are upper-bound estimates.
In this study we focus on inherited CNVs without a known clinical relevance. In 
order to distinguish clinically relevant copy number alterations from normal copy 
number variations, we performed several additional steps (see also de Vries et al. 
20 059). First, we analyzed 89 unaffected parents using the same tiling resolution 
microarrays. These parental samples served as a control population but, in addition, 
provided valuable information on the inheritance of specific copy number changes. 
From this first analysis we identified a large set of inherited CNVs; of these, many 
were detected in multiple unrelated patients as well as unaffected parents. Secondly,
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all nonrecurrent CNVs were validated both in the patient as well as in the parents 
by either MLPA using specifically designed synthetic probe sets and/or fluorescence 
in situ hybridization (FISH). All de novo copy number alterations in the patient were 
excluded from the list of CNVs used in this study, as were CNVs on the sex chro­
mosomes. For the frequency analysis, parental samples were excluded, leading to 
inherited CNVs being counted once only per family.
Other CNV and SD data sets
We obtained all 5,132 and 25,196 CNVs identified by Wong et al. (2007) and Redon 
et al. (2006), respectively, and CNVs identified by Redon et al. were considered 
separately by platform. The 6,461 CNVs identified by Redon et al. (2006) on the 
Affymetrix SNP array platform were herein termed “Redon et al. Affymetrix” CNVs, 
while the 18,735 CNVs identified using the array-CGH platform were herein termed 
“Redon et al. aCGH” CNVs.
In their study, Wong et al. (2007) considered for further analysis only those CN- 
VRs that were observed for three or more (out of 95) individuals. For our analyses, 
however, we considered all Wong et al. CNVs for the reason that their properties 
are broadly consistent with those of the other three sets (Figures 4.2-5; Supple­
mental Table 2). The genomic properties of those Wong et al. CNVRs that encom­
pass CNVs from three or more individuals appear much as would be expected for 
frequent CNVs: They possess proportions of segmentally duplicated bases (19%), 
G+C content (43%), and protein-coding gene content (+53%) that are significantly 
higher than expected from genome-wide distributions.
Segmental duplications, as identified using the method described by Bailey et al. 
200122), were obtained from the University of California Santa Cruz (UCSC) ge­
nome browser74 (http://genome.cse.ucsc.edu, human: hg17, segmental dups track). 
Segmental duplications and CNVs located either on X or on Y chromosomes were 
excluded from our analyses in order to remove any evolutionary biases related to 
sex chromosomes.
Partitioning and merging o f the data sets
We wished to examine the regions of the genome that give rise to observed copy 
number variation or segmental duplication. Thus, within their respective sets, over­
lapping segments were either merged together if they overlapped by 50% or else 
trimmed equally so as not to overlap in order to produce a set of nonoverlapping 
regions. The procedure for merging and trimming of overlapping CNVs was applied 
to the different portions of all four CNVs sets (rare, frequent, gain-and-loss, and [non] 
overlapping with SDs) and to SDs.
As CNVs often overlap, properties averaged over all CNVRs will differ from those 
calculated from all CNVs. If independent copy number variations frequently coincide, 
as they certainly do for gain-and-loss CNVRs, then rarely observed CNVRs will con­
tribute disproportionately to our calculations. Nevertheless, as we find that frequently 
observed CNVRs are associated with the greatest departures of properties from the
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genomic average, our approach is conservative, particularly since results (Figures. 
4.1-5) then represent lower-bound values.
Each of the four CNVR sets was partitioned according to CNV observation frequen­
cy, their overlap with segmental duplications, and whether they contain both copy 
number gains and losses. This resulted in five partitions: (1) CNVRs with 1% ob­
served frequency, termed “rare”; (2) CNVRs observed at higher frequencies (>1%), 
termed “frequent”; (3) CNVRs that overlap with at least one SD, termed “CNVRs with 
SDs”; (4) CNVRs having no overlap with SDs, termed “CNVRs non-SDs”; and, (5) 
CNVRs containing both gain CNVs and loss CNVs, termed “gain and loss CNVRs.”
Genomic data sets
Simple tandem repeats (from Tandem Repeats Finder75) and genomic sequence 
were obtained from the University of California Santa Cruz (UCSC) genome brows­
er74, and gene predictions and annotations were assigned to CNVs according to 
Ensembl44 (Ensembl mart version 37). Ensembl genes annotated as OMIM morbid 
map genes were used to define the set of disease genes76.
Recombination rates across the human genome were obtained from Myers et al. 
(200577) and recast to the NCBI35 assembly using the UCSC NCBI34 ^  NCBI35 
chained alignment78. Rates were calculated as the average recombination rate per 
base pair. Such rate predictions are expected to be less accurate in repetitive se­
quence, simply because marker densities are lower, and also in copy number vari­
able sequence, owing to the uncertainty in physical distances separating markers 
(see Discussion).
Orthologs between human and dog were predicted using PhyOP46. We argue that 
these orthologs will be more reliable than, for example, those between human and 
mouse, because of their lower degree of divergence. These orthologs were those 
that have remained unduplicated between the species’ last common ancestor, as 
well as those arising from lineage-specific gene duplication events. dN and dS val­
ues and their ratios were calculated for orthologs using the codeml program from 
the PAML package79. Ancestral repeats were defined as those RepeatMasker anno­
tated repeats80 that were aligned between the genomes of dog and human within the 
UCSC chained alignment, and therefore we infer to have been present in their last 
common ancestor41. The substitution rate between those aligned ancestral repeats 
that extended over 150 bp was calculated using the REV model in the BASEML pro­
gram from the PAML package81.
Unduplicated 1:1:1:1 human:mouse:dog:opossum orthologs were obtained from the 
OPTIC database82. Similar to PhyOP, OPTIC is an automated orthology assignment 
procedure that defines phylogenetic relationships on the basis of dS trees calcu­
lated through the codeml program from the PAML package77. Synteny breakpoints 
between dog and human genomes were defined as the gaps between the 100kb 
synteny blocks obtained from the Dog Genome Sequencing Consortium47. The dog 
genome sequence is a high-quality and high-coverage sequence and is used here in
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preference to other available genome sequences to be consistent with other evolu­
tionary analyses in this work. As centromeres are always annotated as representing 
synteny breakpoints, these were excluded from our analyses.
Mouse genome informatics (MGI) phenotype data
Information on human NCBI genes whose mouse orthologs’ disruption had been 
assayed were obtained from MGI 3.5453. Two phenotypes, “lethality-embryonic/ 
perinatal” (MP:0005374) and “lethality-postnatal” (MP:0005373), were selected to 
provide two sets of genes whose disruptions were strongly deleterious. Of 4,509 hu­
man NCBI genes whose mouse orthologs’ disruption had been assayed, 739 were 
classed as post natally lethal, while 1,545 were classed as embryonic or perinatally 
lethal.
Statistical tests
To test the null hypothesis that a property is higher or lower within a set of regions 
than elsewhere in the genome, we performed a randomization test. For this, 500 
sets of regions were sampled randomly from the genome assembly; these regions 
were matched in both number and size to the set of regions under consideration. 
We calculated the fraction P of such randomly chosen regions that contained higher 
or lower values of the property. Values of P > 0.025 were generally considered to 
indicate that the CNV data were not significantly different from the genome data 
taken as a whole. The probability that two sets of dN, dS, or dN/dS values sample 
an equivalent distribution was calculated using the two-sided Kolmogorov-Smirnov 
test83. Partial correlations were performed using the service provided at http://faculty. 
vassar.edu/lowry/par.html.
116
References
1. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero 
MH, Carson AR, Chen W, et al. (2006) Global variation in copy number in the human 
genome. Nature 444: 444-454.
2. Shianna KV and Willard HF (2006) Human genomics: In search of normality. Nature 
444: 428-429.
3. Wong KK, deLeeuw RJ, Dosanjh NS, Kimm LR, Cheng Z, Horsman DE, MacAulay 
C, Ng RT, Brown CJ, Eichler EE, et al. (2007) A comprehensive analysis of common 
copy-number variations in the human genome. Am. J. Hum. Genet. 80: 91-104.
4. Sharp AJ, Cheng Z, and Eichler EE (2006a) Structural variation of the human genome. 
Annu. Rev. Genomics Hum. Genet. 7: 407-442.
5. Sharp AJ, Locke DP, McGrath SD, Cheng Z, Bailey JA, Vallente RU, Pertz LM, Clark 
RA, Schwartz S, Segraves R, et al. (2005) Segmental duplications and copy-number 
variation in the human genome. Am. J. Hum. Genet. 77: 78-88.
6. Nguyen DQ, Webber C, and Ponting CP (2006) Bias of selection on human copy- 
number variants. PLoS Genet. 2: e20. doi: 10.1371/journal.pgen.0020020.
7. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, 
Peuralinna T, Dutra A, Nussbaum R, et al. (2003) Synuclein locus triplication causes 
Parkinson's disease. Science 302: 841. doi: 10.1126/science.1090278.
8. Vissers LE, van Ravenswaaij CM, Admiraal R, Hurst JA, de Vries BB, Janssen IM, 
van der Vliet WA, Huys EH, de Jong PJ, Hamel BC, et al. (2004) Mutations in a new 
member of the chromodomain gene family cause CHARGE syndrome. Nat. Genet. 36: 
955-957.
9. de Vries BB, Pfundt R, Leisink M, Koolen DA, Vissers LE, Janssen IM, Reijmersdal S, 
Nillesen WM, Huys EH, Leeuw N, et al. (2005) Diagnostic genome profiling in mental 
retardation. Am. J. Hum. Genet. 77: 606-616.
10. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, 
Freedman BI, Quinones MP, Bamshad MJ, et al. (2005) The influence of CCL3L1 
gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307: 
1434-1440.
11. Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, Smith J, Mangion J, 
Roberton-Lowe C, Marshall AJ, Petretto E, et al. (2006) Copy number polymorphism in 
Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439: 851-855.
12. Koolen DA, Vissers LE, Pfundt R, de Leeuw N, Knight SJ, Regan R, Kooy RF,
Reyniers E, Romano C, Fichera M, et al. (2006) A new chromosome 17q21.31 
microdeletion syndrome associated with a common inversion polymorphism. Nat. 
Genet. 38: 999-1001.
13. Sharp AJ, Hansen S, Selzer RR, Cheng Z, Regan R, Hurst JA, Stewart H, Price SM, 
Blair E, Hennekam RC, et al. (2006b) Discovery of previously unidentified genomic 
disorders from the duplication architecture of the human genome. Nat. Genet. 38: 
1038-1042.
14. Shaw-Smith C, Pittman AM, Willatt L, Martin H, Rickman L, Gribble S, Curley R, 
Cumming S, Dunn C, Kalaitzopoulos D, et al. (2006) Microdeletion encompassing 
MAPT at chromosome 17q21.3 is associated with developmental delay and learning 
disability. Nat. Genet. 38: 1032-1037.
117
C
hapter 4 
C
haracteristics 
of CNVs 
in 
the 
G
eneral P
opulation
15. Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-Favero J, 
Cruts M, van Duijn CM, and Van Broeckhoven C. (2006) APP duplication is sufficient to 
cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 129: 
2977-2983.
16. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T, Yamrom B, Yoon
S, Krasnitz A, Kendall J, et al. (2007) Strong association of de novo copy number 
mutations with autism. Science 316: 445-449.
17. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, Nord 
AS, Kusenda M, Malhotra D, Bhandari A, et al. (2008) Rare structural variants disrupt 
multiple genes in neurodevelopmental pathways in schizophrenia. Science 320: 539­
543.
18. lafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, and 
Lee C (2004) Detection of large-scale variation in the human genome. Nat. Genet. 36: 
949-951.
19. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, Massa H, 
Walker M, Chi M, et al. (2004) Large-scale copy number polymorphism in the human 
genome. Science 305: 525-528.
20. Tuzun E, Sharp AJ, Bailey JA, Kaul R, Morrison VA, Pertz LM, Haugen E, Hayden
H, Albertson D, Pinkel D, et al. (2005) Fine-scale structural variation of the human 
genome. Nat. Genet. 37: 727-732.
21. McCarroll SA, Hadnott TN, Perry GH, Sabeti PC, Zody MC, Barrett JC, Dallaire S, 
Gabriel SB, Lee C, Daly MJ, et al. (2006) Common deletion polymorphisms in the 
human genome. Nat. Genet. 38: 86-92.
22. Bailey JA, Yavor AM, Massa HF, Trask BJ, and Eichler EE (2001) Segmental 
duplications: Organization and impact within the current human genome project 
assembly. Genome Res. 11: 1005-1017.
23. Bailey JA, Gu Z, Clark RA, Reinert K, Samonte RV, Schwartz S, Adams MD, Myers 
EW, Li PW, and Eichler EE (2002) Recent segmental duplications in the human 
genome. Science 297: 1003-1007.
24. Stankiewicz P and Lupski JR (2002) Genome architecture, rearrangements and 
genomic disorders. Trends Genet. 18: 74-82.
25. Hurles M (2005) How homologous recombination generates a mutable genome. Hum. 
Genomics 2: 179-186.
26. Lupski JR and Stankiewicz P (2005) Genomic disorders: Molecular mechanisms for 
rearrangements and conveyed phenotypes. PLoS Genet. 1: e49. doi: 10.1371/journal. 
pgen.0010049.
27. Armengol L, Marques-Bonet T, Cheung J, Khaja R, Gonzalez JR, Scherer SW,
Navarro A, and Estivill X  (2005) Murine segmental duplications are hot spots for 
chromosome and gene evolution. Genomics 86: 692-700.
28. Webber C and Ponting CP (2005) Hotspots of mutation and breakage in dog and 
human chromosomes. Genome Res. 15: 1787-1797.
29. Lindsay SJ, Khajavi M, Lupski JR, and Hurles ME (2006) A chromosomal 
rearrangement hotspot can be identified from population genetic variation and is 
coincident with a hotspot for allelic recombination. Am. J. Hum. Genet. 79: 890-902.
30. Mouse Genome Sequencing Consortium. (2002) Initial sequencing and comparative 
analysis of the mouse genome. Nature 420: 520-562.
118
31. Emes RD, Goodstadt L, W inter EE, and Ponting CP (2003) Comparison of the 
genomes of human and mouse lays the foundation of genome zoology. Hum. Mol. 
Genet. 12: 701-709.
32. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar 
K, Doyle M, FitzHugh W, et al. (2001) Initial sequencing and analysis of the human 
genome. Nature 409: 860-921.
33. Conrad DF, Andrews TD, Carter NP, Hurles ME, and Pritchard JK (2006) A high­
resolution survey of deletion polymorphism in the human genome. Nat. Genet. 38: 
75-81.
34. Hill WG and Robertson A (1966) The effect of linkage on limits to artificial selection. 
Genet. Res. 8: 269-294.
35. Charlesworth B and Charlesworth D (2000) The degeneration of Y chromosomes. 
Philos. Trans. R. Soc. Lond. B Biol. Sci. 355: 1563-1572.
36. McVean GA and Charlesworth B (2000) The effects of Hill-Robertson 
interference between weakly selected mutations on patterns of molecular evolution 
and variation. Genetics 155: 929-944.
37. White SJ, Vissers LE, Geurts van Kessel A, de Menezes RX, Kalay E, Lehesjoki AE, 
Giordano PC, van de Vosse E, Breuning MH, Brunner HG, et al. (2007) Variation of 
CNV distribution in five different ethnic populations. Cytogenet. Genome Res. 118: 
19-30.
38. Turner DJ, Miretti M, Rajan D, Fiegler H, Carter NP, Blayney ML, Beck S, and Hurles 
ME (2008) Germline rates of de novo meiotic deletions and duplications causing 
several genomic disorders. Nat. Genet. 40: 90-95.
39. Bailey JA, Baertsch R, Kent WJ, Haussler D, and Eichler EE (2004) Hotspots of 
mammalian chromosomal evolution. Genome Biol. 5: R23. http://genomebiology. 
com/2004/5/4/R23.
40. She X, Liu G, Ventura M, Zhao S, Misceo D, Roberto R, Cardone MF, Rocchi M,
Green ED, Archidiacano N, et al. (2006) A preliminary comparative analysis of primate 
segmental duplications shows elevated substitution rates and a great-ape expansion 
of intrachromosomal duplications. Genome Res. 16: 576-583.
41. Hardison RC, Roskin KM, Yang S, Diekhans M, Kent WJ, Weber R, Elnitski L, Li J, 
O'Connor M, Kolbe D, et al. (2003) Covariation in frequencies of substitution, deletion, 
transposition, and recombination during eutherian evolution. Genome Res. 13: 13-26.
42. International Human Genome Sequencing Consortium. (2004) Finishing the 
euchromatic sequence of the human genome. Nature 431: 931-945.
43. Cheng Z, Ventura M, She X, Khaitovich P, Graves T, Osoegawa K, Church D, DeJong 
P, Wilson RK, Paabo S, et al. (2005) A genome-wide comparison of recent chimpanzee 
and human segmental duplications. Nature 437: 88-93.
44. Hubbard T, Barker D, Birney E, Cameron G, Chen Y, Clark L, Cox T, Cuff J, Curwen V, 
Down T, et al. (2002) The Ensembl genome database project. Nucleic Acids Res. 30: 
38-41.
45. Birney E, Andrews D, Caccamo M, Chen Y, Clarke L, Coates G, Cox T, Cunningham F, 
Curwen V, Cutts T, et al. (2006) Ensembl 2006. Nucleic Acids Res. 34: D556-D561.
46. Goodstadt L and Ponting CP (2006) Phylogenetic reconstruction of orthology, paralogy, 
and conserved synteny for dog and human. PLoS Comput. Biol. 2: e133. doi: 10.1371/ 
journal.pcbi.0020133.
119
C
hapter 4 
C
haracteristics 
of CNVs 
in 
the 
G
eneral P
opulation
47. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp 
M, Chang JL, Kulbokas EJ, Zody MC, et al. (2005) Genome sequence, comparative 
analysis and haplotype structure of the domestic dog. Nature 438: 803-819.
48. Navarro A, Betran E, Barbadilla A, and Ruiz A (1997) Recombination and gene flux 
caused by gene conversion and crossing over in inversion heterokaryotypes. Genetics 
146: 695-709.
49. Shaw CJ and Lupski JR (2004) Implications of human genome architecture for 
rearrangement-based disorders: The genomic basis of disease. Hum. Mol. Genet. 13: 
R57-R64.
50. Erdogan F, Chen W, Kirchhoff M, Kalscheuer VM, Hultschig C, Muller I, Schulz 
R, Menzel C, Bryndorf T, Ropers HH, et al. (2006) Impact of low copy repeats on 
the generation of balanced and unbalanced chromosomal aberrations in mental 
retardation. Cytogenet. Genome Res. 115: 247-253.
51. Gibbs RA, Weinstock GM, Metzker ML, Muzny DM, Sodergren EJ, Scherer S, Scott G, 
Steffen D, Worley KC, Burch PE, et al. (2004) Genome sequence of the Brown Norway 
rat yields insights into mammalian evolution. Nature 428: 493-521.
52. Feuk L, Carson AR, and Scherer SW (2006) Structural variation in the human genome. 
Nat. Rev. Genet. 7: 85-97.
53. Bult CJ, Eppig JT, Kadin JA, Richardson JE, and Blake JA (2008) The Mouse Genome 
Database (MGD): Mouse biology and model systems. Nucleic Acids Res. 36: D724- 
D728.
54. W inter EE, Goodstadt L, and Ponting CP (2004) Elevated rates of protein secretion, 
evolution, and disease among tissue-specific genes. Genome Res. 14: 54-61.
55. Archibald DJ (2003) Timing and biogeography of the eutherian radiation: Fossils and 
molecules compared. Mol. Phylogenet. Evol. 28: 350-359.
56. Springer MS, Murphy WJ, Eizirik E, and O'Brien SJ (2003) Placental mammal 
diversification and the Cretaceous-Tertiary boundary. Proc. Natl. Acad. Sci. 100: 1056­
1061.
57. Smith NG and Eyre-Walker A (2003) Human disease genes: Patterns and predictions. 
Gene 318: 169-175.
58. Zhang L, Lu HH, Chung WY, Yang J, and Li WH (2005) Patterns of segmental 
duplication in the human genome. Mol. Biol. Evol. 22: 135-141.
59. Zoubak S, Clay O, and Bernardi G (1996) The gene distribution of the human genome. 
Gene 174: 95-102.
60. Wirtenberger M, Hemminki K, and Burwinkel B (2006) Identification of frequent 
chromosome copy-number polymorphisms by use of high-resolution single-nucleotide- 
polymorphism arrays. Am. J. Hum. Genet. 78: 520-522.
61. Cooper GM, Nickerson DA, and Eichler EE (2007) Mutational and selective effects on 
copy-number variants in the human genome. Nat. Genet. 39: S22-S29.
62. Duret L, Eyre-Walker A, and Galtier N (2006) A new perspective on isochore evolution. 
Gene 385: 71-74.
63. Khelifi A, Meunier J, Duret L, and Mouchiroud D (2006) GC content evolution of the 
human and mouse genomes: Insights from the study of processed pseudogenes in 
regions of different recombination rates. J. Mol. Evol. 62: 745-752.
64. Charlesworth B, Sniegowski P, and Stephan W  (1994) The evolutionary dynamics of 
repetitive DNA in eukaryotes. Nature 371: 215-220.
65. Lucito R, Healy J, Alexander J, Reiner A, Esposito D, Chi M, Rodgers L, Brady A,
Sebat J, Troge J, et al. (2003) Representational oligonucleotide microarray analysis:
120
A high-resolution method to detect genome copy number variation. Genome Res. 13: 
2291-2305.
66. Charlesworth D, Charlesworth B, and Morgan MT (1995) The pattern of neutral 
molecular variation under the background selection model. Genetics 141: 1619-1632.
67. Haddrill PR, Halligan DL, Tomaras D, and Charlesworth B (2007) Reduced efficacy of 
selection in regions of the Drosophila genome that lack crossing over. Genome Biol. 8: 
R18. doi: 10.1186/gb-2007-8-2-r18.
68. Dopman EB and Hartl DL (2007) A portrait of copy-number polymorphism in 
Drosophila melanogaster. Proc. Natl. Acad. Sci. 104: 19920-19925.
69. Perry GH, Dominy NJ, Claw KG, Lee AS, Fiegler H, Redon R, Werner J, Villanea FA, 
Mountain JL, Misra R, et al. (2007) Diet and the evolution of human amylase gene 
copy number variation. Nat. Genet. 39: 1256-1260.
70. Rabiner LR (1989) A tutorial on hidden Markov models and selected applications 
inspeech recognition. Proc. IEEE 77: 257-286.
71. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, and Pals G (2002) 
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent 
probe amplification. Nucleic Acids Res. 30: e57. doi: 10.1093/nar/gnf056.
72. White SJ, Vink GR, Kriek M, Wuyts W, Schouten J, Bakker B, Breuning MH, and 
den Dunnen JT (2004) Two-color multiplex ligation-dependent probe amplification: 
Detecting genomic rearrangements in hereditary multiple exostoses. Hum. Mutat. 24: 
86-92.
73. Hehir-Kwa JY, Egmont-Petersen M, Janssen IM, Smeets D, van Kessel AG, and 
Veltman JA (2007) Genome-wide copy number profiling on high-density bacterial 
artificial chromosomes, single-nucleotide polymorphisms, and oligonucleotide 
microarrays: A platform comparison based on statistical power analysis. DNA Res. 14: 
1-11.
74. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, and Haussler D 
(2002) The human genome browser at UCSC. Genome Res. 12: 996-1006.
75. Benson G (1999) Tandem repeats finder: A program to analyze DNA sequences. 
Nucleic Acids Res. 27: 573-580.
76. Hamosh A, Scott AF, Amberger JS, Bocchini CA, and McKusick VA (2005) Online 
Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic 
disorders. Nucleic Acids Res. 33: D514-D517.
77. Myers S, Bottolo L, Freeman C, McVean G, and Donnelly P (2005) A fine-scale map of 
recombination rates and hotspots across the human genome. Science 310: 321-324.
78. Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H, Diekhans 
M, Furey TS, Harte RA, Hsu F, et al. (2006) The Uc Sc  Genome Browser Database: 
Update 2006. Nucleic Acids Res. 34: D590-D598.
79. Yang Z and Nielsen R (2000) Estimating synonymous and nonsynonymous 
substitution rates under realistic evolutionary models. Mol. Biol. Evol. 17: 32-43.
80. Jurka J (2000) Repbase update: A database and an electronic journal of repetitive 
elements. Trends Genet. 16: 418-420.
81. Yang Z (1997) PAML: A program package for phylogenetic analysis by maximum 
likelihood. Comput. Appl. Biosci. 13: 555-556.
82. Heger A and Ponting CP (2008) OPTIC: Orthologous and paralogous transcripts in 
clades. Nucleic Acids Res. 36: D267-D270.
83. Feller W  (1948) On the Kolmogorov-Smirnov limit theorums for empirical distributions. 
Ann. Math. Stat. 19: 177-189.
121
C
hapter 4 
C
haracteristics 
of CNVs 
in 
the 
G
eneral P
opulation

Forging Links between Human Mental Retarda­
tion-Associated CNVs and Mouse Gene Knock­
out Models
Caleb Webber1, Jayne Y. Hehir-Kwa2, Duc-Quang Nguyen1, 
Bert B. A. de Vries2, Joris A. Veltman2*,
Chris P. Ponting1*
1MRC Functional Genomics Unit, 
ics, University of Oxford, Oxford, Uni 
2Department of Human Genetics, 
Radboud University Nijmegen Medi
* These authors contributed equally
irtment of Physiology, Anatomy and Genet- 
Cingdom,
iegen Centre for Molecular Life Sciences,
>l Centre, Nijmegen, The Netherlands
PLoS Genetics 2009 Jun;5(6)

Abstract
Rare copy number variants (CNVs) are frequently associated with common neuro­
logical disorders such as mental retardation (MR; learning disability), autism, and 
schizophrenia. CNV screening in clinical practice is limited because pathological 
CNVs cannot be distinguished routinely from benign CNVs, and because genes 
underlying patients’ phenotypes remain largely unknown. Here, we present a novel, 
statistically robust approach that forges links between 148 MR-associated CNVs 
and phenotypes from ~5,000 mouse gene knockout experiments. These CNVs were 
found to be significantly enriched in two classes of genes, those whose mouse or- 
thologues, when disrupted, result in either abnormal axon or dopaminergic neuron 
morphologies. Additional enrichments highlighted correspondences between rele­
vant mouse phenotypes and secondary presentations such as brain abnormality, 
cleft palate, and seizures. The strength of these phenotype enrichments (>100% 
increases) greatly exceeded molecular annotations (<30% increases) and allowed 
the identification of 78 genes that may contribute to MR and associated phenotypes. 
This study is the first to demonstrate how the power of mouse knockout data can be 
systematically exploited to better understand genetically heterogeneous neurologi­
cal disorders.
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Introduction
Mental retardation (MR) is defined as an overall intelligence quotient lower than 70, 
and is associated with functional deficits in adaptive behaviour, such as daily-living 
skills, social skills and communication. This disorder affects 1%-3% of the popu­
lation and results from extraordinarily heterogeneous environmental and genetic 
causes1. Genetic changes underlying MR are still poorly resolved, especially for the 
autosomes that provide the largest contribution to disease aetiology2. Microscopi­
cally visible chromosomal rearrangements detected by routine chromosome analy­
sis are the cause for MR in, 5%-10% of patients3. Such rearrangements represent 
gains or losses of more than 5-10 Mb of DNA and affect many genes thereby al­
most inevitably leading to developmental abnormalities during embryogenesis. The 
most common effect of these variants is cognitive impairment, but they can also be 
frequently associated with other abnormalities such as heart defects, seizures and 
dysmorphic features4.
Many recent genomic microarray studies have indicated that smaller, submicroscop- 
ic rearrangements, such as copy number variations (CNVs), frequently underlie MR 
(Supplementary Table 1). However, CNVs, defined as DNA deletions or duplica­
tions greater than 1 kb5, are also widespread in the general population which consid­
erably hinders the clinical interpretation of patients’ CNVs6. Until now, most clinical 
CNV studies have focused on the identification of rare de novo CNVs7-9, as the rate 
of de novo large (>50 kb) CNVs in the general population is comparatively low1011. 
Nevertheless, discriminating between benign and pathogenic CNVs solely on the 
basis of size and lack of inheritance is crude and provides no insights into how CNVs 
exert their phenotypic effects.
Fortunately, the genomics era has amassed a wealth of data that have long prom­
ised to associate the disruption of a particular molecular function or cellular pathway 
with clinical observations; in short, to forge links between genotype and disease phe­
notype. These genomic data include behavioural, physiological and anatomical ex­
aminations following the disruption of more than 5,000 individual mouse genes12-14. 
These mouse phenotypic measurements more closely resemble observations from 
human clinical examination than any other systematic genome-wide data source. 
They might be especially relevant to human gene deletion variants, which represent 
a large majority among the rare disease associated CNVs considered here (Table 
5.1 and Supplementary Table 2). Available genomic data also include functional 
annotations such as from the Gene Ontology resource15, tissue expression levels16 
and carefully curated pathway data such as the Kyoto Encyclopedia of Genes and 
Genomes (KEGG)17.
Our approach was to test the null hypothesis that genes present in MR-associated 
CNVs randomly sample all human genes. In particular, are they a random sample 
of genes (i) that, when disrupted in mice, result in particular phenotypes, or (ii) that 
are predominantly expressed in the human brain, or (iii) that participate in specific 
human disease pathways? To ensure that we correctly account for the application
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of multiple tests, we have controlled the false discovery rate (FDR)18 such that there 
is only a small 5% likelihood that any annotation term has been identified as over­
represented in our tests simply by chance. Only if any particular set of genes present 
within MR-associated CNVs form a significantly (FDR<5%) non-random sample can 
we be truly justified in predicting single genes, among the dozens commonly over­
lapped by such CNVs, as contributing to MR disease aetiology. In this study, we 
show both significant and substantial enrichments in phenotypic annotations whose 
power in predicting pathoetiology greatly exceeds that of molecular annotations.
Results
For this study, 148 MR-associated rare CNVs collated from a variety of sources 
(Supplementary Table 1) were merged to obtain a set of 112 distinct non-overlap­
ping CNV regions (CNVRs) and partitioned according to the direction of copy number 
change (Gain or Loss). We also collated a control set of 26,472 benign CNVs (1,388 
CNVRs) from previous publications (see Materials and Methods). MR-associated 
CNVs are most obviously distinguished from benign CNVs by their large sizes and 
by their larger numbers of copy number losses (n = 111, 75%) relative to gains (n = 
37, 25%) (Table 5.1). These differences remained even when comparing benign and 
MR CNVs detected by the same platform (tiling resolution 32 k BAC arrays): the me­
dian size of 40 MR CNVs is approximately twice that of benign CNVs (1.6 Mb versus 
0.85 Mb) while 58.6% of benign CNVs on this platform are losses. This increased 
bias towards loss CNVs would be expected if the MR phenotypes considered here 
result either from haploinsufficiency or from recessive deleterious mutations being 
revealed in the remaining haplotype. There is only a small difference (17.6%) be­
tween the average gene densities of MR-associated and benign CNVs (Table 5.1). 
Consequently, we need to look to gene function, rather than gene numbers, when 
attempting to differentiate disease-associated from benign CNVs.
Nervous system phenotypes and expression
We first tested whether MR-associated CNVR genes were enriched in 33 major cat­
egories of mouse phenotypes (see Materials and Methods). Although for All MR- 
associated CNVRs none of these terms was significant, the set of Loss MR-associ­
ated CNVRs showed a strong and significant enrichment in genes whose knockouts 
in mice produced a nervous system phenotype (+13.6%, or 1.14-fold, enrichment, 
p=3x10-3, FDR<5%; Figure 5.1). An enrichment of genes associated with nervous 
system phenotypes was not observed within the Gain CNVRs (+0.2%).
Given the significant enrichment within the Loss set, we then tested this set against 
each of 147 finer-scale mouse nervous system phenotypes. Two of these terms 
were significantly enriched (FDR<5%): abnormal axon morphology (obs= 19, exp 
=7.1, +170% enrichment, p=3x10-5), and abnormal dopaminergic neuron morphol­
ogy (obs=9, exp= 2.5, +260% enrichment, p=3x10-4) (Figure 5.1). Both of these 
mouse neural phenotypes are relevant to human MR phenotypes owing to these 
mouse phenotype’s abnormalities in neuronal and cerebral cortex morphologies 
(see Discussion). Within Gain CNVRs, we observe a non-significant enrichment of
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genes associated with abnormal axon morphology (obs=6, exp=2.7, +120% enrich­
ment, p=5x10-2) but a non-significant depletion of genes associated with abnormal 
dopaminergic neuron morphology (obs=0, exp=0.95, -100% deficit, p=0.38).
The neurological phenotypes of MR patients suggested that MR-associated CNVs 
might contain an unusually high density of genes that, when mutated, are involved 
in human neurological disease. Considering those genes classified by KEGG to be 
involved in 6 neurodegenerative pathways, we indeed found MR associated CNVRs 
to be significantly enriched in genes involved in the Parkinson’s disease pathway 
(obs=8, exp=2.7, +196% enrichment, p=3x10-3, FDR<5%; Figure 5.2). While enrich­
ments of this pathway’s genes were observed both for Loss CNVRs (obs=7, exp=2.1, 
+230% enrichment, p=3x10-3, FDR<5%) and for Gain CNVRs (obs=2, exp=0.8, 
+151% enrichment, p=0.19), significance was reached only for Loss CNVRs. As 
Parkinson’s disease is a condition characterized by the degeneration and dysfunc­
tion of dopaminergic neurons19, these enrichments corroborate our finding that or- 
thologues of genes whose disruption in mouse gives rise to abnormal dopaminergic 
neuron morphology are enriched in MR-associated CNVRs (see 
above).
The allelic changes underlying MR phenotypes might also be expected to prefer­
entially involve ‘brain-specific’ genes, those that are highly expressed in the human 
brain relative to other human tissues. Indeed, All MR-associated CNVRs were sig­
nificantly enriched in brain-specific genes (+24% enrichment, p=1x10-2; Figure 5.3), 
specifically for Loss (+31% enrichment, p=8x10-3) but not for Gain CNVs (+4% en­
richment, p=0.45). The significant enrichments observed when testing mouse phe­
notypes are thus corroborated by enrichments in human gene expression.
Distinction from benign CNVs
These findings would have little or no predictive potential if apparently ‘benign’ CNVs 
(those present in the general human population) also exhibit such biases. However, 
in contrast to the above results, benign CNVs show no significant enrichments of (i) 
genes that are highly-expressed in the brain (211% deficit, p=0.2; Figure 5.3), (ii) 
genes present in neurodegenerative disease pathways (232% deficit, p=0.1; Figure
5.2), or (iii) genes with nervous system phenotypes when disrupted in mice (211% 
deficit, p=0.01; Figure 5.1). Instead, benign CNV genes show significant tendencies 
to encode proteins with roles in immunity and host defense20 21. Each of these three 
features thus may be exploited to distinguish MR-associated CNVR genes from 
benign CNVR genes.
MR-associated and benign CNVs show no significant tendency to overlap (p=0.1). 
Nevertheless, by excluding all genes in MR associated CNVs whose gain/loss- 
matched copy number change is also seen in benign CNVs we enhanced the dis­
crimination of genes whose copy number change is predicted to contribute to MR 
aetiology. This was specifically the case for mouse fine-scale nervous system phe­
notypes and human neurodegenerative disease pathways (Figure 5.1 and Figure
5.2). Moreover, after excluding benign CNV-overlapped genes, not only Parkinson’s
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Table 5.1. Genomic extent and NCBI gene content for MR-associated and benign CNVs.
CNVR number 
(median size)
CNV number 
(median size)
Gene
Count
MR CNV 
genes also 
contained 
within be­
nign 
CNVs
MR CNV 
genes not 
contained 
within be­
nign 
CNVs
Genome
covered
(Mb)
Gene
density/
Mb
All MR 112 (2.76 Mb) 148 (2.74 Mb) 4,009 703 3,397 440.1 9.1
Gain MR 32 (1.90 Mb) 37 (2.55 Mb) 1,189 283 907 92.9 12.8
Loss MR 85 (3.04 Mb) 111 (2.85 Mb) 3,159 449 2,711 367.8 8.6
Benign 1,388 (0.17 Mb) 26,472 (0.21 Mb) 4,576 N/A N/A 429.0 10.7
% change 
over 
expected
15/ '  
10
5
0
-5 /  
-10 / 
-15-
n
Nervous System
200/
Benign CNVRs
Abnormal Axon 
Morphology
All MR CNVRs
Abnormal 
Dopaminergic Axon 
Morphology
I All MR CNVRs minus 
I benign CNVRs
Loss MR CNVRs Loss MR CNVRs minus 
benign CNVRs
Figure 5.1. Enrichments of MGI phenotype terms among genes overlapped by MR-associated CNVRs. One phenotypic category (Nervous 
System) and two specific nervous system phenotypes (Abnormal Axon Morphology and Abnormal Dopaminergic Neuron Morphology) are 
significantly over-represented in genes overlapped by All or Loss-only MR-associated CNVRs. The phenotypes result from the disruption 
of mouse genes that have been mapped to their unique human orthologue. MR CNVR sets denoted “ minus benign CNVs” have had 
genes removed that are also overlapped by benign CNVRs when matched on the direction of copy number change (i.e. Gain or Loss). 
Columns marked with an asterisk (“*” ) are significantly enriched (FDR,5%).
Figure 5.2. Human gene enrichm ents corroborate m ouse phenotypic enrichm ents.
(A) Enrichments of genes involved in Parkinson's disease or human neurodegenerativa 
disease pathways that are overlapped by MR-associated CNVRs. These genes are 
described by KEGG as belonging to the Parkinson's disease pathway (HSA05020) or 
belonging to any of six neurodegenerative pathways (namely, HSA05010, HSA05020, 
HSA05030, HSA05040, HSA05050, and HSA05060). MR-associated CNVR sets denoted 
“ minus benign CNVs'' have had genes removed that are also overlapped by benign 
CNVRs showing the same direction of copy number change (i.e. Gain or Loss) as its 
overlapping MR-associated CNVR. Columns marked with an asterisk (“ *” ) are significantly 
enriched (FDR<5%). (B) All genes contained in the KEGG Parkinson's disease pathway 
(HSA05020). Of the 18 genes in this pathway, 8 (highlighted in red) are involved in a rare 
de novo CNV from at least one or more patients. The remaining genes (depicted in grey) 
lie outside of the 148 MR CNVs that we considered.
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disease pathway genes, but genes from 5 other neurodegenerative disease path­
ways (namely, Alzheimer’s disease, Amyotrophic Lateral Sclerosis, Huntington’s 
disease, Dentatorubropallidoluysian atrophy and Prion Diseases) when considered 
together, became significantly enriched (+60% enrichment; p=0.02) in this analysis. 
These results would be explained if MR-causative alleles segregate more with se­
quence that is copy number variable in MR individuals than with CNVs observed in 
the general population.
Additional clinical features
We considered whether our method could identify significant associations between 
mouse and human patient phenotypes other than MR. We investigated 7 clinical 
features that were present in our patient population in addition to the MR phenotype, 
namely brain-, cleft palate-, eye-, facial-, heart- or urogenital- abnormalities and sei­
zures (see Materials and Methods). We tested whether CNVs from individuals with 
these specific clinical features were significantly enriched in genes associated with 
phenotypically relevant mouse phenotypes. In order to limit the large number of 
statistical tests that could be performed we matched mouse phenotype categories 
(each containing between 129 and 220 terms) to each of the 7 clinical features 
based on clinical experience (see Materials and Methods) before performing the 
association tests. We found that 4 of the 7 additional clinical features were signifi­
cantly associated (FDR<5%) with between 1 and 6 mouse phenotypic terms (Figure 
5.4). For example, the CNVRs of the 8 MR patients presenting with cleft palate were 
significantly enriched with genes whose mouse orthologues, when disrupted, also 
exhibited cleft palate (Figure 5.4). Importantly, no significant associations were ob­
served between CNVs from humans without a particular clinical feature apart from 
MR and any mouse phenotype category matched to patients with that clinical fea­
ture, with the notable exception of ‘abnormal axon morphology’ that thus appears to 
be a term of broad relevance to the primary MR presentation (Figure 5.4). These 
findings demonstrate the relevance of mouse gene knockout observations to both 
the MR phenotype and associated phenotypes in patients.
Predicting genetic etiology
The distinctions between MR-associated and benign CNVR genes, described 
above, allowed the identification of genes whose copy number change may contrib­
ute to MR and associated phenotypes. To identify such candidate genes, we could 
not exploit Gene Ontology annotations (Supplementary Figure 1) or brain expres­
sion enrichments (Figure 5.3) as these enrichments provide insufficient discrimina­
tory power (<30% increase over expected). Of the 4,009 genes present in the 148 
MR-associated CNVs, 55 are annotated with either a mouse knockout phenotype 
(n = 29) and/ or a neurodegenerative disease pathway (n =29) that was significantly 
over-represented in MR-associated Loss CNVRs (Table 5.2). 50 of the MR-associ­
ated CNVs (33%) contain at least 1 of these 55 candidate genes. We calculate that 
our list represents a ~120% increase of likely phenotype-contributing genes over the 
random expectation (see Materials and Methods). Similarly, 34 genes were identi­
fied as potential candidates for additional clinical features such as cleft palate, facial
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or brain abnormalities, or seizures, 23 of which were not associated with MR itself 
(Table 5.2). We note that whilst some of these candidate genes might have been pri­
oritized from among the 4,009 CNVRs genes using a priori subjective expectations, 
our method is the first to generate a candidate gene set on the basis of objective and 
statistically sound criteria.
Discussion
If de novo MR-associated CNVs do not contribute to disease etiology their gene 
contents would not be expected to exhibit biases in gene function or expression. 
Instead, we demonstrate the first evidence for significant tendencies of MR-associ­
ated CNV genes to be brain-expressed, to belong to neurodegenerative pathways, 
and to present particular phenotypes when disrupted in mice, all of which validate 
the assumption that large de novo CNVs commonly underlie MR phenotypes. These 
results could not have been obtained without collating data from a number of sourc­
es. For example, essentially all (147 of 148) CNVs were required to obtain a signifi­
cant enrichment of genes whose mouse orthologues’ knockout produced a nervous 
system phenotype (Supplementary Figure 2). It was only by harnessing the statisti­
cal power of a research community’s large data set that this meta-analysis achieved 
significance of statistical associations (see Materials and Methods).
The significant signals seen in Loss CNVs, but not in Gain CNVs, imply that MR phe­
notypes commonly result from gene dosage sensitivity (haploinsufficency). Howev­
er, we cannot discount that they may occur from the uncovering, by DNA loss, of rare 
recessive alleles. While we did not observe an enrichment within the Gain CNVRs 
of genes associated with abnormal dopaminergic neuron morphology or of genes 
that showed brainspecific expression, we did observe non-significant enrichments of 
genes associated with abnormal axon morphology and of Parkinson’s disease path­
way genes. Given that the Gain CNVRs overlap 38% of the number of genes over­
lapped by the Loss CNVRs (Table 5.1), it is plausible that these enrichments might 
reach significance as more Gain MR-associated CNVs are reported and analysed.
Our results are in contrast with previously-reported sporadic and familial cases of 
MR whose associated genes are enriched in both X-chromosome location and en­
zymatic function22. Nevertheless, this is explained by Wright’s physiological theory 
of dominance: haplosufficient genes, such as those lying on the X chromosome, 
have an expected tendency to encode enzymes, whereas haploinsufficient genes, 
such as those expected to underlie our autosomal MR disorders, have an expected 
tendency to encode transcription regulatory genes23. Indeed, we do observe a sig­
nificant enrichment of genes associated with transcriptional regulation within MR- 
associated CNVRs (Supplementary Figure 1). In contrast to X-linked MR genes, 
of which approximately one quarter encode postsynaptic proteins24, we observe a 
small and nonsignificant depletion (p =0.39) of postsynaptic protein genes among 
our MR-associated CNVs.
None of the human CNVs recorded in this study represent homozygous losses.
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■ All MR CNVRs minus benign CNVRs
Loss MR CNVRs
■ Loss MR CNVRs minus benign CNVRs
Brain-specific Genes
Figure 5.3. Enrichment of genes, overlapped by MR-associated CNVRs, that are 
expressed highly in the brain relative to other-tissue (brain-specific genes). Such genes 
are defined as those whose level of expression in the brain exceeds 4 times the median 
expression level in all other tissues (see Materials and Methods). MR-associated CNVR 
sets denoted ‘‘minus benign CNVs’’ have had genes removed that are also overlapped by 
benign CNVRs showing the same direction of copy number change (i.e. Gain or Loss) as its 
overlapping MR-associated CNVR. Columns marked with an asterisk (‘‘*’’) are significantly 
enriched (FDR<5%).
134
F igure 5.4. Enrichments of MGI phenotype terms for genes overlapping secondary clinical 
feature-grouped CNVRs. 5 secondary feature-grouped CNVs revealed between 1-6 
significantly enriched phenotypic terms (Cleft Palate, panels (A) to (F); Facial abnormality, 
panel (G); Brain Abnormality, panels (H) and (I); Seizures, panel (J)). These MGI terms are 
significantly over-represented in genes overlapped by All or Loss-only secondary feature- 
grouped CNVRs (see main text). The phenotypes result from the disruption of mouse 
genes that have been mapped to their unique human orthologue. MR CNVR sets denoted 
‘‘minus benign CNVs’’ have had genes removed that are also overlapped by benign CNVRs 
showing the same direction of copy number change (i.e. Gain or Loss) as its overlapping 
MR-associated CNVR. Columns marked with an asterisk (‘‘*’’) are significantly enriched 
(FDR<5%).
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Thus it may initially appear problematic to compare human phenotypes directly with 
those from mice harbouring homozygous gene disruptions. Nevertheless, without 
sequence information confirming the genetic integrity of the surviving haplotype we 
cannot be certain that these human hemizygous loss CNVs do not contain inde­
pendent disruptions of each allelic copy. To gain some insight into this issue we 
considered 21 of the 55 candidate genes that contribute to a significantly enriched 
mouse knock-out phenotype identified in our study (Table 5.2), and whose pheno­
type has been recorded in the MGI resource when in the hemizygous state. Of these 
21, four (namely, En1, Mn1, Plp1 and Pmp22) also exhibit the phenotype of interest 
when hemizygously disrupted25-28. Of the remaining 17 genes, all exhibit abnormal 
phenotypes, and thus are haploinsufficient, with the exceptions of Mapt and Slc6a3 
29 30. Importantly, these mouse hemizygous phenotypes are often closely-related to 
the homozygous phenotypes, while some hemizygous phenotypes appear particu­
larly relevant to the associated human phenotype. For example, Scn1a (which con­
tributes to the tremors phenotypic enrichment we find to be associated with patients 
presenting with seizures) exhibits a seizures phenotype when in the hemizygous 
state in mice31.
Does our analysis allow us to link particular mouse gene knockout phenotypes to hu­
man CNV phenotypes? Obviously, a direct comparison between mouse neural phe­
notypes and human MR phenotypes is hindered because the invasive procedures of 
brain biopsies in patients are unacceptable. Results from a limited number of post­
mortem studies of MR patients suggest that abnormalities of dendritic spines are a 
general neuropathological feature of MR32. The mouse gene knockout phenotypes do 
provide a plausible explanation for the brain phenotypes observed in some patients 
as a consequence of the structural variation identified in their genomes. An example 
of this is the myelinassociated glycoprotein (MAG) gene that is deleted in one patient 
(case 123, Supplementary Table 2) and duplicated in another (case 124), whilst the 
knockout of its orthologous gene in mice leads to both abnormal axon morphology 
and tremors phenotypes33. Underexpression of MAG in transfected Schwann cells 
is known to lead to hypomyelinisation34. Therefore, the delayed brain myelinisation 
observed in the patient with the MAG deletion could be caused by under-expression 
of MAG during brain development. By contrast, over-expression of MAG is known 
to lead to accelerated myelinisation35. Whether the macrocephaly in the patient with 
the MAG duplication is related to over-expression of MAG during brain development 
remains unknown.
Our enrichment analysis revealed 8 genes associated with cleft palate in humans, 
present in 6 different patients (cases 10, 13, 27, 48, 96, and 141). Seven of these 
genes were located in Loss CNVs on human chromosomes 1p31.1p31.3 (containing 
LHX8), 1q41q42.13 (DISP1), 2q24.3q31.1 (DLX1, DLX2 and GAD1), 4q31.21q31.23 
(EDNRA) and 22q12.1 (MN1), and one with a Gain CNV on human chromosome 
16p13.2-p13.3 9 (CREBBP). Except for DISP1, all these genes have been associ­
ated with cleft palate in mouse models26 36-39, whereas only LHX8 and GAD1 have 
been associated with cleft palate disorders in humans40 41. This strongly suggests 
that our approach revealed 6 novel orofacial cleft (OFC) candidate genes in humans.
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Strikingly, the hemizygous loss of five of these OFC candidate genes may also con­
tribute to MR. Absence of both Dlx1 and Dlx2 in mice results in abnormal differentia­
tion within the forebrain36,42. Both genes also regulate Arx, a homeobox transcrip­
tion factor required for the migration of interneurons, whose human equivalent ARX, 
when mutated, is associated with X-linked MR and epilepsy43. In addition, mutations 
and deletions of CREBBP causes the Rubinstein-Taybi syndrome which is charac­
terized by MR44. Ednra is involved in cranial neural crest cell migration from the pos­
terior midbrain and hindbrain to the arches45. Lhx8 is required for the development of 
many cholinergic neurons in the mouse forebrain 46, whereas GAD1, which encodes 
the GABA producing enzyme, may play a role in the development and plasticity of 
the central nervous system39. In conclusion, it appears that our approach identified 
a large number of interesting and plausible novel candidate genes for both MR and 
associated clinical phenotypes.
Mouse phenotype data have not previously been exploited in a systematic genome- 
wide analysis, and our results clearly show its utility in addressing a particularly 
difficult and contemporary challenge in the field of neurological genomic disorders. 
The functional biases we see for MR-associated CNV genes can now be exploited 
to prioritise genes for further investigation in MR individuals without large de novo 
CNVs (Table 5.2). We suggest that all human genes whose orthologues present 
specific phenotypes when disrupted in mice (Figure 5.1) deserve particular scrutiny 
for fine-scale insertion, deletion or point mutations contributing to MR. Mouse ortho- 
logue knockout data are available currently for only, 25% of all human genes. More 
specifically, of the 4,009 genes overlapped by the MR-associated CNVs considered 
here, 830 (~21%) have available phenotypic annotations. Thus, we would expect 
that many more candidate genes possessing these annotations will be discovered 
within MR-associated CNVs as further knockouts are generated. Furthermore, we 
consider all genes that are involved in the specific molecular pathways we have iden­
tified, such as Parkinson’s disease and other neurodegenerative disorder pathways, 
to represent candidates for MR and/or associated phenotypes when hemizygous. 
We propose that the contribution of these candidate genes (Table 5.2) to many MR 
phenotypes can now be investigated thoroughly in mouse model systems: specifi­
cally, the 55 genes whose hemizygous deletions may be associated with MR are 
now amenable to study using hemizygous knockout mouse models.
Our study has exploited CNVs identified using several different platforms. As the 
identification technologies have improved, CNVs called using earlier technologies 
have been shown to over-estimate the true extent of a CNV’s boundaries47. Thus, 
we expect enhanced resolution of pathogenic CNVs to also increase the power by 
which genic enrichments can be identified. However, it should also be noted that 
CNVs have been shown to affect the expression of neighbouring genes and it is pos­
sible that pathogenic CNVs may exert their genetic effect through outlying genes48.
Finally, there is no reason why this approach can not be applied successfully to other 
complex neurological diseases, including schizophrenia and autism, which show a 
high frequency of rare de novo CNVs8 9 49-51. Many studies that are currently under­
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powered to demonstrate significance after correcting for multiple testing may yet 
prove informative of the genetic etiology of complex genomic disorders. For this, it 
will be crucial to collect large disease-associated CNV sets from well-phenotyped 
cohorts, as our analysis has shown that only then is there sufficient power to detect 
significant associations (Supplementary Figure 2).
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Table 5.2: Candidate genes for MR and associated clinical features. These are present 
in MR-associated CNVRs and belong to any of three significantly enriched annotations; 
namely, mouse knockout phenotypes of abnormal dopaminergic neuron morphology or 
abnormal axon morphology (F igure 5.1), and KEGG neurodegenerative pathway genes 
(F igure 5.2). Neurodegenerative pathway genes within the Parkinson's disease pathway 
are marked with an asterisk ('*'). The remaining genes lie within CNVs associated with the 
particular secondary clinical features and belong to significant enrichments identified as 
specific to those clinical feature (see main text and Figure 5.5).
MGI phenotype o r KEGG  
pathway
Gene in Loss MR CNVR
Gene in 
Gain MR 
CNVR
- associated with Mental Retardation
Abnormal dopaminergic neuron EN1 LOC390992 SLC6A3
morphology HES1 MAPK10 SNCA
(M P0003243) KCNJ6 SLC18A2 SPP1
APG5L MAPT LGI4
MAG
SCN1B
SCYL1
TYROBP
ZIC5
ARSA MBP PTPN13
Abnormal axon morphology 
(M P0005404)
CLCN6
LEPR
LGI4
MFN2
NEFH
NR2F1
SCN1B
SIM1
SNCA
MAG PLP1 TYROBP
MAN2B1 PMP22
ALS2
APLP1
BACE2
CAGLP
CASP7
CASP8
CLTB
CLTCL1
HD
HSPD1
MAPT
NCOR1
NEFH
PARK7*
PEN2
PNUTL1*
RAC1
RERE
SNCA*
SOD1
APLP1
BAD
CLTCL1
KEGG Neurodegenerative 
Pathway genes
SSR4
STX1A*
UBB*
UBE2J2*
UBE2L3*
CREBBP
HADH2
PEN2
PNUTL1
UBE1*
- associated with Brain Abnormality
Abnormal myelination 
(M P0000920)
HPN
LGI4
MAG
OLIG2
PLP1
TYROBP
HPN
LGI4
MAG
TYROBP
LGI4 PLP1
SCN1B
TYROBP
LGI4
Abnormal axon morphology 
(M P0005404)
MAG
MAPT
NR2F1
MAG
SCN1B
TYROBP
- associated with Cleft Palate
Abnormal basisphenoid bone
morphology
(M P0000106)
DISP1
DLX1 DLX2
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MGI phenotype o r KEGG  
pathway
Gene in Loss MR CNVR
Gene in 
Gain MR 
CNVR
Cleft palate 
(MP0000111)
DLX1
DLX2
EDNRA
GAD1
LHX8
MN1
CREBBP
Abnormal maxilla morphology 
(MP0000455)
DLX1
DLX2
EDNRA
GAD1
Abnormal alisphenoid bone
morphology
(MP0003235)
DLX1
DLX2 EDNRA
Absent stapedial artery 
(MP0004666) DLX1 DLX2
Abnormal palatine bone
morphology
(MP0005249)
DLX1
DLX2
EDNRA
LHX8
MN1
- associated with Facial Dysmorphism
Abnormal zygomatic arch
morphology
(MP0004469)
ACVR1
CHRD
IDUA
TBX1
ZMPSTE24
IDUA
NFATC2
TBX1
- associated with Seizures
Tremors
(MP0000745)
ATF2
EN1
ESPN
GLI2
HD
KCNAB2
KCNJ6
MAPT
SCN1A
SELE
SELP
SLC25A12
ZMPSTE24
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Materials and Methods
Rare de novo CNVs in mental retardation
For this study we collected 148 rare structural variants associated with MR from the 
literature, the Decipher database (https://decipher.sanger.ac.uk/), as well as from 
our own in-house diagnostic microarray group52 (Supplementary Table 1). The ma­
jority of these CNVs (n =135, 91%) were proved to have occurred de novo in the pa­
tient and all were independently validated. Thirteen rare autosomal CNVs for which 
parental samples were unavailable were included, as were seven rare maternally 
inherited CNVs on the X chromosome in male patients that are considered to be as 
clinically relevant as de novo CNVs on the autosomes. Importantly, at the point of 
discovery none of these CNVs were known to greatly (50%) overlap with a collection 
of 15,000 CNVs identified in healthy individuals as collected in the Database of Ge­
nomic Variants version 3 (http://projects.tcag.ca/variation/). All CNVs were mapped 
to NCBI35 coordinates. The median number of Entrez genes within a CNV was 35. 
Overlapping CNVs were merged to obtain a non-redundant set of 112 CNV regions 
(CNVRs) totalling 440 Mb of unique sequence (14.3% of the total NCBI35 human 
genome assembly; Table 5.1). CNVR sets were also formed separately from Gain 
and from Loss CNVs (Table 5.1). For 121 of the 148 CNVs, information regarding 
distinct anatomical or physiological abnormalities presented by the patient in addi­
tion to MR was available (Supplementary Table 2). These clinical features were 
used to form 7 non-exclusive groupings for additional tests.
Benign CNV datasets
We obtained 25,196 CNVs identified in 270 individuals from Redon et al.11. To these, 
we added 1,276 inherited CNVs identified in 494 individuals with a 32k BAC tiling 
path array. This last set is described in Nguyen et al.53 and, together with the Koolen 
et al.52 MR-associated CNV data, are available from the Gene Expression Omnibus 
(http://www.ncbi.nlm.nih. gov/geo/) with accession number GSE7391. Combined, 
these apparently benign CNVs represent 430 Mb of unique sequence (14.0% of the 
total NCBI35 human genome assembly; Table 5.1). In the absence of information 
suggesting that any of the individuals present with MR, we conservatively assume 
that genes overlapped by these apparently benign CNVs do not contribute to the MR 
phenotypes.
Genomic data sets
Assignment of protein-coding genes depended upon the particular analysis per­
formed: for protein-coding gene counts and the Gene Ontology analysis, we as­
signed genes to CNVs according to Ensembl54 (Ensembl mart version 37), whereas 
for KEGG pathway and MGI analyses we assigned genes to CNVs according to 
Entrez genes55.
Mouse Genome Informatics (MGI) phenotype data
Information on human NCBI genes whose mouse orthologues’ disruption had been 
assayed were obtained from the Mouse Genome Informatics (MGI) resource (http:// 
www.informatics.jax.org, version 3.54)12-14. We employed the MGI’s human/ mouse
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orthology and marker assignment to map MGI mouse marker phenotypes to Hu­
man Entrez genes55. We mapped, using unambiguous gene orthology relationships, 
5,075 different MGI phenotypic annotation terms to 4,999 human genes. We con­
sidered all phenotypic annotations from all experimental methodologies described 
within the MGI resource. While the vast majority of these annotations are derived 
from the disruption of mouse genes, some phenotypes were derived from experi­
ments in which mutant alleles are introduced into the mouse (e.g. Shelbourne et. 
al.56). Nonetheless, we regard the phenotypic information from these experiments 
as remaining informative of the biological functions or pathways to which the gene 
contributes. It is noted, however, that the phenotypes of all genes underlying the 
phenotypic enrichments we report in this work (Figure 5.1 and Figure 5.2; Table
5.2) were obtained through gene disruption experiments.
The MGI phenotypic annotations are categorised non-exclusively into 33 over-arch­
ing terms (Supplementary Table 3). When examining finer phenotypic terms be­
neath an over-arching term(s) we considered only those finer terms that possessed 
at least 1% of the genes annotated with the over-arching term(s). This allowed a 
reduction in the number of tests performed thereby limiting spurious and uninforma­
tive results. The phenotypes associated with the Entrez genes overlapped by a given 
set of genomic regions were compared to the frequency of that phenotype across 
the whole genome. All p-values were obtained by application of the hypergeometric 
test and were subject to a false discovery rate (FDR) of <5%18 (see below). Given 
the large number of phenotypic terms and the unrealistic assumption of terms’ inde­
pendence when applying an FDR, application of this significance threshold is likely 
to be conservative.
Linking mouse knockout phenotypes to patient phenotypes 
Many of the MR patients used in this study show additional clinical features. We 
tested for associations between commonly occurring non-MR clinical features in 
patients and a subset of MGI phenotypes. We scored patients for the presence of 
7 common features derived from the London Dysmorphology Database57. These 
were: (i) seizures/abnormal EEG, (ii) facial dysmorphism, (iii) cleft palate, (iv) heart, 
general abnormalities, (v) eye abnormalities, (vi) brain, general abnormalities, and 
(vii) urogenital system abnormalities. Patients were excluded if specific phenotypic 
data were unavailable (all 19 cases from the Decipher database). As these sec­
ondary clinical feature grouped CNVs were fewer in number than the entire set of 
MR-associated CNVs, and therefore relatively diminished in statistical power, the 
most relevant MGI phenotypic categories were selected (from a total of 33; Supple­
mentary Table 3) in order to reduce the number of tests. Two pairs of paralogous 
genes, DLX1 & DLX2 and SELE & SELP, contributed to the significant phenotypic 
enrichments reported within the secondary clinical feature grouped CNVs (Table
5.2). However, significant phenotypic enrichments that these pairs of paralogues 
contributed to all remained significant after removing one of the paralogous pairs 
(p<0.05; single test). Nevertheless, we note that an increased penetrance of a result­
ing phenotype might be expected if these pairs of paralogues provided a degree of 
redundancy to one another, and therefore the concurrent copy number variation of
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both paralogues may prove even more significant than variation involving only one42. 
Kyoto Encyclopedia of Genes and Genomes (KEGG)
Annotations of genes involved in neurodegenerative pathways were obtained from 
KEGG17. KEGG genes were collated if they belonged to KEGG Pathways section 
5.3, namely Alzheimer’s disease (KEGG pathway 05010), Parkinson’s disease 
(KEGG pathway 05020), Amyotrophic Lateral Sclerosis (KEGG pathway 05030), 
Huntington’s disease (KEGG pathway 05040), Dentatorubropallidoluysian atrophy 
(KEGG pathway 05050) and Prion Diseases (KEGG pathway 05060). KEGG genes 
were mapped to NCBI Entrez genes using associations provided by KEGG.
Tissue expression of genes
For human gene expression data, we used GNF’s gene atlas data for the MAS5-con- 
densed human U133A and GNF1H chips, considering all 74 non-cancer tissues16. 
Expression levels were mapped to LocusLink identifiers and to 11,594 Ensembl Ens- 
mart 37 (NCBI35) genes using the annotation tables supplied by GNF. To identify 
genes that are highly expressed in the brain we selected those genes whose expres­
sion in the whole brain exceeded by 4-fold their median expression in all other non­
brain tissues after excluding cancerous tissues. This resulted in 435 genes (3.75%) 
being classified as exhibiting strong expression in the brain relative to other tissues. 
However, the significant enrichments reported in the Results were also found when 
brain-specificity was redefined at 2-, 3-, 7-, 10-, 11-, 12-, 13-, and 14-fold expression 
in the brain above the median across all other tissues.
Postsynaptic protein genes
A set of postsynaptic protein genes was obtained from Collins et al.58 and matched 
to human orthologues using Ensembl Compara59. Over- or under-representation of 
these genes within human CNVs was assessed using the hypergeometric distribu­
tion and all human Ensembl genes as the background set.
Statistical tests
The significance of enrichments or deficits of genes associated with particular MGI 
knockout phenotypes, genes involved in KEGG neurodegenerative pathways, genes 
associated with particular GO terms and brain-specific genes were evaluated using 
hypergeometric tests. Where multiple tests were performed, a False Discovery Rate 
(FDR) multiple testing correction was applied to ensure a less than 5% likelihood 
of any significant term being a false-positive18. Explicitly, an FDR correction was 
applied when testing for enrichments of genes: (i) associated with MGI phenotypic 
terms, (ii) belonging to individual KEGG neurodegenerative pathways or (iii) annotat­
ed with Gene Ontology terms (Supplementary Figure 1). All other tests performed 
were single tests.
Calculation of the fold-enrichment within MR-associated CNVs for the final set of 55 
MR-associated candidate genes was performed by random sampling. 1,000 gene 
sets, matched in gene number to that within the Loss MR-associated CNVRs, were 
obtained by random sampling and the median expected number of genes, 23 (std.
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dev. = 4.6), annotated with one or more significantly-enriched terms (Figure 5.1 and 
Figure 5.2) was recorded. Given the 50 candidate genes within the Loss CNVRs, we 
thus estimate a ~2.2-fold enrichment over the number expected by chance.
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Abstract
Copy number variants (CNVs) have recently been recognized as a common form of 
genomic variation in humans. Hundreds of CNVs can be detected in any individual 
genome using genomic microarrays or whole genome sequencing technology, but 
their phenotypic consequences are still poorly understood. Rare CNVs have been 
reported as a frequent cause of neurological disorders such as mental retardation 
(MR), schizophrenia and autism, prompting widespread implementation of CNV 
screening in diagnostics. In previous studies we have shown that, in contrast to 
benign CNVs, MR-associated CNVs are significantly enriched in genes whose 
mouse orthologues, when disrupted, result in a nervous system phenotype. In this 
study we developed and validated a novel computational method for differentiating 
between benign and MR-associated CNVs using structural and functional genomic 
features to annotate each CNV. In total 13 genomic features were included in the 
final version of a Naïve Bayesian Tree classifier, with LINE density and mouse knock­
out phenotypes contributing most to the classifier’s accuracy. After demonstrating 
that our method (called GeCCO) perfectly classifies CNVs causing known MR- 
associated syndromes, we show that it achieves high accuracy (94%) and negative 
predictive value (99%) on a blinded test set of more than 1,200 CNVs from a large 
cohort of individuals with MR. These results indicate that this classification method 
will be of value for objectively prioritizing CNVs in clinical research and diagnostics.
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Introduction
Improvements in microarray resolution and hybridization robustness have resulted 
in the widespread implementation of genomic microarray technologies in medical 
research and diagnostics. This technology is most effective in detecting genomic 
deletions and duplications larger than 1kb, known as copy number variants (CNVs). 
Genomic microarrays are commonly used to identify rare, but highly penetrant, and 
commonly single CNVs in patients suffering from neurological disorders such as 
autism1-3, schizophrenia4-6 and mental retardation (MR; also known as learning 
disability)7-9. However CNVs have also been recently recognized as a common 
form of genomic structural variation: high resolution microarrays and sequencing 
approaches are able to identify 600 - 900 CNVs in a single individual10-14. Current 
clinical interpretation therefore needs to contrast the frequencies of a CNV in affected 
versus unaffected individuals, as well as determining the inheritance of CNVs via 
parental analysis1516. The identification of a CNV that is (1) relatively large, (2) 
overlaps genes, (3) is rare, and (4) de novo in a patient provides a strong indicator 
of clinical significance, because this combination is extremely rare in the normal 
population owing to a low structural mutation rate outside of hypervariable ‘hot spot’ 
regions101718. Increases in microarray resolution are revealing both a much higher 
rate of rare CNVs than previously thought19 and an increasing number of genomic 
loci being reported that show variable inheritance and penetrance. Such examples 
have been reported for CNVs at 1q21.12021, 15q13.32223, and 16p13.1124 25. These 
loci demonstrate that there are limitations in considering CNVs as either benign 
when common and inherited, or causal when rare and de novo.
At present up to 5% of the human genome has been shown to vary in large scale 
copy number in numerous healthy controls13 26 and novel CNVs continue to be 
identified27. In Nguyen et al. (2008)28 we reported a number of genomic features 
whose frequencies are significantly different in apparently benign CNV regions 
compared with the genome as a whole. In particular, CNV regions are enriched in 
repetitive sequences of near identical DNA known as segmental duplications29 and 
are less prone to recombination. Furthermore, these CNV regions are characterized 
by tendencies to coincide with between-species break-points in synteny and to be 
prone to elevated nucleotide substitution rates, whilst their encoded proteins tend 
to exhibit elevated evolutionary rates. In a separate study we compared a large set 
of rare de novo CNVs associated with MR with CNVs identified in healthy control 
individuals. This study demonstrated that MR-associated CNVs are significantly 
enriched in genes whose mouse orthologues, when disrupted, result in abnormal 
axon or dopaminergic neuron morphologies, and in genes from neurodegenerative 
disease pathways30. Importantly, we showed that benign CNVs do not display such 
properties. Such observations can thus now be used to prioritize dosage-sensitive 
candidate genes for MR. Of relevance to this study is that these distinctions of MR- 
associated CNVs may be exploited to aid the development of an objective method 
for distinguishing disease-associated CNVs from benign CNVs that does not rely 
solely on allele inheritance and frequency in the normal population.
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Although a large number of methods are available for the computational prioritization 
and classification of genomic data31-34, none thus far has been developed specifically 
for CNV data. For this study we implement a Naive-Bayesian Tree classifier (NBTree). 
This hybrid approach combines a decision tree with Naive-Bayesian classifiers, and 
exploits the segmentation of decision trees and the accumulation of Naive-Bayes 
evidence. There are four major advantages of decision-tree classifiers for assigning 
pathogenicity to CNVs. These classifiers are (i) fast and (ii) their results are easily 
comprehensible. They are (iii) very robust to irrelevant features and (iv) classification 
takes into account evidence from many attributes in arriving at a final prediction35. 
In this study our aim was to validate the use of an NBTree, based upon genomic 
features, to accurately separate disease-associated CNVs from benign CNVs.
Results
We started by selecting genomic features (Table 6.1), based on our previous 
observations28 30, as the basis attribute set for development of the classification 
procedure. In addition, we collected a large cohort of CNVs identified in healthy 
controls (termed “benign CNVs”) and a large set of CNVs associated with MR 
(termed “MR-associated CNVs”)30. These CNVs were used for training and testing 
the Naive-Bayesian Tree classifier (NBTree). After optimization, the accuracy of the 
classifier was initially assessed by applying the classifier to a small independent set 
of CNVs known to be pathogenic (“Decipher known syndromes”). We subsequently 
applied the classifier to a third, much larger set of CNVs identified during routine 
MR microarray diagnostics, termed “MR diagnostics CNVs” (see Supplementary 
Figure 1 for study design). Finally, we studied two further sets of CNVs whose 
clinical significance is currently unknown. The first contained rare CNVs for which 
inheritance could not be determined (“candidate CNVs”). The second set contained 
rare, privately inherited CNVs.
Development of the Classifier
We identified a total of 16 genomic features as suitable attributes for the classifier 
which could be divided into either: (1) structural features such as segmental 
duplication density, and (2) functional features, such as gene density (Table 6.1). 
These genomic attributes were also considered to be either continuous or categorical 
features. To compensate for the dependencies of CNV length on the frequencies 
of features (e.g. LINE, SINE, segmental duplication and gene numbers) we also 
calculated the densities of LINEs, SINEs, segmental duplications and ENSEMBL 
gene models. A categorical feature was created to be set as ‘true’ when a CNV 
contains at least one gene whose mouse orthologue, when disrupted exhibits 
a mouse nervous system phenotype (and otherwise ‘false’). Previously we have 
shown that MR CNV genes are enriched in the KEGG neurodegenerative pathway 
(namely, hsa01510). This feature was also represented in the classifier, specifically 
as a categorical feature when at least one CNV gene is a member of this KEGG 
pathway. Finally, we incorporated in the classifier information regarding the gene 
expression variance from microarray expression experiments performed in 176 
HapMap EBV cell lines, reasoning that dosage-sensitive genes tend to show less
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variable expression levels36 37.
Table 6.1: Genomic attributes investigated as potential classification features. Each 
feature is either categorical or a continuous numerical feature. Furthermore, each feature 
relates to either a structural genomic attribute or a functional genomic attribute.
Genomic
Feature Structural Functional Categorical Continuous
1 Type (Gain / * *Loss)
2 Length * *
3 # LINEs * *
4 LINE density * *
5 # SINEs * *
6 SINE density * *
7 # Segmental * *Duplications
Segmental
8 Duplication
Density
* *
9 # Genes1 * *
10 Gene Density1 * *
11 dS3 * *
12 dn4 * *
13 dn/dS2 * *
14 KEGG Pathway * *(hsa01510)
15 MGI Phenotype * *(MP:0003631)
16 Gene * *expression
1 For these features we counted the number of genes overlapping the CNV; 2These features 
did not contribute to the accuracy of the classifier and were removed from the final version; 
3dS = Synonymous substitution rate; 4dn= Non-synonymous substitution rate
Optimal balance between among CNVs in the training set.
The relative frequencies of the two different classes of CNV in the training set are 
very different (they are ‘imbalanced’). MR-associated CNVs are identified in ~10% of 
MR patients screened and, for these, in the large majority of cases MR is attributable 
to only a single CNV (see Introduction for specific details regarding current clinical 
practise for identifying clinically-relevant CNVs). By contrast, 5 to 10 benign CNVs 
can be identified per non-patient individual, depending on the microarray platform 
being used10-13. We started by investigating the impact of this imbalance between 
the two CNV classes on the accuracy of the classifier during training. We performed
156
1,000 training and test runs of the classifier each with 30 different levels of imbalance 
between MR-associated and benign CNVs in the training set. Initially, a random 
selection was made consisting of half of all available benign CNVs (n=1,413) and half 
of all MR-associated CNVs (n=82). The remaining CNVs were used subsequently 
as test instances. The imbalance was then gradually decreased until equal numbers 
(n = 82) of MR-associated and benign CNVs were present in the training set (see 
Methods). The most imbalanced training set, consisting of 5.5% MR-associated 
and 94.5% benign CNVs (82:1,413), produced a classifier with the lowest mean 
accuracy (80.4% ± 2.9%) (Figure 6.1). The highest mean accuracy (87.3% ± 2.6%) 
was achieved using a balanced training set containing 82 MR-associated and 82 
benign CNVs: this scenario takes advantage of only 5% of all available benign CNVs 
for the training set.
750  0.1 0.2 0.3 0.4 0.5
Fraction of the benign CNVs
Figure 6.1: Effect o f the imbalance between MR-associated and benign CNVs in the 
training set on the accuracy o f the classifier. This figure shows the relationship between 
the fraction of available benign CNVs used in the training set and the accuracy of the 
classifier (calculated over 1,000 independent test and training runs). Maximum accuracy 
is achieved with a similar number of MR-associated and benign CNVs in the training set ( 
~5% of the benign CNV instances available).
Optimal selection o f the training set
A consequence of using a balanced training set with equal numbers of MR-associated 
and benign CNVs is that not all available benign CNVs are used during training. In 
order to select the optimal training set we randomly re-sampled the training set over
10,000 iterations selecting 82 MR-associated CNVs and 82 benign CNVs, with the 
remaining benign CNVs being placed in the test set. A mean accuracy of 86% (± 
2.8%) was obtained from these iterations, which demonstrates that the classifier 
achieves a reasonable level of accuracy irrespective of which benign CNVs are 
selected for the training set. In addition, this analysis identified an optimal subset of 
CNVs for training which achieved a maximum accuracy of 95.7% and an area under 
the ROC curve of 0.98 when classifying the test set of CNVs. The resulting classifier 
using this optimal training set contains 5 tree nodes with univariate splits based on
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the CNV length, and on the segmental duplication, LINE, SINE and gene densities. 
The 6 leaves of the tree each contain a different Bayesian classifier based on all 
features used during training.
Feature Contribution to classification accuracy
The optimal training set was obtained by training the classifier on all 16 available 
features. To quantify the contribution of each feature to the accuracy of the classifier 
we used a leave-one-out policy for each feature, retrained the classifier and then 
measured the percentage decline in classification accuracy (Figure 6.2).
H
Lengtf^Gain/^LINEs .ine #SINEs SINE #Seg Seg Dup 
Loss Density Density Dupsa Density8
-1
-2 
-3 
-4  
-5 
-6
#Genes Gene KEGG MGI Gene dS dÑ dÑTdS 
Density Pathway Pheno Expr*
Figure 6.2: Analysis o f the relative contribution o f each genomic feature to  the CNV 
classifier. Both structural and functional genomic features are evaluated for their impact on 
classification accuracy. This analysis is performed by measuring the decrease in accuracy 
of the classifier as each classification feature is removed individually. KEGG Pathway refers 
to the CNV region containing at least one gene implicated in a KEGG neurodegenerativa 
pathway, and MGI Pheno refers to the CNV region containing at least one gene displaying 
a nervous system phenotype in a knockout mouse. Gene Expression refers to the 
stability of gene expression of genes present in the CNV. Removal of the LINE density 
from the classifier results in the largest decrease in accuracy (6%) whilst removing MGI 
knockout phenotypes results in a drop of 5% in accuracy. The number of SINE elements, 
the non-synonymous substitution rate (dN), and the ratio of the synonymous versus non- 
synonymous substitution rate (dN/dS) individually have no effect on the accuracy of the 
classifier.
However, in order to exclude the effect of length on the classifier, the features SINE, 
LINE, segmental duplication and gene count features were simultaneously removed 
with the length feature. For example, removing the LINE density or the length from 
the classifier resulted in a 6% decrease in accuracy, whilst removing the mouse MGI 
knock-out phenotypes resulted in more than a 5% decrease in accuracy. A 4.2% 
decrease in accuracy was measured when any one of the segmental duplication
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density, gene count, KEGG pathway or mean ds value was removed. Removing 
the CNV type (either gain or loss) resulted in a 3.7% decrease in accuracy. A similar 
decrease in accuracy was observed when removing the number of segmental 
duplications. Smaller effects were seen when any one of the LINE count, SINE 
density, gene density and gene expression features was removed from the classifier. 
By contrast, leaving out the number of SINE elements, mean dN value, or mean dN/ 
dS ratio had little or no effect on the performance of the classifier. Consequently, 
these three features were excluded from the final classifier.
Validation of the Classifier
Application to MR Syndromes
The Decipher database of known syndromes associated with genomic structural 
variants (https://decipher.sanger.ac.uk) provides a large set of pathogenic CNVs 
that is suitable for the independent validation of the classifier. In this database the 
genomic locations (based on microarray studies) of 58 syndromes are reported, 
32 of which are associated with MR. We applied the classifier to these 32 genomic 
regions and found that 31 regions were classified as pathogenic. The 80kb critical 
region of Rubinstein-Taybi Syndrome was not correctly classified (Supplementary 
Table 1). This region is a composite of overlapping microdeletions, ranging in size 
from 1.5 -  3.5Mb, identified in 3 individuals with this syndrome. When we tested 
these three regions individually each was classified as pathogenic. From this we 
concluded that the classifier was able to correctly identify known pathogenic CNVs.
Application to MR Diagnostics
We performed a second more extensive study to validate the accuracy of the 
classifier using an independent set of 584 MR patients in which 1,203 CNVs (the 
set “MR diagnostics”) had been identified during routine diagnostics using Affymetrix 
250k SNP microarrays. These CNVs were identified as being associated with MR (n 
= 49) based on de novo occurrence and the absence of similar CNVs in the normal 
population, or as being benign CNVs (n =1,154) known to be present in the normal 
population. Of the 1,203 CNVs in the validation set, 94% of the CNVs were classified 
correctly, with a sensitivity of 88% and a specificity of 94% (Figure 6.3A). More 
specifically, 43 of 49 MR-associated CNVs were correctly classified, 37 of which 
had a distance of less than 0.1 from the MR class, showing that these classifications 
have a high confidence. Each node of the NBTree contains a Bayesian classifier 
resulting in the most likely class (benign or MR-associated) for each CNV being 
predicted. In addition, the probability (a distance function) is calculated that a CNV 
belongs to the MR-associated CNV class or to the benign CNV class. The overall 
false positive rate was 0.05 and the false negative rate 0.12. The positive predictive 
value was 0.38 (indicating the number of CNVs correctly classified as MR, divided 
by the total number of CNVs classified as being MR). The negative predictive value 
was 0.99 (indicating the number of CNVs correctly classified as benign, divided by 
the total number of CNVs classified as benign) (Table 6.2). 1,085 of 1,154 benign 
CNVs (94%) were correctly classified whilst 69 (6%) were incorrectly classified as 
an MR-associated CNV (Table 6.2). To exclude the possibility that the initial training 
set did not contain sufficient biological coverage to represent the variance of each
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classification feature, and to train the optimal classifier, we combined the test and 
training sets and retrained the classifier. The accuracy of the resulting classifier was 
then tested on the validation set. The training set was jack-knifed to contain equal 
numbers of MR-associated and benign CNVs (n = 164) and 10,000 iterations were 
performed. The mean accuracy across all iterations was 76% and the maximum 
achieved accuracy was 94%, equal to that gained with the smaller training set. 
Thus we conclude that the training set with 82 MR-associated and 82 benign CNVs 
contained sufficient biological coverage to model the data accurately.
To further investigate the contribution of particular features to misclassification rates 
we calculated the mean values for each feature in the correctly and incorrectly 
classified CNV groups (Supplementary Table 2). This highlighted some general 
differences between correctly and incorrectly classified CNVs. For example, 78% 
of the incorrectly classified benign CNVs were copy number gains and contained, 
on average, fewer segmental duplications than correctly classified benign CNVs. In 
addition, 86% of the correctly classified MR-associated CNVs contain at least one 
gene whose mouse orthologue knockout results in a nervous system phenotype, 
whereas only 33% of the incorrectly classified MR-associated CNVs contain such 
genes. We also noted that correctly classified MR-associated CNVs have an 
average genomic size of 7.7Mb, whereas CNVs incorrectly classified as benign 
have, on average, a much smaller size of 1.1Mb. Likewise, incorrectly classified 
benign CNVs also had a smaller average size (319kb) than benign CNVs correctly 
classified (492kb). We therefore investigated the accuracy of the classifier on 971 
CNVs smaller than 1.1Mb in more detail. For these smaller CNVs, 9 of the 13 MR- 
associated CNVs as well as 890 of the 958 benign CNVs were classified correctly. 
The performance of the classifier on these small CNVs was comparable to the overall 
performance on the complete validation set with an accuracy of 93% and specificity 
of 93%, with the exception of sensitivity which dropped by 18% to 70%. Analysis 
of the genomic features in smaller CNVs showed that despite differences in CNV 
lengths, small MR-associated CNVs show many similarities to larger MR-associated 
CNVs such as similar SINE and gene densities (Supplementary Table 2).
Application of the Classifier to CNVs of unknown Clinical Significance 
Finally we sought to use our classifier on two further CNV datasets with unknown 
clinical significance, termed candidate CNVs and rare inherited CNVs. We first 
selected a set of 53 rare CNVs identified in the clinic, not known to vary in copy 
number among the general population, for which inheritance could not be established 
due to the unavailability of one or both parents. Due to their unknown inheritance and 
rare status, we are unable to determine using current diagnostic procedures whether 
these CNVs are indeed causal. In total, 46 of these 53 CNVs were classified as MR- 
associated CNVs (Table 6.2). We also applied the classifier to a set of rare, privately 
inherited CNVs that are not known to vary in the general population (Figure 6.3b). 
Twenty-seven of the 41 rare inherited CNVs were classified as an MR-associated 
CNV, and 14 were classified as a benign CNV (Table 6.2) displaying a significant 
enrichment in the number of CNVs classified as MR-associated when compared to 
size matched CNVs selected randomly from the genome (p = 7.0x10-3).
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Table 6.2: Application o f the classifier to  CNVs obtained in routine diagnostics of 
patients w ith mental retardation. The accuracy of the classifier developed was tested on 
an independent cohort of CNVs. Phase 1 contained the validation set of 1,203 CNVs known 
to be either rare de novo or commonly inherited. 43 of the 49 rare de novo CNVs known to 
be associated with MR were correctly classified, and 1,085 of the 1,154 common inherited 
CNVs known to be benign were correctly classified, thus giving an overall classification 
accuracy of 94%. The false positive rate was 0.05 and the false negative rate was 0.12. 
The positive predictive value was 0.38 and the negative predictive value was 0.99. Phase 
2 consisted of the application set containing 94 CNVs of unknown clinical significance. Of 
the 41 rare inherited CNVs the classifier identified 27 CNVs as MR-associated and 14 as 
being benign. 53 candidate CNVs for which the inheritance could not be determined were 
also classified, from which 46 were classified as being MR and 7 CNVs were classified as 
being benign.
Classifier
Output
Validation Set
(Rare de novo vs. common inherited 
CNVs)
Application Set 
(CNVs of unknown clini­
cal significance)
(Rare de 
novo vs. 
common 
inherited 
CNVs)
Benign
CNVs
(recurrent
inherited)
Sub Total RareInherited
Rare 
CNVs of 
unknown 
inheritance
MR 43 69 112 27 46
Benign 6 1,085 1,091 14 7
Total 49 1,154 1,203 41 53
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Figure 6.3: Benign CNVs are separable from MR-associated CNVs using a distance function that reflects the probability that a 
CNV belongs to the MR-associated CNV class. The CNVs are ranked and their probability of belonging to the MR-associated CNV 
class is plotted, (A) 1,203 CNVs with known inheritance collected from routine diagnostics are classified with a sensitivity of 88% and 
a specificity of 94%. 1,085 of the 1,154 of the common inherited CNVs were correctly classified (blue), and 43 of 49 CNVs previously 
associated with MR were correctly classified as MR-associated (green). 6 CNVs which had been interpreted as not being associated with 
MR, were classified as MR-associated (red), as well as 69 CNVs classified as MR-associated which had previously been interpreted as 
benign (purple). (B) Similarly, 41 rare inherited CNVs with unknown clinical significance are classified, 27 of which were classified as MR- 
associated with a MR distance > 0.5 (green), and 14 were classified as benign (MR distance < 0.5, blue).
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Table 6.3: Mean (and standard deviation) of each genomic feature used by the classifier during the validation and application studies. For each class of 
CNV the feature mean and (standard deviation) for the correctly and incorrectly classified CNVs are indicated.
Sort # LINE SINE
#
Seg SegDup # Gene MGI Genes Evol
N1 Length (%Gain) LINE Density Density Dup2 Density Genes Density KEGG3 Pheno4 Exp tf,5
MR CNVs 49 6,868,119 0.143 3,413 0.045 0.076 112 0.003 65 (111) 0.002 0.061 0.796 0.157 0.04(13,483,761) (7,621) (0.01) (0.04) (218) (0.004) (0.002) (0.06) (0.06)
Rare
Inherited
CNVs
41 1,179,475 0.634 545 0.048 0.055 13 0.001 7(13) 0.001 0.000 0.171 0.178 0.003(1,998,736) (820) (0.010) (0.031) (24) (0.002) (0.001) (0.117) (0.006)
Benign 1,154 482,023 0.677 227 0.047 0.059 73 0.008 3(3)
0.001 0.001 0.000 0.121 0.006CNVs (582,532) (274) (0.010) (0.039) (117) (0.008) (0.002) (0.137) (0.034)
Candidate 53 2,567,026 0.547 1,246 0.047 0.069 56 0.002 34 (50) 0.001 0.000 0.509 0.151 0.014CNVs (3,926,881) (2,028) (0.008) (0.032) (115) (0.003) (0.002) (0.088) (0.073)
Correctly 
Predicted 
MR CNVs
43 7,676,020 0.140 3,816 0.045 0.078 115 0.002 72 (117) 0.002 0.070 0.860 0.159 0.009(14,221,898) (8,062) (0.01) (0.04) (226) (0.003) (0.002) (0.06) (0.016)
Incorrectly 
Predicted 
MR CNVs
c; 1,078,163 0.167 524 0.048 0.063 92 0.006 15(17) 0.001 0.000 0.333 0.144 0.0000 (725,264) (384) (0.01) (0.02) (159) (0.007) (0.001) (0.032) (0.000)
Correctly
Predicted 1,085 492,408 0.670 232 0.047 0.058 77 0.008 3(3) 0.001 0.000 0.006 0.120 0.006Benign
CNVs
(596,653) (280) (0.010) (0.039) (119) (0.008) (0.002) (0.139) (0.031)
Incorrectly
Predicted
Benign
CNVs
69 318,731(223,884) 0.783
149
(112)
0.046
(0.01)
0.073
(0.044) 8 (20)
0.002
(0.003) 3(5)
0.001
(0.002) 0.000 0.174
0.160
(0.081)
0.016
(0.082)
Small MR
13 659,115 0.231 277 0.042 0.084 10 0.001 13 (14) 0.002 0 0.538 0.164 0.009CNVs (336,878) (155) (0.006) (0.049 (17) (0.002) (0.003) (0.072) (0.024)
1n=Number of CNVs; 2#Sep Dup = Number of Segmental Duplications; 3KEGG Path=Presence of genes from hsa01510; 4MGI Phenotypes=Presence of
genes from MP:0003631; 5Synonymous substitution rate
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Discussion
In this study we present a novel computational method to objectively identify 
clinically relevant CNVs using an NBTree classifier and 13 diverse genomic features. 
This is the first description of such a method applied to CNVs that can significantly 
improve interpretation of this important class of genomic variation. Our classification 
method has been validated on a set of 1,203 CNVs detected in 584 patients with 
MR, achieving a high accuracy (94%), with a sensitivity of 88% and a specificity of 
94% (Figure 6.3A).
Several other computational methods have been developed previously to predict if 
disruption or disturbance of genomic elements have pathogenic consequences. Often 
these methods are focused on identifying disease genes or on predicting if mutation or 
splicing events are pathogenic31-34. Such methods make use of protein structure and 
stability measures, and phylogenetic or sequence conservation data3839, and often 
cross-validate their predictions using OMIM (Online Mendelian Inheritance in Man) 
data40. These approaches may be less applicable for larger structural variants such 
as CNVs because they predict the effect of a single change on a single disease gene, 
rather than a large change involving many genes. Our approach differs in that we 
directly predict the causal CNV from genome-wide copy number scans on the basis of 
the distinguishing features of benign and disease-causing CNVs. In addition, OMIM 
does not provide a suitable source for validating the performance of a classification 
method for CNVs as dosage-sensitive genes are largely underrepresented in this 
database (<5% of the entries describe haploinsufficient genes41), and because a 
precise mapping of CNVs in OMIM is lacking. In contrast to OMIM, the Decipher 
database list of known syndromes (https://decipher.sanger.ac.uk) provides a suitable 
list of CNVs for external validation of the classifier with high-resolution mapping of 
their genomic locations. Our classification method correctly identified all the CNVs 
listed in this database as causing MR-associated syndromes.
The classifier incorporated specific knowledge about CNVs via 13 diverse structural 
and functional genomic features (including a number of different transposable 
element types). The proximity of these elements to CNVs has been reported 
previously and it has been hypothesized that they mediate the formation of recurrent 
CNVs18 26 42. We confirm previous results that benign CNVs are enriched in both LINE 
and segmental duplication elements13 28 and show that both the LINE density and 
the segmental duplication density substantially contribute to the classifier’s accuracy 
(Supplementary Table 2). Previous studies have also reported that CNV gains are 
enriched in many of the same features as CNV losses30. Our feature contribution 
results support this finding: when the CNV type was removed from the classifier only 
a 3.7% decrease in accuracy was observed, and 7 additional features had a greater 
contribution to the classifier’s accuracy. In addition to these transposable elements, 
we included functional genomic elements which have recently been shown to assist 
in distinguishing benign from MR-associated CNVs3043. The significant enrichment 
of MGI mouse nervous system phenotypes in MR loss CNVs has previously been 
reported30. We show that the MGI mouse knock-out phenotype feature is effective in
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distinguishing benign from MR-associated CNVs: 80% of all MR-associated CNVs 
contain one or more genes whose unique orthologue’s disruption in mouse reveals 
a nervous system phenotype, whereas benign CNVs only rarely contain such genes 
(Supplementary Table 2).
Despite the MGI mouse phenotype dataset being incomplete, this feature contributes 
greatly to the classifier’s accuracy (5%). To date, gene knockout experiments 
with recorded ontology based phenotype information have been performed for 
approximately 5,000 of the possible 15,287 genes with mouse 1:1 orthologues44 45. 
Furthermore the MGI phenotype data are included in the classifier as a binary feature 
(which is labelled as ‘true’; when a CNV contains 1 or more genes exhibiting a 
nervous system phenotype; MP:0003631). However, as the MGI phenotype dataset 
is incomplete, our approach is conservative with respect to missing values. This is 
because CNVs overlapping genes whose disruption does not result in a nervous 
system phenotype are weighted equally to those CNVs overlapping genes whose 
disruption phenotypes are currently unknown. Thus, we expect that increased 
coverage by the MGI mouse knock-out dataset will significantly improve the 
accuracy of the classifier. In addition, further genomic features such as CpG islands 
or conserved non-coding regions46 can now be tested for their potential to improve 
the accuracy of this approach. Nevertheless, as the densities of many genomic 
features are strongly correlated28, it is likely that the addition of further features to the 
classifier will not result in a substantial improvement in predictive power.
Most of the CNVs we used to train the classifier were identified on low-resolution 
(BAC-based) microarray platforms. In contrast, the replication set contained 
CNVs collected solely from Affymetrix 250k SNP microarrays. Despite the different 
microarray technologies used, only a negligible decrease in classification accuracy 
(-1.7%) was observed between the training and the replication set. This indicates 
that the classifier is platform-independent and will not require retraining when used 
on data generated from comparable microarray platforms.
MR-associated CNVs discovered thus far are, in general, larger than benign CNVs30. 
Previously developed CNV risk assessments for identifying disease-associated 
CNVs use a length greater than 3Mb as a distinguishing criterion16. Closer inspection 
of the MR-associated CNVs from our validation study indeed revealed a larger 
mean length (6.8Mb) compared to the benign CNVs (474kb). Despite this large size, 
25% of the MR-associated CNVs in the validation set were smaller than 1.1Mb. 
We separately tested the accuracy of the classifier on CNVs smaller than 1.1Mb 
which revealed it to exhibit a decrease in sensitivity (-18%) but still a high accuracy 
(93%). As might be expected, small MR-associated CNVs showed a decrease in 
the number of MGI knock-out genes displaying a nervous system phenotype, but 
their SINE and gene densities are comparable to those of larger MR-associated 
CNVs (Supplementary Table 2). Importantly, the classifier was still able to correctly 
classify 9 of the 13 small MR-associated CNVs, demonstrating the advantage of 
the classifier in comparison to conventional interpretation methods which often are 
unable to clearly identify clinically relevant CNVs unless specific information about
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their genomic content is known47.
Although current clinical interpretation of CNVs focuses on large, rare and de 
novo CNVs, an increasing number of genomic loci being reported show variable 
inheritance and penetrance20-24. Our replication study contained a number of such 
CNVs, including CNVs at 1q21.1 and 15q13.3 which, in addition, show variation in 
genomic size and content20-23. Three rare inherited CNVs encompassing the 1q21.1 
critical region were all classified as associated with MR, even though their genomic 
breakpoints differed. Two rare de novo CNVs in the 15q13.3 region were classified 
differently, one as benign and one as pathogenic. In addition, three inherited CNVs 
at this locus were all classified as benign. Interestingly, the distal breakpoint for all 
five CNVs was identical whereas the proximal breakpoint of the four CNVs classified 
as benign was extended by an additional 150kb. This difference in classification 
is explained by the fact that the 150kb region showed a higher repeat element 
count and density due to repetitive elements surrounding the 15q13.3 critical region 
(Supplementary Table 2)23. This particular example highlights the current challenge 
in clinical interpretation of CNVs which relies on the availability of large control 
datasets. We do not claim that our classification method replaces the need for 
such datasets. Our method does show that 27 out of 41 (66%) rare inherited CNVs 
identified in patients contain genomic features similar to previously recognized MR- 
associated CNVs, a significant proportion when compared to the remainder of the 
genome (Figure 6.3B). This provides independent support for the clinical relevance 
of this group of CNVs and shows that the interpretation of CNVs should not be 
limited to rare de novo CNVs with a fully penetrant dominant effect48. Furthermore, 
in the set of 53 rare CNVs with unknown inheritance, 46 CNVs were classified as 
being MR-associated, the vast majority with high confidence. These rare CNVs with 
unknown inheritance demonstrate strong similarities to rare de novo CNVs in that 
they have a low segmental duplication density, a high SINE density, often contain 
genes whose mouse knockouts result in nervous system phenotypes, have similar 
gene expression values and similar synonymous substitution rates. This suggests 
that these rare CNVs with unknown inheritance are indeed similar in pathoetiology to 
rare de novo CNVs and thus can be considered strong candidates for being causal 
CNVs. The ability of the classifier to identify such CNVs of unknown inheritance 
should be of great benefit to the diagnostic communities.
This CNV classifier may also be informative of disorders other than mental 
retardation. This is of particular relevance because CNVs have recently been 
associated with other neurodevelopmental disorders such as autism and 
schizophrenia145 but screening for causal CNVs in these diseases has yet to be 
implemented in most clinics. Interestingly, many of the CNVs associated with autism 
and schizophrenia, as well as mental retardation, contain genes whose proteins 
are involved in neurotransmission or in synapse formation and maintenance. This 
supports the existence of shared biological pathways that are disrupted in each of 
these neurodevelopmental disorders49. Our CNV classifier trained on MR CNVs may 
therefore already have predictive power for CNVs in other neurological disorders. It 
is likely, however, that this predictive power can be further optimized by retraining
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the classifier using disease-specific CNVs. In addition, the KEGG and MGI features 
selected for the MR patient cohort are also easily configurable for pathways and 
phenotypes which are more relevant to these other disease cohorts. For this reason 
we have made the Java source code of the CNV classifier, called GeCCO, freely 
available (see Methods).
In conclusion, we have developed a novel objective method to identify disease- 
associated CNVs which has overcome several limitations with current CNV 
interpretation methodology. Our NBTree classifier is able to distinguish between 
MR-associated CNVs and benign CNVs with high accuracy without the use of data 
from large control cohorts or parental samples. Results indicate that computational 
classification methods can be used for objectively prioritizing CNVs in clinical 
research and diagnostics. The tool for classifying CNVs, called GeCCO (Genomic 
Classification of CNVs Objectively), as well as the Java source code, are readily 
available online. The benefits of such methods will increase with advancements in 
microarray technology, which already identifies many thousands of such structural 
variants per individual50-53, and in whole genome resequencing technology. 
Establishing objective criteria and methods for interpretation of these genomic 
variants will be crucial for implementation of these technologies in a clinical setting.
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Methods
Classifier Development
In this study we investigate if rare de novo CNVs and commonly inherited CNVs 
could be successfully classified without the use of inheritance information. In order 
to achieve this we collected from the literature a large number of rare CNVs known 
to be de novo (n = 164) and a number of common CNVs known to be benign (n = 
1,413). These CNVs were used for training and testing the classifier. A total of 20 
genomic features were initially investigated. Initially 16 features were selected as 
attributes during the development of the classifier, which was then further optimized 
to a set of 13 features (Table 6.1). To test the accuracy of the classifier we first 
tested the classifier on a set of CNVs previously identified as being associated with 
MR (Decipher known syndromes), and then created an independent validation 
set containing rare de novo and common inherited CNVs, collected from routine 
diagnostics, to be used in a validation study (MR diagnostic CNVs). Finally two 
application sets were created containing CNVs without a clinical interpretation that 
were either a) candidate CNVs, due to unavailability of parental samples, or b) rare 
privately inherited CNVs.
Data sets
The CNVs used during the training and test phase (164 rare de novo CNVs termed 
“MR-associated CNVs” and 1,413 common inherited CNVs termed “benign CNVs”) 
were identified on a number of different microarray platforms in previously published 
studies15'19’28’30. All aberrations were mapped using HG17 coordinates and converted 
when necessary using UCSC liftOver54. The Decipher known syndromes’ (https:// 
www.decipher.sanger.ac.uk) dataset contained 32 pathogenic CNVs based on 
microarray studies and associated with MR. The remaining 26 syndromes were 
excluded as they do not have either mental retardation as a prominent phenotype or 
a fully penetrant phenotype.
MR Diagnostics and application datasets were collected through in-house routine 
diagnostics using Affymetrix 250k SNP microarrays (Affymetrix, Santa Clara, USA), 
and consisted of 584 samples containing 1,297 CNVs. Regions were excluded that 
contained fewer than 5 microarray targets, that were smaller than 10kb in size or 
that were the result of a mosaic or complex chromosomal aberration. In total, the 
validation/application set contained 49 rare de novo CNVs, 41 rare inherited CNVs, 
53 candidate CNVs and 1,154 common inherited CNVs.
Classifier Training
Initially a training set was created by randomly selecting 82 of the 164 rare de novo 
CNVs with an equal number of commonly inherited CNVs. The remaining CNVs 
were placed in the test set. The NBTree classification algorithm as implemented in 
Weka 3.6.055 was selected and incorporated into our Java based tool called GeCCO 
(Genomic Classification of CNVs Objectively). An executable version and all source 
code for GeCCO are readily available via http://genomegecco.sourceforge.net. 
NBTree is a hybrid method combining a decision tree with Naïve-Bayesian classifiers.
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The Naive-Bayesian classifiers calculate the posterior probability (a distance 
function) that the CNV belongs to either class (MR-associated CNV or benign CNV). 
The definition of the training set was then investigated. Given the imbalance that 
exists in the data (see Results) we sought to incorporate this prior into the training 
set. We tested increasingly imbalanced versions of the training set, starting with the 
most unbalanced training set, by placing half of all available CNVs in the training set 
(164 de novo and 2,826 common inherited), and gradually decreasing the imbalance 
until the training set contained only 5% (n = 143) of all available common inherited 
CNVs. The training set imbalance was then further tested in 1% decrements until 
the minimum was reached of 82 rare de novo CNVs and 28 common inherited 
CNVs. Once an optimal balance of CNV classes in the training set was identified the 
optimal subset of the CNVs in the training set was determined. This was achieved 
by randomly selecting CNVs as training and test instances over 10,000 iterations 
and then identifying the set that produced the maximum accuracy. In addition, 
enrichment analysis of the rare inherited CNVs was performed by generating 1,000 
sets of random genomic regions matched for size against the rare inherited CNVs 
and the proportion of sets with greater than or equal to 27 CNVs classified as being 
MR was calculated.
Genomic Features used for Classification
In total 20 different genomic features were investigated as potential classifier 
attributes. The variance inflation factor (VIF) was used to measure the co-linearity 
within the model across the repeat, gene and evolution measures (simple repeats, 
repeat masker, LINE, SINE, long terminal repeats, RNA gene elements, segmental 
duplications, ENSEMBL genes, mean non-synonymous substitution rate (dN), 
synonymous substitution rate (dS) and the dN/dS ratio of genes). Based on the 
VIF, features were removed until the model contained only independent features 
resulting in 16 different structural and functional genomic features that were used 
subsequently for training the classifier (Table 6.1). The included structural features 
were CNV type (loss:gain), CNV length, the numbers of LINE, SINE and segmental 
duplication elements lying within the CNV, as well as the densities of the LINE, SINE 
and segmental duplication elements. The density values were determined as the 
number of elements per base pair. Segmental duplications were downloaded from 
the UCSC table genomicSuperDups. The numbers of LINE and SINE elements were 
extracted from the UCSC table from rmsk and the RNA gene elements from sno/ 
miRNA.
The functional genomic features consisted of the gene count, gene density and the 
variance in gene expression levels, the mean non-synonymous substitution rate (dN), 
synonymous substitution rate (dS) and the dN/dS ratio. In addition KEGG pathway 
and MGI knockout phenotypes were added as features. Genes involved in the 
KEGG (Kyoto Encyclopedia of Genes and Genomes) neurodegenerative pathway 
(hsa01510)56 were added as a categorical feature. This pathway includes KEGG 
genes belonging to KEGG Pathways section 5.2, namely Alzheimer’s disease (KEGG 
pathway 05010), Parkinson’s disease (KEGG pathway 05020), Amyotrophic Lateral 
Sclerosis (KEGG pathway 05030), Huntington’s disease (KEGG pathway 05040),
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Dentatorubropallidoluysian atrophy (KEGG pathway 05050) and Prion Diseases 
(KEGG pathway 05060). KEGG genes were mapped to NCBI Entrez genes using 
associations provided by KEGG. Genes which were annotated as having the MGI 
mouse knockout phenotype, MP:0003631: nervous system phenotype were also 
added as a categorical feature. These genes were identified via human NCBI genes 
whose mouse orthologue’s disruption had been assayed and were obtained from the 
Mouse Genome Informatics (MGI) resource (http://www.informatics.jax.org, version 
3.54)45. Substitution rates were obtained from EPGD57. The stable expression was 
calculated via the standard deviation of log2 intensities across 176 Hapmap cell lines 
(CEU and YRI) hybridized onto an Affymetrix GeneChip Human Exon 1.0 ST array 
(GSE7761).
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Recent improvements in microarray-based genome profiling technologies have 
resulted in dramatic increases in coverage and resolution. These developments have 
also raised a number of important issues affecting the implementation of genomic 
microarrays to the identification of copy number variants (CNVs) in both research 
and clinical diagnostic settings, such as (i) how will the increase in target density 
affect CNV identification and (ii) how should microarray data from different platforms 
be compared and interpreted? In addition, one may wonder how and when will it be 
possible to detect all CNVs present throughout the entire human genome. Recent 
developments in e.g. next generation sequencing technologies will undoubtedly lead 
to a significant improvement in CNV detection. In fact, the first individual genomes 
that have been fully sequenced indicate that a person’s genome may contain on 
average 600-900 CNVs1-3. These large numbers per individual emphasize the 
importance of developing comprehensive CNV interpretation tools.
The focus of this thesis has been on solutions to current and emerging bottlenecks in 
both the identification and interpretation of CNVs, using mental retardation as model 
for a common disease exhibiting both extensive genetic and clinical heterogeneity. 
These bottlenecks include the robust detection of CNVs smaller than 5-10 kilobases 
(kb) in size, reducing the reliance on a single reference genome, developing the 
ability to measure CNVs quantitatively including their positional information, and the 
occurrence of CNVs with partial penetrance. Existing interpretation methodologies 
can be extended to include such CNVs, as also multiple (simultaneous) CNV events, 
and their relevance to other common (neurological) diseases. Once new CNV 
identification and interpretation methods have been developed it is also important 
to consider how these advancements can be implemented into clinical diagnostics.
1. CNV Identification
1.1 Resolution: robust detection of small CNVs using microarrays 
Initial limitations in microarray-based CNV detection resolution hindered the 
robust genome-wide detection of CNVs smaller than 100kb in size (see Chapter 
2). Since the start of this PhD work, however, several new microarray platforms 
have become available containing increasing numbers of targets; the Agilent 1M 
array containing 974 thousand targets, the Illumina 1M array containing 1.2 million 
targets, the Affymetrix 6.0 array containing 1.8 million targets, the NimbleGen 2.1M 
array containing 2.1 million targets and the Affymetrix 2.7M array containing 2.7 
million targets. The targets on these platforms are reported to have a median inter­
probe spacing of 2.1 kb, 1.5 kb, 700 basepairs (bp), 1.2 kb and 735 bp, respectively. 
A CNV can confidently be distinguished from experimental noise by combining 
data from consecutive targets or, alternatively, by combining data from replicate 
experiments. As a result, microarray coverage does not necessarily translate into 
resolution (Chapter 2) and thus these microarray platforms will have a much lower 
CNV detection resolution than the inter-probe distance would suggest4-8. It is for this
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reason that the initial microarray platforms exhibited a relatively low CNV detection 
level. More recently, in-house data from two of these new microarray platforms (the 
Affymetrix 6.0 and 2.7M) were used to repeat the statistical power analysis described 
in Chapter 2. This analysis revealed a remarkable increase in detection power when 
compared to the previously studied microarray platforms. The Affymetrix 6.0 platform 
(see Table 7.1) can confidently detect all CNVs larger than 50kb and the Affyemtrix 
2.7M platform is able to confidently detect all single copy number losses larger than 
10kb in size (i.e., confidence of 0.95). This increase in detection power will facilitate 
the reliable identification of many more, potentially novel, CNVs per individual.
Table 7.1. The probability o f detecting a single copy number loss or gain using 
the recently released Affym etrix 6.0 and 2.7M microarrays in comparison to the 
Affym etrix 250k microarray.
Affym etrix 250K Affym etrix 6.0 Affym etrix 2.7M
Loss Gain Loss Gain Loss Gain
1kb - - 0.02 0.01 0.65 0.01
2kb - - 0.07 0.02 0.86 0.11
5kb - - 0.33 0.15 0.94 0.75
10kb 0.12 0.02 0.72 0.52 0.95 0.92
50kb 0.68 0.38 0.95 0.95 0.95 0.95
100kb 0.88 0.75 0.95 0.95 0.95 0.95
200kb 0.94 0.91 0.95 0.95 0.95 0.95
500kb 0.95 0.95 0.95 0.95 0.95 0.95
Recent ultra-high resolution microarray-based studies have shown that the majority 
of CNVs present in humans may actually be less than 50kb in size9, thereby revealing 
more of the CNV size continuum9 and the inverse relationship between CNV size 
and frequency1. This notion has raised the question of how many targets will be 
required to reliably detect all CNVs larger than 1 kb in size. By extrapolating the 
results obtained from the power calculation for detecting single copy number losses 
of 10 kb, 50 kb and 100 kb in size, a power curve could be generated for detecting 
single copy number losses of 1 kb (Figure 7.1). This projection indicates that the 
robust detection of such losses (with a confidence greater than 0.95) requires a
180
microarray containing more than 4.2 million targets, assuming the current levels 
of experimental noise and probe sensitivity. However, the detection of single copy 
number gains will remain difficult, as this requires even more targets as well as 
improvements in the dynamic range of the targets (Figure 7.1). It is expected that 
microarrays capable of detecting all single copy number losses larger than 1kb in 
size will become available within the next one or two years given the current rate of 
improvement in microarray design10.
1.2 The human reference genom e
The currently used human reference genome consists of a haploid sequence 
extracted from 5 individuals21112. Recent studies have discovered an estimated ~5 
million basepairs (Mb) of novel sequence not present in the reference genome by 
integrating assembly data from sequencing Asian and African individuals13. These 
sequences, not contained in the current version of the human reference genome, 
are also not represented by targets on the currently available microarray platforms, 
therefore prohibiting microarray-based CNV detection within these genomic regions. 
The so-called human pan-genome represents a non-redundant collection of all 
human DNA sequences present in the entire human population. This pan-genome 
is imperative for a better understanding and interpretation of personal genomes14, 
and is estimated to contain ~19-40 Mb of novel sequence. Projects such as the 
‘1000 genomes project’ employ next generation sequencing methods to produce 
a complete catalogue of human variation occurring with a frequency of at least 
1% throughout the entire human genome15. Such efforts to catalogue the extent of 
variation in the human genome and to remove the reliance on a single reference 
genome will be instrumental for detecting the true extent and genomic context of 
CNVs. Results from these studies can then be used for the design of even better 
microarrays that will allow the identification of all CNVs.
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Figure 7.1. Projection o f the power curves o f a single copy number loss (A) and
a single copy number gain (B) against the number of microarray probes based on 
experimental data from Affymetrix microarrays.
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1.3 CNV detection: microarrays versus next generation sequencing 
In a microarray experiment genomic copy numbers in a test sample are determined 
relative to a reference sample or, alternatively, to a pool of reference samples. 
The resulting copy number ratios thus represent the ratios of the test sample in 
comparison to the reference sample(s). These ratios, however, do not always 
represent true underlying copy numbers in the test sample. A test over reference 
ratio can for example become distorted when the base copy number of the reference 
is not two. A loss in genomic material in the reference sample may thus be detected 
as a gain in the test sample. The effect of CNVs present in the reference sample 
can be neutralized by using reference pools containing many different reference 
samples. It has also been shown that the base copy number for some loci can vary 
in different ethnic populations. Therefore the ethnicity of both the test and reference 
sample(s) will affect the way how CNVs are detected16. Very high copy number 
counts at a genomic locus can result in oversaturation of the signal intensities at the 
corresponding targets on the microarray. As a result, it becomes difficult to detect 
subtle differences in higher order copy numbers within the experimental noise of 
the log2 test over reference ratios1617. As an alternative, next generation sequencing 
(NGS) methods can be used to calculate true copy numbers and it has been reported 
that NGS does not suffer from oversaturation due to high copy number counts17-19.
The genomic locations of CNVs detected using microarrays are determined via the 
annotations of the microarray targets, which are mapped to the reference genome. 
This reliance on annotation affects in particular the detection of copy number gains, 
since duplicated segments may be positioned in tandem to the original sequence, but 
may also be inverted or located at different positions within the genome. Furthermore, 
balanced rearrangements cannot be detected using microarrays, such as inversions, 
which are known to play a role in disease20. NGS not only allows improved resolution 
of CNV breakpoint mapping, it can also provide positional and directional information 
when detecting copy number gains as well as balanced rearrangements such as 
inversions.
Currently, NGS comprises three main methods, (i) pyrosequencing (Roche 454 
technology), (ii) sequencing with reversible terminators (Solexa technology) and (iii) 
sequencing by ligation (SOLiD technology)21-24. Methods used for CNV detection 
within NGS data1 17-19 25-30 can be placed into two categories; depth of coverage 
methods and paired-end methods. Depth of coverage methods are used for 
shotgun sequencing. During shotgun sequencing, the genome is sheared into small 
fragments that can be massively sequenced in parallel. The sequenced fragments 
are then assembled into contigs based on the overlap in the sequence reads (de 
novo assembly) or, alternatively, realigned to a reference genome31. Abnormalities in 
the expected number (i.e., depth) of overlapping reads and the measured depth after 
alignment are used to identify potential CNVs.
Paired-end sequencing can also be used to identify CNVs. This approach provides 
detailed positional information including directional information allowing the 
identification of not only unbalanced variants but also balanced rearrangements,
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such as translocations and inversions132. It is estimated that in 0.78% of the clinical 
referrals for mental retardation a balanced chromosomal rearrangement, which could 
potentially be detected by NGS, remains undetected by current microarray-based 
methods33. During paired-end sequencing the genomic DNA is randomly sheared, 
size selected and cloned into a library. The reads are obtained by sequencing both 
ends of the fragments within the resulting DNA library. Due to the size selection, the 
expected positional information constrains the placement of paired reads within the 
reference genome during alignment. Deviations from the expected size distribution 
are indicative for potential structural variation. However, current paired-end methods 
are still complex and they appear to have a low sensitivity for detecting genomic 
variation in regions containing repetitive DNA sequences, as they rely primarily 
on unique mapping of sequence reads. This may be a problem as regions rich in 
segmental duplications are particularly prone to the formation of CNVs34-40. In spite 
of its potential drawbacks, it can be expected that NGS technologies will soon allow 
high-resolution CNV identification and mapping, as well as the detection of balanced 
variants, thereby overcoming current limitations of microarray-based technologies 
(Table 7.2). At present, however, NGS cannot provide the same robustness and 
throughput for CNV detection as microarrays can. It is, therefore, likely that a 
combination of microarray- and NGS-based approaches will in the near future be 
the preferred choice for studying genomic variation.
2 CNV Interpretation
2.1 Limitations of current clinical interpretation of CNVs 
The clinical interpretation of CNVs is currently limited to rare CNVs for which the 
inheritance pattern can be determined41-43 and the vast majority of CNVs currently 
associated with disease exert dominant effects. These CNVs are highly penetrant 
and, because of their association with e.g. severe forms of mental retardation, they 
rarely accumulate in the general population44. The Database of Genomic Variants45 
is a public repository containing CNVs encountered in the general population. These 
CNVs are often used as a control cohort during CNV interpretation. The use of these 
control cohorts relies on the assumption that CNVs commonly seen in the general 
population are unlikely to exert dominant disease effects. Hence, CNVs exhibiting 
dominant disease effects are in general rare and occur de novo. The information 
present in the Database of Genomic Variants, as well as in other control cohort 
databases, requires large sample sizes to identify effectively and reliably CNVs 
occurring at a frequency of more than 1% in the general population. In addition, 
data sets from different microarray platforms are hard to integrate and platform- 
or laboratory-specific biases may be present within these control databases. 
Consequently, large platform-specific control CNV datasets (greater than 1,000 
individuals) are required for use as a filter to identify rare (pathogenic) CNVs in 
patients.
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Table 7.2. Strengths and weaknesses to detect structural variation of high-resolution microarray and sequencing methods.
High resolution microarrays Shot gun Sequencing Paired-end sequencing
Strengths
Weaknesses
High throughput;
Robust method
No detection of balanced 
rearrangements;
Relative copy numbers; 
No positional information
Detection of CNVs in 
repeat-rich regions
Dependent on mapping 
algorithm
Positional and directional 
information
Low sensitivity in repeat-rich 
regions
Table 7.3: Differences in clinical interpretation of CNVs as a result of introducing the CNV classifier in combination with existing 
diagnostic interpretations.
Frequency 
in Control 
population
. . .. Classification _ . . .  . . .  New Inheritance _ . Current interpretationConfidence r  interpretation
<1% Inherited >0.95 Unknown MR associated
<1% Inherited <0.05 Unknown Not MR associated
<1% Unknown >0.95 Unknown MR associated
<1% Unknown <0.05 Unknown Not MR associated
<1% De novo <0.05 MR associated Unknown
>1% Inherited >0.95 Not MR associated Unknown
M R=M ental Retardation
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In addition to the availability of large control cohorts to determine the frequency of 
a CNV, parental samples are also required to determine whether a CNV is inherited 
or has occurred de novo. This is particularly important as there are many so called 
private CNVs in the general population that will be inherited by offspring37 46-48. 
Although the use of control CNV datasets and inheritance information is of great use 
in current clinical diagnostic settings, it is commonly accepted that mental retardation- 
associated CNVs are not always fully penetrant49. Therefore, only focusing on rare 
de novo CNVs oversimplifies the way CNVs may exert a phenotypic effect. A number 
of recurrent susceptibility loci for mental retardation have been identified, such as 
those on 1q21.150-52, 15q13.35354, 16p11.255-57 and 16p13.1158 59. All these loci suffer 
from both its corresponding phenotypic diversity and its incomplete pentrance, and 
many of them have been associated not only with mental retardation but also with 
autism, schizophrenia and/or epilepsy. Furthermore, these susceptibility loci are 
flanked by repetitive elements, which may explain the relatively high frequency at 
which they occur60. Assessment of the frequencies at which these CNVs occur in 
patient cohorts versus control cohorts has led to the association of these CNVs to 
mental retardation and, as such, to their identification as susceptibility loci. Relying 
solely on inheritance and frequency to determine the association of CNVs with 
mental retardation, however, ignores the underlying biological characteristics of 
these disease-associated CNVs.
Model organisms can be used to gain biological insights into disease6162. However, 
finding suitable animal models to study mental retardation is challenging since 
intelligence phenotypes cannot easily be assessed and, instead, surrogate 
phenotypes are often used. A model organism such as the fruit fly (Drosophila 
melanogaster) is amenable to functional analyses63 64, but it has fewer genes with 
1-1 orthologs in man than for example the mouse. In Chapter 5, mouse knock­
out models that have been systematically characterized and catalogued using 
the Mouse Phenotype ontology were employed65. A selection was made of all 
mouse phenotypes linked to genes whose 1-1 ortholog had been affected by a 
mental retardation-associated CNV in humans. By using this set of genes, it was 
possible to systematically show that CNVs associated with mental retardation are 
enriched in genes that, when knocked-out in the mouse, result in nervous system- 
associated phenotypes. Specific enrichments in mouse phenotypes involving axon 
morphology and dopaminergic neuron morphology were observed. As yet, neither 
of these phenotypes can be determined non-invasively in humans. Through the 
mouse models, 55 novel candidate genes for mental retardation in humans could be 
predicted. The discovery of recurring CNVs and/or functional studies are required to 
confirm these predictions. This study, however, was restricted by the incompleteness 
of the mouse genome informatics (MGI) dataset, which at the time of the study only 
contained approximately 5,000 genes that, when knocked-out in the mouse, have 
had their corresponding phenotypes recorded. This study also focused on mouse 
knock-out models, whilst the corresponding human CNVs represented single copy 
losses and gains. Clearly, the analysis of knock-in (gain-of-function) models instead 
of knock-out (loss-of-function) models may be more relevant for copy number 
gains. Nevertheless, the functional annotation of CNVs, for example via mouse
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phenotypes, is important for gaining a better insight into both disease-associated 
CNVs and CNVs occurring in the general population. In addition, data from model 
organisms can be used to predict novel candidate genes for human disorders such 
as mental retardation.
2.2 Diagnostic application of a  CNV classifier
The functional annotation of CNVs (Chapters 4 and 5) revealed distinct differences 
between CNVs associated with mental retardation and those occurring in the general 
population. By using these annotation features, we developed a classifier (Chapter 
6) to delineate mental retardation-associated CNVs from CNVs seen in the general 
population. We do not claim that, in its current state, this classifier obsoletes the need 
for control cohorts or parental samples. Instead, this classifier is able to complement 
existing clinical diagnostic workflows. The ability to predict the phenotypic effect 
of a CNV is particularly useful when parental samples are not available or when 
a rare inherited CNV may potentially contribute to the disease phenotype. These 
two classes of CNVs are identified in approximately 20% of the mental retardation 
patient population (Figure 7.2). Currently, these variants are reported as CNVs with 
“unknown clinical significance”. Using the classifier, however, an additional 70% of 
rare inherited CNVs and CNVs with unknown inheritance can now be confidently 
classified as either mental retardation-associated or as benign. The classifier can 
also be used to independently confirm the pathogenicity of rare de novo CNVs. This 
is of importance as recent studies have shown that small de novo CNVs can also 
arise in the general population32, thereby further blurring the division between de 
novo CNVs as disease-associated, and inherited CNVs as not disease-associated.
Not all classification results have an equally high confidence, and classifications 
made with a low confidence may be of little use in a clinical diagnostic setting. The 
classification results of rare inherited CNVs and CNVs with unknown inheritance 
from the study in Chapter 6 were re-analysed using an additional rejection criterion 
for classifications made with a low confidence. Based on the results provided in 
Chapter 6 a confidence threshold of 0.95 for the classification distance measure was 
selected, since 37 out of the 43 mental retardation-associated CNVs were classified 
with a distance measure greater than 0.95. Only the classifications made with a high 
confidence score were considered, i.e., with a classification distance measure less 
than 0.05 or greater than 0.95. Using these thresholds, 20 of the 41 rare inherited 
CNVs were confidently classified as associated with mental retardation, 10 were 
classified as not associated with mental retardation and classification of 11 CNVs 
was impossible due to a low confidence (Figure 7.3). In this study, we also classified 
53 CNVs of unknown clinical significance due to the unavailability of parent samples. 
In Chapter 6, 46 of these CNVs were classified as mental retardation-associated. 
After applying the rejection criteria (for classifications between 0.05 and 0.95), 37 
of the 53 CNVs were classified as associated with mental retardation, 2 as not 
associated with mental retardation and the classification results of 16 CNVs was 
rejected due to low confidence scores (Figure 7.4). Thus, in total 69 of the 96 CNVs
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that would otherwise be interpreted as being of “unknown clinical significance” could 
be interpreted.
The implementation of predictive computational methods in clinical practice requires 
extensive validation. We have recently repeated the validation study reported in 
Chapter 6 on an independent set of 3,678 CNVs identified in a cohort of 1,182 
individuals with unexplained mental retardation. The CNV classifier achieved a 
comparable high accuracy (91%) when classifying common inherited and rare de 
novo CNVs. Based on these data it is possible to conclude that the use of high 
confidence classification results would greatly benefit the interpretation of CNVs 
when used in parallel to existing diagnostic workflows in the clinical diagnostics of 
mental retardation.
It is possible that the classification results will not always be concordant with 
existing CNV interpretations. The CNV classifier results that are highly confident, 
but discordant with existing interpretations, are shown in Table 7.3. In some cases, 
such as rare inherited CNVs and CNVs of unknown inheritance, the classifier has a 
clear added value to existing interpretation methodologies. However, the confident 
classification of a rare de novo CNV as not associated to mental retardation, and 
the confident classification of a common inherited CNV as being associated to 
mental retardation, contends existing interpretation methodologies and indicates 
that these CNVs require further analysis to firmly establish their contribution to the 
patient’s phenotype. The addition of the classifier to existing CNV interpretation 
methodologies, which are based on frequency and inheritance, provides additional 
objective information on CNVs based on their genomic content.
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Figure 7.2. Outcomes o f 1,763 mental retardation patients screened fo r CNVs larger 
than 100 kilobases using Affym etrix 250k microarrays.
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Figure 7.3. Classification o f 41 rare inherited CNVs (x-axis) w ith a rejection criterion 
(0.5< and >0.95) based on the classification distance measure (y-axis). 10 CNVs 
(blue) are classified as not associated to mental retardation, and 20 (green) are classified 
confidently as associated to mental retardation. The remaining 11 CNVs (red) have their 
prediction rejected due to low prediction confidence.
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Figure 7.4. Classification o f 53 CNVs with unknown inheritance (x-axis) w ith a 
rejection criterion (0.5< and >0.95) based on the classification distance measure 
(y-axis). 2 CNVs (blue) are classified as not associated to mental retardation, 35 (green) 
are classified as associated to mental retardation, and 16 CNVs (red) have predictions 
greater than 0.05 and less than 0.95 and are, therefore, rejected.
2.3 The characteristics of rare inherited CNVs
Rare inherited CNVs are commonly identified in mental retardation patients (see 
Figure 7.2 and Chapter 3)49. In a routine clinical diagnostic setting using 250k 
Affymetrix microarrays, rare inherited CNVs are observed in ~11% of otherwise 
unexplained mental retardation patients. A number of loci have been reported 
with varying inheritance and penetrance patterns such as1q21.150-52, 15q13.35354, 
16p11.255-57 and 16p13.15859 (see 2.1). Our novel CNV classifier, discussed above, 
suggested that many rare inherited CNVs may be associated with mental retardation, 
including those at 1q21.1 and 15q13.3. Furthermore, the classification confidence of 
CNVs at 16p13.11 as being benign was extremely low (0.5) which raises doubts 
whether these CNVs are truly benign. Several genetic models may explain the 
contribution of rare inherited CNVs to the mental retardation phenotype: (i) loss of 
one allele through micro-deletion may unmask a recessively mutated or imprinted 
risk allele, (ii) a CNV may result in a phenotype only in concert with additional 
genomic variants and/or environmental factors, or (iii) a CNV is not present in all 
cells of the transmitting parent (mosaicism). Further research, including sequencing 
the retained alleles of deletion CNVs, screening of large case-control cohorts66 
and follow-up via functional studies, is needed to substantiate these hypotheses. 
In addition, there is a great need for the further development of statistical models 
capable of associating multiple genomic variants to (orchestrated) phenotypes67.
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The analysis of multiple variants is particularly important with the increasing use of 
NGS technologies that allow for the simultaneous detection of both CNVs and single 
nucleotide variants throughout an entire individual’s genome1.
2.4 Extension to other d isea se  cohorts
It is often difficult to make a clear clinical distinction between different neurological 
disorders. For example, autism and schizophrenia patients may suffer from pre­
existing mental retardation50 68-70. Clinically relevant CNVs have been associated with 
all of these disorders. These CNVs often contain genes involved in neurotransmission 
and/or in synapse formation and maintenance, supporting the existence of shared 
biological pathways between these neurodevelopmental disorders71. The classifier 
developed in Chapter 6 was trained on CNVs specifically associated with mental 
retardation. In order to test the classifier’s ability to generalize and, thus, to be 
applicable to other diseases, its performance using 36 CNVs associated with 
schizophrenia without additional training was evaluated72-74. The classification 
results indicated that 29 of the 36 CNVs could be classified as disease-associated 
(Figure 7.5), 13 with a high confidence (greater than 0.95). These preliminary 
data indicate that CNVs associated with schizophrenia are more similar to mental 
retardation-associated CNVs than to CNVs that are encountered in the general 
population. However, a number of issues may confound these results: (i) the study 
design used to identify CNVs associated with schizophrenia differs from that used 
to identify CNVs associated with mental retardation; many of these CNVs have 
been linked to schizophrenia because they occur more frequently in patients with 
schizophrenia than in healthy controls, but inheritance information is lacking for the 
majority of them, and (ii) patients with schizophrenia may also suffer from mental 
retardation7174. Therefore, it is possible that those CNVs most confidently classified 
as mental retardation-associated belong to individuals who suffer from both mental 
retardation and schizophrenia. Nevertheless, we hypothesize that some of the 
genomic features applicable to identifying mental retardation-associated CNVs 
will also be relevant for other neurological disorders. The functional annotation of 
large numbers of CNVs that are clearly associated with well-phenotyped patients is 
required to study overlaps and differences between CNVs identified in patients with 
mental retardation, autism and schizophrenia in further detail.
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Figure 7.5. Classification o f 36 CNVs associated to schizophrenia (x-axis), using 
a classifier trained on mental retardation data. 29 CNVs are classified as mental 
retardation-associated with a distance value greater than 0.5 (13 with a high confidence 
>0.95) and 7 are classified as common variants as their distance value is less than 0.5 
(y-axis).
3 Computational methods for predicting disease
Numerous computational approaches exist to classify and predict disease genes75-85. 
Chapter 6 presents a novel method for classifying disease-associated CNVs. This 
raises the question whether our CNV classifier performs any different from well- 
established disease gene classifiers, such as those listed in Table 7.4. To some 
extent these classifiers must be similar as disease genes are by nature also 
contained within disease-associated CNVs. However, a CNV may contain multiple 
genes and the classification of CNVs is thus not performed per gene. While some 
of the features used by both types of classifiers are suitable for both classification 
tasks, (e.g. data from animal models and gene networks), not all features effective 
in disease gene classification are appropriate for CNV classification and vice versa.
3.1 Are d isea se  gene  features relevant for CNV classification? 
Computational methods for disease gene prediction (Table 7.4) combine a variety 
of different data sources to prioritize the most likely candidate disease gene(s) at 
a specific locus. These computational methods make use of existing knowledge 
about disease genes. For example, disease genes tend to (i) be highly conserved86 
(ii) encode longer proteins87 and (iii) represent hubs in gene interaction networks79. 
Much of what is known about disease genes has been extracted from OMIM (Online
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Mendelian Inheritance in Man)88 as well as from mutation databases such as HGMD 
(Human Gene Mutation Database)89. Using HGMD, it has been possible to predict the 
effects of missense mutations on the basis of sequence conservation, sub-cellular 
protein localization, alterations in 3D structure and stability of the resulting protein90. 
Features used for identifying disease genes can be grouped into 5 broad categories 
including gene properties (such as length and gene expression), gene similarity 
measures (such as membership to particular gene families), gene and protein 
interaction networks, and data from animal models and disease terms (Table 7.4). 
Some of these features are also transferrable to gross structural rearrangements 
such as CNVs.
Gene properties provide objective genome-wide functional features suitable for both 
CNV and disease gene classification methods37’46’4799. Such features are suitable for 
identifying novel disease genes and are less biased by the relatively small number 
of genes currently identified for mental retardation. CNVs associated with mental 
retardation (Chapter 5) contain genes, which have on average more exons per 
gene in comparison to control CNVs. It has previously been observed that disease 
genes are often hubs in gene interaction networks100101. In contrast we report in 
Chapter 4 that CNVs in the general population often contain genes on the periphery 
of gene networks. Furthermore, new studies in redundancy within transcription 
networks could potentially provide new features for both disease gene and CNV 
classification102-104.
Gene similarity measures can also be effective in identifying disease genes80. The 
use of these properties relies on the assumption that genes similar to previously 
identified disease genes, e.g. belonging to the same gene family, may share 
similar functionalities and, therefore, serve as proper candidate disease genes. 
However, in the case of mental retardation or any other disease with extensive 
genetic heterogeneity and with a relatively small number of identified causal genes, 
the reliance of this feature on previously identified disease genes constrains this 
approach. Likewise, the use of disease terms to select candidate mental retardation 
genes is limited, again due to the relatively low number of identified causal genes and 
the fact that specific phenotypes cannot always be retrieved from mental retardation 
patient cohorts.
Animal models (see 2.1) may provide independent genetic signatures and, in 
addition, allow for extensive phenotyping. These models, however, may also be 
limited by the fact that not all human phenotypes are transferrable. In Chapter 5, 
we demonstrated the statistical significance of specific phenotypes in mouse knock­
out models corresponding to genes affected by mental retardation-associated CNVs 
in humans. These mouse knock-out features were then incorporated into the CNV 
classifier (Chapter 6), resulting in a clear contribution (5%) to its overall accuracy. 
Despite sometimes being limited due to incomplete datasets, we anticipate that 
animal models will continue to be instrumental for predicting both disease-causing 
genes and disease-associated CNVs.
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Table 7.4: Computational methods for disease gene prediction and the data resources used by each method as a basis for 
prediction.
Predictor Gene properties GeneSimilarity
Gene/protein
networks Animal models Disease terms
GeneSeeker[75] * *
eVOC[76] * *
d g p [77] *
Prospectr[78] *
Suspects1781
Prioritizer[79] * * *
G2D[S0] * * *
POCUS'81] *
ENDEAVOUR1821 * *
TOM[83] *
ToppGene[84] *
GFINDer[85] *
CMP and CPSt91] *
Freudenberg et * *
al[92]
CARESAR[93] * * *
Oti et al[94] *
CGI[95] *
Lage et al[96] *
Gene Distiller1971 * * * *
GeneWandere[98] *
3.2 Are CNV features relevant for d isea se  g en es?
Existing disease gene classifiers rely solely on gene-related features. Our CNV 
classifier, however, also makes use of non-gene related features. Repetitive 
elements such as LINEs, SINEs and segmental duplications are in particular 
pertinent for identifying CNVs in the general population, as reported in Chapter 437. 
Segmental duplications may facilitate CNV formation through non-allelic homologous 
recombination mechanisms and can result in unstable “hotspots” for the generation 
of copy number variation, including recurrent duplications and deletions60. It is likely 
that these repetitive element features are relevant for predicting the frequency of a 
CNV and thus, indirectly, for predicting if a CNV maybe disease associated.
3.3 The effectiveness of d isease  gene  and d isea se  CNV predictors 
The majority of disease gene classifiers has been trained on mutation datasets and not 
on datasets including a significant amount of CNVs. Approximately 5% of the OMIM 
entries can been linked to dosage-sensitive genes. In contrast to mutation prediction 
programs such as PolyPhen105, Panther106 and SIFT107, disease gene classifiers do 
not use specific details about mutations as input. Without the use of specific details, 
disease gene classifiers can do little more than identifying genes that are similar 
to genes previously found to contain disease-causing mutations. However, not all 
mutations or genomic variations in a disease gene result in disease (for example 
synonymous substitutions are only infrequently pathogenic). Similarly, a disease- 
associated CNV may also contain non-disease related genes and several disease- 
causing gene(s) within CNVs still remain to be identified. Nonetheless, similarity 
measures underlie all forms of classification based on previous observations, 
including CNV classification.
There is a fundamental difference between disease gene classifiers and our newly 
developed disease CNV classifier. Disease gene classifiers are predominantly 
designed to identify a candidate gene within a given genomic region. In contrast, our 
CNV classifier can consider all CNVs genome-wide and predict which CNV is likely 
to be pathogenic. Currently, both forms of classification use features that are “gene- 
centric” (gene focussed). Recent studies have demonstrated that CNVs may also 
exert long-range position effects elicited by enhancers, silencers and/or insulators108. 
It is possible that an enrichment for either one of these elements is as important as 
an enrichment for a specific gene and/or its related pathway and, as such, they may 
in the future serve as valuable new features for further improvement of the CNV 
classifier9.
4 Concluding Remarks
The increasing use of microarray-based copy number profiling, and the systematic 
cataloguing of CNVs identified in disease cohorts as well as in the general population,
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has been pivotal for studying this important form of genomic variation and its link 
to disease. Without large cohorts of patients and their phenotypic information, it 
would not have been possible to establish any robust statistical associations. There 
is no doubt that the development of novel CNV identification technologies such as 
NGS will further enhance our understanding of genome variation as a whole and its 
relationship to disease in particular. Additional functional annotation of CNVs will be 
essential to our understanding of how they exert their phenotypic effects. Further 
investigation of rare de novo CNVs as well as CNVs with incomplete penetrance, 
and of CNVs that occur simultaneously with other variants, is required to enhance 
our understanding of the role of CNVs in health and disease. It is imperative for both 
clinical diagnostic and research applications to reliably and accurately distinguish 
and understand the differences between disease-causing CNVs and benign CNVs 
occurring in the general population.
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Summary
Mental retardation (MR; also known as learning disability) affects 3% of the population 
(i.e. an intellectual quotient (IQ) of 70 which is more than 2 standard deviations 
below the mean) and is often associated with the presence of genomic copy number 
variations (CNVs) such as deletions and duplications. CNVs that have reliably been 
associated to neurological disorders such as mental retardation are infrequent in 
the general population. However, CNV also represent a common form of genomic 
variation in the human population.
Genomic microarrays have matured into an effective and robust method for the 
detection of CNVs and are therefore being rapidly adopted in the field of diagnostic 
laboratory genetics. Microarrays are for example replacing kayotyping as the method 
of choice in the diagnosis of patients with unexplained mental retardation.
The design and production of microarrays has undergone a rapid evolution, resulting 
in a dramatic increase in coverage from ‘in-house’ arrays with thousands of targets to 
commercially produced microarrays containing millions targets per array. This raises 
a number of challenges. How can it be ensured that experimental data collected 
from different microarray platforms remains comparable? Also, it is unclear how 
this increase in target density impacts the achievable resolution at which a genome 
wide copy number scan can be performed. Both of these issues are addressed in 
Chapter 2, through the development of a novel statistical method to compare the 
performance of different microarray platforms. Using this method, it is demonstrated 
that in 2007, commercial oligonucleotide microarray platforms were able to robustly 
detect CNVs larger than 200kb.
Not only do results differ between microarray platforms, laboratory specific differences 
can also be observed, which may hamper widespread clinical implementation 
and data exchange. Chapter 3, reports the results of a multi-centre study using a 
commercially available SNP microarray platform and demonstrates that microarray 
technology is sufficiently mature for diagnostic applications. Included in the study 
were both a validation and an application study. The microarray platform was 
validated by identifying known disease associated CNVs defined by independant 
methods. In the application study, 120 patients with unexplained mental retardation 
were tested along with their parents using the Affymetrix 500k microarray platform. 
Rare de novo CNVs were identified in 15% of cases.
SNP microarrays provide genotyping data in addition to copy number data. The 
extended capabilities of SNP microarrays platforms are demonstrated in Chapter 
3. It is hypothesized that the widespread use of these microarray platforms can 
be exploited to greatly improve our understanding of the genetic causes of mental 
retardation and many other common disorders through the post-hoc analysis of 
genotypic information.
CNVs have only recently been recognized as a common form of genomic variation
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in human, and relatively little is known about their genome-wide distribution, their 
genomic content and their evolutionary characteristics. In Chapter 4 is reported 
a systematic analysis of CNVs identified in the general population. These CNVs 
occur commonly in the general population, are highly heritable, and have unique 
characteristics in comparison to the remainder of the genome. They contain a 
large amount of highly repetitive elements and suffer from reduced efficiency of 
selection. This model is supported by the enrichment of non-essential genes and 
the depletion of genes in these CNVs whose mouse orthologs, when disrupted by 
knock-out experiments, result in pre- and postnatal lethality. These findings provide 
an overarching view of how CNVs arise and segregate in the human population.
In contrast to CNVs observed in the general population, most MR-associated CNVs 
are rare and relatively large, they often contain tens to hundreds of genes. Pinpointing 
exactly which particular gene or genes are responsible for MR in an individual patient 
is therefore challenging and limits diagnostic applications. Chapter 5 contains the 
results of an investigation of the functions of genes present within a large collection 
of MR-associated CNVs by comparing them in silico to data from large-scale mouse 
knock-out experiments. MR-associated CNVs were found to contain greater than 
expected numbers of genes that give specific nervous system phenotypes when 
disrupted in the mouse. Not only does this study provide independent evidence for 
the association of these CNVs with MR, but it also narrows down the list of candidate 
disease genes in these CNVs from thousands to several dozen. This reduced list of 
genes brings widespread gene mutation analysis for MR one-step closer, especially 
when combined to next generation sequencing technology. This will provides a better 
understanding of the biology behind MR that could reveal new drug targets.
Rare CNVs are a frequent cause of neurological disorders such as MR. However, 
copy number variants are also commonly identified in the general population. 
It is therefore crucial for both diagnostic and research applications to be able to 
distinguish between disease-causing CNVs and CNVs occurring as normal genomic 
variation. Separating these two types can take advantage of significant differences 
in their genomic contents. For example, as shown in Chapter 4, benign CNVs are 
enriched in repetitive sequences. By contrast, CNVs associated with MR tend to 
have high densities of functional elements, including genes whose mouse orthologs, 
when knocked-out, lead to specific nervous system abnormalities (Chapter 5). In 
Chapter 6 is presented a novel objective approach that is effective in distinguishing 
MR-associated CNVs from benign CNVs based on the presence of 13 genomic 
attributes. This method is able to achieve high accuracies in a cohort of CNVs known 
to cause MR and in a cohort of individuals with unexplained MR. The development 
and application of this objective CNV classifier can be of great value in the clinical 
decision making process, independently or in combination with additional information 
about CNV frequency in the general population as well as inheritance information.
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Samenvatting
Mentale retardatie (MR, letterlijk geestelijke vertraging), ook wel verstandelijke 
handicap genoemd, is een ontwikkelings- of leerstoornis waarbij de verstandelijke 
vermogens zich niet met de normale snelheid ontwikkelen en meestal ook nooit 
een normaal niveau bereiken. Wanneer een intelligentiequotiënt (IQ) lager dan 70 
wordt vastgesteld is er sprake van MR. MR komt voor bij 3% van de bevolking en 
heeft vaak een erfelijke (genetische) oorzaak. In dit proefschrift is gekeken naar 
één specifieke vorm van genetische oorzaken genaamd genomische copy number 
variaties (CNVs), deleties of duplicaties van delen van ons erfelijk materiaal. CNVs 
komen voor bij alle mensen, en dus is het belangrijk om onderscheid te maken 
tussen CNVs die MR veroorzaken en degene die dit niet doen.
Genomische microarray analyse heeft zich in de laatste jaren ontwikkeld tot een 
efficiënte en robuuste techniek voor de detectie van CNVs. Microarrays hebben 
bijvoorbeeld karyotypering nagenoeg geheel vervangen in de diagnostiek van 
patiënten met onverklaarde mentale retardatie. De snelle vooruitgang in ontwerp 
en fabricage van genomische microarrays heeft bijgedragen aan een toename 
in toepassingsmogelijkheden voor de diagnostiek. De oorspronkelijk “in house/ 
home-made”-arrays met enkele duizenden genomische merkers zijn geëvolueerd 
naar commerciëel-geproduceerde microarrays met miljoenen van deze merkers 
per array. Dit brengt een aantal experimentele en analytische uitdagingen met zich 
mee. Hoe kan bijvoorbeeld worden gewaarborgd dat de resultaten van verschillende 
microarrays (bv. platform, versie, fabrikant) vergelijkbaar blijven? Ook is het 
onduidelijk in hoeverre de resolutie van de genomische microarrays toeneemt bij 
toenemende aantallen genomische merkers. Beide kwesties worden behandeld 
in hoofdstuk 2. Hierin wordt een nieuwe statistische methode beschreven die de 
prestaties van verschillende microarray platforms kan vergelijken. Deze methode 
toonde aan dat commerciële oligonucleotide microarray platforms in staat zijn CNVs 
groter dan 200,000 baseparen betrouwbaar te detecteren.
Naast verschillen tussen microarray platforms, zijn er ook laboratorium-specifieke 
verschillen waargenomen, die een wijdverbreide klinisch toepassing en de 
uitwisseling van gegevens belemmeren. Hoofdstuk 3, beschrijft de resultaten van een 
multi-center studie met behulp van een commercieel beschikbaar Single Nucleotide 
Polymorphism (SNP) microarray platform en toont aan dat deze microarray 
technologie robuust en geschikt is voor diagnostische toepassingen. De validatie van 
dit microarray platform werd uitgevoerd middels het testen van DNA samples met 
reeds bekende MR-geassocieerde CNVs. Tevens werd een klinische studie gedaan 
waarbij 120 patiënten met onverklaarde mentale retardatie samen met hun ouders 
getest werden met behulp van een Affymetrix 500K microarray platform. In 15% van 
de patiënten werden zogeheten de novo CNVs geïdentificeerd. Dit zijn CNVs die 
wel in de patiënt voorkomen, maar niet in de ouders. Naast copy number gegevens 
leveren SNP microarrays ook genotypering gegevens. De voordelen hiervan worden 
ook gedemonstreerd in hoofdstuk 3.
CNVs worden sinds kort erkend als een veelvoorkomende vorm van genomische 
variatie in mensen, maar er is nog maar relatief weinig bekend over het voorkomen
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van CNVs in ons genoom, over de genomische eigenschappen of structuur van 
CNVs alsmede over de evolutie van CNVs. In hoofdstuk 4 wordt een systematische 
analyse beschreven van CNVs die aanwezig zijn in de algemene bevolking. Deze 
CNVs zijn in hoge mate erfelijk en hebben unieke kenmerken in vergelijking met de 
rest van het genoom. Zij bevatten een grote hoeveelheid zeer repetitieve elementen 
en ze lijken tijdens de evolutie niet sterk geselecteerd. Dit wordt bevestigd door onze 
bevinding dat CNVs relatief rijk zijn (t.o.v. de rest van het genoom) aan genen zonder 
belangrijke functie. In de muis kun je dezelfde genen zelfs uitschakelen zonder dat 
dit tot grote problemen leidt. Deze bevindingen geven een mogelijk beeld van hoe 
CNVs evolutionair ontstaan zijn en geselecteerd worden in de menselijke populatie.
In tegenstelling tot CNVs die worden waargenomen in de algemene bevolking, zijn 
de meeste MR-geassocieerde CNVs zeldzaam en relatief groot: ze omvatten vaak 
tientallen tot honderden genen. Het is dan ook moeilijk om precies te bepalen welk gen 
of genen verantwoordelijk zijn voor de MR in een individuele patiënt, en dit beperkt de 
diagnostische toepassingen. Hoofdstuk 5 beschrijft een studie naar de functies van 
genen die aanwezig zijn in een grote collectie van MR-geassociëerde CNVs, door 
ze in silico (op de computer) te vergelijken met gegevens van grootschalige muis 
knock-out experimenten. MR-geassocieerde CNVs bleken een significant groter 
aantal genen te bevatten die specifieke zenuwstelsel fenotypes geven wanneer ze 
uitgeschakeld worden in de muis. Deze studie levert niet alleen het onafhankelijke 
bewijs voor de betrokkenheid van deze CNVs bij MR, maar verkort ook de lijst 
van kandidaat-genen van duizenden tot enkele tientallen. Deze verkorte lijst van 
genen brengt grootschalige genmutatie analyse voor MR een stap dichterbij, vooral 
wanneer deze gecombineerd wordt met nieuwe methodes van DNA sequencing. 
Hiermee verbetert ons inzicht in de genetische oorzaken van MR aanzienlijk.
CNVs zijn vaak een oorzaak van neurologische aandoeningen zoals MR maar 
komen ook veel voor in de algemene bevolking. Het is daarom van groot diagnostisch 
belang om een onderscheid te kunnen maken tussen ziekte-veroorzakende CNVs 
en CNVs die optreden als normale genomische variatie. Een objectieve manier om 
deze twee soorten te onderscheiden is door gebruik te maken van verschillen in 
hun genomische eigenschappen. Goedaardige CNVs zijn bijvoorbeeld verrijkt in 
repetitieve sequenties, zoals weergegeven in hoofdstuk 4. CNVs geassocieerd 
met MR daarentegen bevatten vaak veel functionele elementen, zoals genen 
waarvan de muis orthologen, in geval van een knock-out, leiden tot specifieke 
zenuwstelsel afwijkingen (hoofdstuk 5). In hoofdstuk 6 wordt een nieuwe objectieve 
methode gepresenteerd die MR-geassocieerde CNVs op basis van 13 genomische 
eigenschappen kan onderscheiden van goedaardige CNVs. Deze methode is in 
staat om met hoge nauwkeurigheid te bepalen welke CNVs MR veroorzaken in een 
cohort van personen met onverklaarde MR. De ontwikkeling en toepassing van deze 
objectieve CNV “classifier” (genaamd GeCCO: Genomic Classification of CNVs 
Objectively) kan van grote waarde zijn in de klinische besluitvorming, onafhankelijk 
of in combinatie met aanvullende informatie over bijvoorbeeld, CNV-frequentie in de 
algemene bevolking en erfelijkheidsinformatie.
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Word of Thanks

Cool, WE made it, says she with a true feeling of content and satisfaction. 
Everything that you see here is the result of a combination of input, collaborations 
and shear teamwork of many people. Without whom, none of this would have been 
possible. A big THANKYOU to you all.
There aren’t too many people who can claim such an impressive team of promoters 
and co-promoters. Ad, Han and Joris, I feel truly honoured to have be able to work 
together with all of you on this project. I was seriously intimidated the first few times 
we meet, at the speed at which the conversation and ideas flew about. The beta 
version of my Australian->Dutch translator definitely felt the strain at times. @Joris, 
it was quite a windy path that eventually lead me to your group. Right from the start 
you were willing to take the gamble and give me a go, to take on someone who 
barely knew what a chromosome was. Your openness and patience meant that I 
never felt like I was asking a stupid question. Thank you for all of the ideas, energy, 
and editing. @Ad, Thanks for being the calm and steady guiding hand, for always 
supporting the Bioinformatics team and your contribution to this whole process. 
Thanks for everything, even all the bits that I don’t know about. @Han, thanks for all 
of the thought provoking discussion, and most of all for all of the questions. I do like 
a good question, one that you can chew on for a while. After all, you need to “ask the 
right questions if you’re to And the right answers.” (V. Redgrave)
Diederick, Michael E, Christian, Nienke, Alejandro, Eugène, Joep, Marisol, Luminita, 
Elisa and Bart, thanks for putting up with me, especially my long boot time in the 
morning. And for the truly spectacular dinglish that I sometimes flap out, and then 
expect you all to understand. I hope that I haven’t destroyed your Dutch / English too 
badly. Remember to be lief to your computer every once and a while :-)
To all of the (ex) ‘microarray’ group, Walter, Irene, Lisenka, Simon, Marloes, Eveline, 
Petra, Suzanne, Konny, Michael K, Bart, Peer, Alex, Ben, Marcus, Roland and Esme; 
many of whom are now so busy with sequencing. (I always was a fan of irony.) To 
think just 5 years ago my days were filled dealing with, the appropriately named, 
MAD server and results would fit inside a single excel worksheet. We have come a 
long way. Ik kan zelfs nu een beetje nederlands en dat is te danken aan jullie. Oke, 
het accent is niet helemaal correct, maar ja, ik blijft toch een Aussie.
Thanks for all of the cricket gossip Ram. I will definitely take you up on that IPL offer 
someday. Terry, thanks for the company. I think that we have easily solved most 
of the world’s problems on those many trips between Utrecht and Nijmegen, well 
except for that blasted HWE. But I’m still on it.
Het niet gelukt om dit proefschrift schrijven zonder de microarray diagnostiek groep. 
De systematische en nauwkeurige analyse van die microarrays door Rolph, Nicole, 
Ineke, Ine, Nico, Sabine, Trudi, Monique, Martijn, Han en Ronald, heeft de weg naar 
dit boekje sterk vergemakkelijkt. En dan gekoppeld aan de klinsche data van Bert, 
Bregje, Janneke en David, maakt ons team echt bijzonder.
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Caleb, Duc, Chris, I had a fabulous time when I came and visited that very first time 
in Oxford, (and every other time). Who would have thought that a country bumpkin 
like me could end up in a place like that. You not only inspire me to do good science 
but are genuinely great people. You need only look at the chapters in this book to 
understand how fruitful our collaboration has been.
To my friends from the RSG Netherlands, Miranda, Jeroen, Jurgen, Hanka, Inke; 
without you I would have been on a bioinformatics island in a sea of biologists. And 
then coupled with Nils, Magali, AJ, Avanish and Abhi and the rest of the ISCB SC,
I definitely have no right to make such claims. You have all been fundamental in 
opening my eyes to the wider world of bioinformatics and it’s been great fun on the 
way. I’m looking forward to the rest of my term in office.
To my Australian friends in Australia: Kathryn, Alicia, Hannah, Micha and Chris thanks 
for always being there as I breeze through for those few weeks every year or so. You 
are essential for my yearly sanity check. To my Australian friends in Holland: Peter, 
Andrew, Paul, Tony and Michael, thanks for all of the good food and great company. 
Peter, I am truly very sorry how I’ve been neglecting you and I’m looking forward to 
having some crazy and outrageous nights again.
Dad, so, this is how they do it here in the Netherlands. Not bad hey. Thanks for 
all of the patience and understanding. And as someone famous in my life can be 
quoted, “Trust me,” she’ll be right. Mum, sorry that you couldn’t see this, or maybe 
you did? In any case, here are the results of what for you probably seemed a random 
conversation that night when we were driving back from Dryandra. Julie and Andrew 
thanks for always providing me with a home away from home, always having a 
couch that I can plop myself onto and great new music to listen to. Tjoan, Tine, 
Stefan and Flo, bedankt voor alle de steun.
And finally Marcel, last but very not least, you set the groove in more than just the 
band, reminding me when I should be really putting my head down and focusing, 
and when it’s time to stop and play. You are my extremely effective, not-so-secret 
weapon and I couldn’t be happier having you in my corner. And so, Lucy the lamb 
bounced over the crest of the hill through the dew kissed blossoms.
If you know what I mean ;-)
The End
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Figure 1.3. (A) Normal female karyotype obtained after G-banding of the chromosomes. 
(B) Identification of a SNP (marked by red arrow) after Sanger dye termination sequencing 
of three individuals, (C) Genome-wide array CGH based DNA copy number screen. 
Examples of a copy number gain (up) and loss (down) are marked by arrows.
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Gene 3
Figure 1.10. A two-step approach is used to identify dosage sensitive genes associated 
to mental retardation. First, a pathogenic CNV is identified then, by analyzing the genes 
affected by the CNV, the causative gene can be identified.
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Figure 3.1. Example cases of rare de novo CNVs, rare inherited CNVs and rare copy number 
neutral homozygous regions, as identified in patients with MR.
These chromosome plots were obtained using the CNAG software package (Nannya et al., 2005). Each case 
consists of 4 panels; In the top panel the normalized and log2-transformed patient-over-reference intensity ratio 
for each SNP is displayed (in red) according to its chromosomal position. This plot also shows the result of the 
statistical HMM algorithm in blue, with a normal copy at the 0-line, a copy number loss going down and a gain going 
up. Below this plot, a moving average of these intensity ratios from 10 adjacent SNPs is displayed (in blue). Below 
each chromosome drawing with indicated banding pattern is shown, and on the bottom all heterozygous SNPs are 
displayed (in green) to identify stretches of homozygosity. The pink as well as the blue horizontal bars below these 
plots show homozygous regions detected with high confidence. A-D) Examples of rare de novo CNVs smaller than 
1 Mb: (A) Patient B18 with a 671 kb de novo duplication at 8q21, (b ) Patient B28 with a 163 kb de novo deletion at 
9q34, (C) patient T32 with a 163 kb de novo deletion at 16q23, and (D) patient T14 with a 750 kb de novo deletion at 
17p13. E-H) Examples of rare inherited CNVs larger than 1 Mb: (E) patient T26 with a 3.1 Mb rare inherited deletion 
at 16p13, (F) patient N16 with a 5.9 Mb rare inherited deletion at 4q22, (G) patient B14 with a 1.5 Mb rare inherited 
duplication at 16q22, and (H) patient N20 with a 1.3 Mb rare inherited duplication at 3p14. I-L) Examples of rare copy 
number neutral homozygous regions larger than 1 Mb: (I) patient T9 with a 10.7 Mb rare copy neutral homozygous 
region at 3q13, (J) patient T38 with a 5.3 Mb rare copy neutral homozygous region at 7q21, partially overlapping with 
a rare inherited duplication, (K) patient T6 with a 8.7 Mb rare copy neutral homozygous region at 3q12, and (L) patient 
N17 with a 7.8 Mb rare copy neutral homozygous region at 16p13.
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Figure 4.1. The departures from expected values fo r the coincidence o f CNVRs with 
human and dog synteny breakpoints (A,B) and human and dog orthologs' synonymous 
substitution rates within CNVRs (C,D), calculated for sets of Nijmegen CNVRs and Redon 
et al. aCGH CNVRs. Results are shown as percentage differences from values expected 
by random sampling of the human genome reference assembly (see Methods). (A,C) 
Nijmegen aCGH CNVRs; (B,D) Redon et al. aCGH CNVRs. For either Nijmegen or Redon 
et al. aCGH data, the set of genomic regions are: “All CNVRs,” all CNV regions; “Rare 
CNVRs,” genomic regions in which CNVs were identified in <1% of the individuals sampled; 
“Frequent CNVRs,” CNVRs in which CNVs were identified in >1% of the individuals 
sampled; “CNVRs with SDs,” CNV regions overlapping with at least one SD; “CNVRs 
without SDs,” CNV regions having no overlap with SDs; and “All SDRs,” the set of all 8051 
SD regions (shown accompanying each CNVR set). Bars annotated with an asterisk (*) 
are significant at P < 0.025.
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Figure 4.2. Percentage of G+C contents for CNVRs and SDRs compared with size- 
matched randomized sets for Nijmegen CNVRs (indicated within black arrows), Redon 
et al. Affymetrix CNVRs (cyan), Redon et al. aCGH (green), Wong et al. CNVRs (red), 
and SDRs (pink). The first column shows G+C contents for the entire sets. The G+C 
contents of CNVR sets partitioned according to frequency are shown in the second and 
third columns (“Frequent,” CNVRs at >1% observed population frequency; “Rare,” CNVRs 
at <1% observed population frequency). The fourth and fifth columns show G+C contents 
of CNVR sets partitioned according to their overlap, or not, with SDs. Additionally, the G+C 
contents of SDRs overlapped, or not, by CNVs, are shown in the fourth and fifth columns, 
respectively. The frequency distribution of the G+C contents for 500 randomly sampled 
sets of genomic regions, matched in size to Nijmegen CNVRs (gray density curve) and to 
SDRs (pink density curve), are also shown.
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Median CNV size per CNVR in kb
Figure 4.3. Relationships between CNVR size and G+C content. We partitioned by 
CNVR size the Redon et al. aCGH set into four equally populated bins; this data set was 
chosen, as it provides CNVRs covering the broadest logarithmic range of size variation. 
Differences in G+C content between each of the two largest bins when compared with either 
of the two smallest bins are significant (P < 4 103). Even when discarding segmentally 
duplicated bases, the two larger CNVR sets exhibit significantly increased G+C content 
(Nijmegen set, 44.2%; Redon et al. aCGH set, 41.5%; P < 1 103). For each data set, the 
median size of CNVs within a CNVR is plotted against the CNVs' median G+C content 
(filled circles). Redon et al. aCGH CNVRs were also partitioned into four equally populated 
bins according to median CNV sizes (open circles).
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Figure 4.4. The departures from expected values for evolutionary rates, recombination 
rates, and disease gene count estimated within Nijmegen CNVRs, Redon et al. Affymetrix 
CNVRs, Redon et al. aCGH CNVRs, Wong et al. CNVRs and SDRs. Evolutionary rates 
and disease gene counts have been obtained only for genes that entirely lie within these 
CNVRs. Results are shown as percentage differences from values expected from random 
sampling of the human genome reference assembly (see Methods). (A) Departures of the 
rate of protein volution (dN/dS), recombination rate per base (cM/bp) and disease gene 
count are shown as percentage differences from the value expected from random sampling 
of the human genome. Bars annotated with an asterisk (*) are significant at P < 0.025. 
(B) Departures of the same properties as in A, after splitting the different CNVR data sets 
according to their overlap with SDs.
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Figure 4.5. The departures from expected values fo r the coincidence o f CNVRs 
with segmentally duplicated basepairs (A,B) and with Ensembl protein-coding genes 
(C,D), calculated for sets of Nijmegen CNVRs and Redon et al. aCGH CNVRs. Results are 
shown as percentage differences from values expected by random sampling of the human 
genome reference assembly (see Methods). (A,C) Nijmegen aCGH CNVRs; (B,D) Redon 
et al. aCGH CNVRs. CNVR sets are described in the legend to Figure 2. Bars annotated 
with an asterisk (*) are significant at P < 0.025.
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Figure 5.1. Enrichments of MGI phenotype terms among genes overlapped by MR-associated CNVRs. One phenotypic category (Nervous 
System) and two specific nervous system phenotypes (Abnormal Axon Morphology and Abnormal Dopaminergic Neuron Morphology) are 
significantly over-represented in genes overlapped by All or Loss-only MR-associated CNVRs. The phenotypes result from the disruption 
of mouse genes that have been mapped to their unique human orthologue. MR CNVR sets denoted “minus benign CNVs” have had 
genes removed that are also overlapped by benign CNVRs when matched on the direction of copy number change (i.e. Gain or Loss). 
Columns marked with an asterisk (“*”) are significantly enriched (FDR,5%).
Figure 5.2. Human gene enrichments corroborate mouse phenotypic enrichments.
(A) Enrichments of genes involved in Parkinson's disease or human neurodegenerativa 
disease pathways that are overlapped by MR-associated CNVRs. These genes are 
described by KEGG as belonging to the Parkinson's disease pathway (HSA05020) or 
belonging to any of six neurodegenerative pathways (namely, HSA05010, HSA05020, 
HSA05030, HSA05040, HSA05050, and HSA05060). MR-associated CNVR sets denoted 
“ minus benign CNVs'' have had genes removed that are also overlapped by benign CNVRs 
showing the same direction of copy number change (i.e. Gain or Loss) as its overlapping 
MR-associated CNVR. Columns marked with an asterisk (“*” ) are significantly enriched 
(FDR,5%). (B) All genes contained in the KEGG Parkinson's disease pathway (HSA05020). 
Of the 18 genes in this pathway, 8 (highlighted in red) are involved in a rare de novo CNV 
from at least one or more patients. The remaining genes (depicted in grey) lie outside of the 
148 MR CNVs that we considered.
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Figure 5.3. Enrichment of genes, overlapped by MR-associated CNVRs, that are 
expressed highly in the brain relative to other-tissue (brain-specific genes). Such genes 
are defined as those whose level of expression in the brain exceeds 4 times the median 
expression level in all other tissues (see Materials and Methods). MR-associated CNVR 
sets denoted ‘‘minus benign CNVs’’ have had genes removed that are also overlapped by 
benign CNVRs showing the same direction of copy number change (i.e. Gain or Loss) as its 
overlapping MR-associated CNVR. Columns marked with an asterisk (‘‘*’’) are significantly 
enriched (FDR<5%).
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F igure 5.4. Enrichments of MGI phenotype terms for genes overlapping secondary clinical 
feature-grouped CNVRs. 5 secondary feature-grouped CNVs revealed between 1-6 
significantly enriched phenotypic terms (Cleft Palate, panels (A) to (F); Facial abnormality, 
panel (G); Brain Abnormality, panels (H) and (I); Seizures, panel (J)). These MGI terms are 
significantly over-represented in genes overlapped by All or Loss-only secondary feature- 
grouped CNVRs (see main text). The phenotypes result from the disruption of mouse 
genes that have been mapped to their unique human orthologue. MR CNVR sets denoted 
‘‘minus benign CNVs’’ have had genes removed that are also overlapped by benign CNVRs 
showing the same direction of copy number change (i.e. Gain or Loss) as its overlapping 
MR-associated CNVR. Columns marked with an asterisk (‘‘*’’) are significantly enriched 
(FDR,5%).
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Figure 6.3: Benign CNVs are separable from MR-associated CNVs using a distance function that reflects the probability that a 
CNV belongs to the MR-associated CNV class. The CNVs are ranked and their probability of belonging to the MR-associated CNV 
class is plotted, (A) 1,203 CNVs with known inheritance collected from routine diagnostics are classified with a sensitivity of 88% and 
a specificity of 94%. 1,085 of the 1,154 of the common inherited CNVs were correctly classified (blue), and 43 of 49 CNVs previously 
associated with MR were correctly classified as MR-associated (green). 6 CNVs which had been interpreted as not being associated with 
MR, were classified as MR-associated (red), as well as 69 CNVs classified as MR-associated which had previously been interpreted as 
benign (purple). (B) Similarly, 41 rare inherited CNVs with unknown clinical significance are classified, 27 of which were classified as MR- 
associated with a MR distance > 0.5 (green), and 14 were classified as benign (MR distance < 0.5, blue).
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Figure 7.1. Projection o f the power curves o f a single copy number loss (A) and
a single copy number gain (B) against the number of microarray probes based on 
experimental data from Affymetrix microarrays.
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Figure 7.2. Outcomes o f 1,763 mental retardation patients screened fo r CNVs larger 
than 100 kilobases using Affym etrix 250k microarrays.
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Figure 7.3. Classification o f 41 rare inherited CNVs (x-axis) w ith a rejection criterion 
(0.5< and >0.95) based on the classification distance measure (y-axis). 10 CNVs 
(blue) are classified as not associated to mental retardation, and 20 (green) are classified 
confidently as associated to mental retardation. The remaining 11 CNVs (red) have their 
prediction rejected due to low prediction confidence.
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Figure 7.4. Classification o f 53 CNVs with unknown inheritance (x-axis) w ith a 
rejection criterion (0.5< and >0.95) based on the classification distance measure 
(y-axis). 2 CNVs (blue) are classified as not associated to mental retardation, 35 (green) 
are classified as associated to mental retardation, and 16 CNVs (red) have predictions 
greater than 0.05 and less than 0.95 and are, therefore, rejected.
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